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The WHO has identified obesity as one of the most important current global health 
burdens1. One of the major concerns of the obesity epidemic is the surge in obesity-related 
comorbidities in adolescents, such as insulin resistance (IR), dyslipidaemia and non-alcoholic 
fatty liver disease (NAFLD)2. Especially high insulin resistance has been related to increased 
risk of type 2 diabetes mellitus (T2DM) development early in life. 
This thesis aims to provide an overview of the current knowledge of determinants 
related to pubertal insulin resistance in adolescents with overweight/obesity, as well 
as evaluate the effects and feasibility of a lifestyle intervention aiming to decrease IR in 
adolescents at risk. 
Childhood overweight and obesity
Excess body fat is related to a wide range of comorbidities and health risks in children and 
adolescents3,4. Childhood obesity rarely develops as a consequence of underlying genetic, 
syndromic or endocrine conditions, but rather as a result of excess energy intake relative to 
energy expenditure over a long time5. Medical conditions resulting in overweight or obesity 
in childhood include hypothyroidism, growth hormone deficiency, Cushing’s syndrome, 
Prader-Willi syndrome, Bardet-Biedl syndrome, defective leptin signalling and genetic 
factors, such as mutations in the melanocortin 4 receptor (MC4R)5,6. Also medications 
such as antipsychotics and thyreomimetics have been related to weight gain7. However, 
it is thought that only a few percent of all childhood obesity cases can be traced back to 
these secondary causes of obesity6. Most cases of childhood overweight and obesity are 
related to lifestyle-associated factors in our so-called “obesogenic” environment. For years, 
the amount of foods (in g) and beverages, caloric density of food, and energy intake per 
meal has increased both at home and while eating out, with a specific increase in snacks8,9. 
The increased availability and reduced costs of fast foods has resulted in increased intake 
of high-caloric snacks, sugar-sweetened beverages, high-glycaemic foods, fast foods 
containing high amounts of fat, and larger portion sizes6,7,10-12. Food intake is also associated 
with social class, where the intake of whole grains, lean meats and fresh vegetables and fruit 
were more commonly seen in participants with higher socio-economic status9. Decreased 
physical activity (PA) and increase in sedentary behaviour, which may be related to increased 
television and media use, are also contributors to the obesogenic environment13,14. Lastly, 
recently more evidence has emerged that early life factors such as maternal diabetes, 
breastfeeding and catch-up growth in early childhood may be related to increased risk of 
developing overweight and obesity at an early age7,15. 
Obesity in childhood is the most important predictor for overweight, obesity, and 
obesity-associated comorbidities in adulthood16-20. Even in childhood, a myriad of obesity-
related comorbidities has been described affecting nearly every organ system. Onset 
of puberty and further weight gain have been identified as the strongest predictors for 
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transition of metabolically healthy obese to metabolically unhealthy obese status, and 
is related to increased morbidity and mortality19-21. One of such complications is glucose 
metabolism dysregulation, such as T2DM. 
Identifying adolescents at highest risk of T2DM development 
T2DM was typically considered to be an adult-onset disease that developed as a 
consequence of long-term glucose dysregulation and pancreatic β-cell failure22. With the 
childhood obesity epidemic, the incidence of T2DM in adolescents has increased and is 
now estimated to be ~45% of all new diabetes cases in youth23. Especially worrying is that 
progression of impaired glucose tolerance to T2DM is much faster in adolescents compared 
to adults and can occur as fast as in 21 months24. It is not yet feasible to study prevention 
of T2DM in adolescents as this would require extremely large cohorts and long follow-up 
time. Therefore diabetes prevention studies in children often use variables known to be 
precursors of, or associated with, T2DM to assess intervention effects. One of these is insulin 
resistance, which is the focus of this dissertation. 
There is currently no uniformly accepted definition and cut-off value for IR in ado-
lescents25. The gold standard technique for assessing IR is the hyperinsulinemic-euglycemic 
clamp, but due to it’s invasive, expensive and time-consuming nature this is not achievable 
in paediatric practice26. Currently, approximately six techniques have been described 
for assessing IR in adolescents, of which the Homeostatic Model Assessment of Insulin 
Resistance (HOMA-IR) is the most commonly used due to it’s inexpensive, easy and relatively 
non-invasive technique27-29. Cut-off values for HOMA-IR to define adolescents as insulin 
resistant ranged from 2.0-5.56 in adolescents of all ages27 (Swindell & Dorenbos, submitted). 
For detecting metabolic syndrome, cut-off points ranged between 1.7-2.6. A clearly defined 
method and cut-off value of assessing IR in adolescents will be beneficial in assessing 
normal and increased IR, prevalence of IR in puberty and monitoring therapeutic outcomes. 
HOMA-IR between 0.5-1.0 is commonly observed in lean prepubertal adolescents, 
although adolescents with overweight/obesity frequently present with higher HOMA-
IR30,31. Therefore, in the studies in this thesis the HOMA-IR cut-off value of >2.0 was used for 
pubertal adolescents (Tanner stages ≥3) or any HOMA-IR in prepubertal adolescents with 
overweight or obesity.
Insulin resistance in adolescents with overweight and obesity
IR is defined as a state of decreased sensitivity of tissues to insulin, which would induce 
hyperglycaemia, resulting in a compensatory increased insulin secretion by the pancreatic 
β-cell to maintain normal blood glucose concentrations32. IR is a major risk factor for the 
development of T2DM, and thought to play a key role in advancement of obesity-related 
comorbidities such as the metabolic syndrome26,33,34. Depending on the method and cut-off 
value used, up to 44% of adolescents with overweight present with IR27.
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IR in adolescents is further complicated by a physiological increase in insulin resistance 
during puberty which is thought to facilitate growth35. Pubertal growth requires increased 
tissue proliferation, resulting in increased glucose demands by these tissues. The body’s 
natural glucose reserves, known as glycogen stores, are small and the use of protein stores 
for producing new glucose will result in rapid muscle and protein loss35. In a state of IR the 
glucose uptake in certain tissues is decreased, leading to higher glucose availability for 
rapidly proliferating tissues. 
IR in puberty normally follows a typical pattern, first described by Amiel et al36. Typically, 
during puberty IR increases by 25-50%, nadirs at mid-puberty (corresponding with Tanner 
stages 3-4) and then recovers when pubertal development is complete31,37,38. Although the 
exact mechanisms for pubertal IR are not fully understood yet, the increase in IR during 
puberty has been partly explained by sex, hormones and ethnicity. In multiple studies, 
girls were found to be more insulin resistant than boys, which might have been related to 
the increase in fat mass during puberty in girls27,37. One study found that sex differences 
disappeared when children had a BMI >27kg/m2, which might indicate that extreme 
adiposity might mask sex differences37. 
Obesity has been identified as an important contributor to IR in adolescents. Cross-
sectional studies and one longitudinal study showed that adolescents with overweight 
and obesity had a similar but exaggerated pattern of IR during puberty, in which IR was 
higher at the onset of puberty, increased more during puberty, and did not always recover 
at the end of puberty31,32,37-42. IR appeared to increase with the level of obesity. Odds ratios 
for becoming insulin resistant were found to be 2.4 (1.2-4.9) and 6.0 (3.1-11.9) for boys and 
girls with overweight, and 9.1 (95% CI 4.0-20.4) and 13.2 (4.7-36.9) for boys and girls with 
obesity41. Mechanistically, excess fat mass and ectopic fat deposition are thought to be the 
main drivers for IR in adolescents, which is underlined by a study showing that increased 
visceral fat and fat depots in muscles and liver were directly related to the degree of IR43,44. 
Increased ectopic fat results in increased concentrations of free fatty acids (FFA), which 
decrease insulin sensitivity. FFA also alters mitochondrial function which produces increased 
reactive oxygen species (ROS), leading to intracellular endoplasmic reticulum dysfunction. 
This might result in defective insulin secretion of β-cells34. FFA and other adipocytokines 
released by adipose tissue induce a chronic inflammatory state, which also reduces muscle 
glucose uptake, furthering IR45. Familial factors, such as a family history of T2DM, have also 
been related to increased IR in adolescence although the importance of familial T2DM might 
differ between ethinicities33. Maternal gestational diabetes (GDM), small for gestational age 
(SGA) birth and catch-up growth early in life, too, have been related to IR46,47. 
Progression from IR to more advanced glucose dysregulation stages, specifically impaired 
glucose tolerance (IGT) or impaired fasting glucose (IFG) and to T2DM in youth is preceded by 
β-cell dysfunction, which can be illustrated in a model by Cree-Green et al. (Figure 1.1)32,33,48-
51. In lean adolescents, rising insulin resistance during puberty is compensated by increased 
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insulin secretion from the pancreatic β-cell to maintain normoglycemia. In adolescents 
with additional risk factors, such as obesity, abnormal fat partitioning and a family history 
of T2DM, insulin demands outreach the insulin secreted by the pancreatic β-cell and FGT/
IGT may occur32. Hyperglycaemia, as a result of increased IR, is associated with low-grade 
inflammation which further impairs functioning of pancreatic β-cells32. Hyperglycaemia, 
increased insulin demands and stress are associated with β-cell hypertrophy and ultimately 
a rapid decline in number of β-cells32. Even if IR decreases towards the end of puberty, this 
pancreatic damage is permanent and hyperglycaemia may be persistent. The progression 
of FGT/IGT to T2DM in adolescents is faster than in adults and can occur in as little as 
Figure 1.1: Patterns of insulin resistance and pancreatic β-cell function during puberty (as 
proposed by Cree-Green et al32). 
____ insulin resistance (IR), and ••••• pancreatic β-cell function. In lean adolescents, during mid-puberty a mild 
increase in IR occurs, which is matched by a compensatory increased insulin production by the pancreatic 
β-cell so that normal glucose tolerance (NGT) remains (A). Adolescents with obesity show a more dramatic 
increase in IR and IR does not drop to pre-pubertal levels at the end of puberty. However, the increased IR is 
matched adequately by pancreatic insulin secretion and adolescents remain NGT (B). Adolescents with obesity 
and additional risk factors, such as unfavourable fat partitioning or a family history of T2DM, the increased IR 
and resulting increased insulin demands outreach pancreatic β-cell function and impaired glucose tolerance 
(IGT) occurs. As IR decreases towards the end of puberty, insulin secretion is sufficient again to match the IR 
and NGT occurs. These adolescents may be at risk for redevelopment of FGT/IGT again in the case of additional 
physiological stressors (Figure C). A small portion of adolescents with obesity, increased IR and FGT/IGT have 
continued insulin deficiency and will progress to develop type 2 diabetes mellitus (T2DM, Figure D). 
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21 months24. Furthermore, IR and hyperglycaemia increase risk for the development of 
NAFLD, hypertriglycideamia, and cardiovascular dysfunction related to obesity42,52-54.
Sleep is a possible third modifiable determinant for adolescent obesity and IR
More evidence is emerging that sleep is a third modifiable contributor to energy balance, 
and consequently to overweight and obesity-related comorbidities. Short sleep and sleep 
debt have also been reported to be associated with increased risk of obesity in adults and 
children, and, albeit less strongly, IR in cross-sectional studies in children55-58. Even though 
there is still debate on what the optimal sleep time is for children and adolescents, sleep 
duration declines significantly during puberty59-62. An increasing number of studies linked 
sleep shortage and inadequate quality as independent risk factors for weight gain in 
youth, even after correction for BMI or screentime55,62,63. Moreover, sleep deprivation has 
been suggested to have a negative effect on markers of glucose metabolism. In a small but 
important study 21 adolescent boys were subjected to 3 nights of short sleep (4h/night) 
and 3 nights of long sleep (9h/night). HOMA-IR was significantly higher after the short sleep 
condition compared to after the long sleep condition64. The Cleveland Children’s Sleep and 
Health Cohort observed an U-shape association between duration of sleep and HOMA-IR. 
Adolescents that slept 7.75 hours had the lowest HOMA-IR, but adolescents that slept either 
5.0 or 10.5 hours had a 20% higher HOMA-IR. 
It is likely that endocrine stress, as a consequence of too little or inadequate sleep 
quality, might drive these relationships with obesity and IR. Short sleep duration is related 
to increased cortisol concentrations, higher sympatic nerve system activation, high ghrelin 
concentrations and low leptin concentrations in the blood, all of which promote hunger and 
food consumption65,66. Sleep deprived individuals showed a preference for sugary and high 
caloric foods, and a decrease in physical activity56. However, most previous studies have been 
performed in a cross-sectional design and little is known yet about the effects of changes 
in sleep duration and architecture parameters on IR in adolescents with overweight and 
obesity. Until now, few studies have assessed the effects of sleep duration and sleep quality 
on obesity and IR in adolescents and children. Most studies however used a cross-sectional 
design or questionnaires as method of sleep assessment, but no objective measurements of 
sleep. Moreover, many studies did not correct for pubertal stage, sex or obesity status while 
all of these have been related to cardiometabolic risk factors58. 
Identifying the effect of sleep on obesity status and the development of obesity-
related comorbidities in adolescents might aid in optimizing treatment strategies and 
prevent development of morbidities for adolescents with overweight and obesity. One 
PREVIEW substudy presented in this thesis is a proof-of-principle study that aimed to assess 
associations between sleep duration and architecture with intervention-related changes in 
BMI z-score and IR in adolescents with overweight and obesity. 
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NAFLD might affect BMI z-score and IR outcomes during intervention 
Non-alcoholic fatty liver disease is generally considered to be a consequence of obesity and 
IR, but very recent evidence has also suggested NAFLD to contribute to the development 
and maintenance of IR67,68. NAFLD encompasses a spectrum of liver diseases in the absence 
of excessive alcohol consumption ranging from simple hepatosteatosis (>5% fat) to liver 
cirrhosis, and has been related to obesity69,70. IR and NAFLD frequently co-develop in 
adolescents with overweight and obesity and appear to affect each other negatively. 
Especially circulating FFA were related to hyperinsulinemia, ectopic lipid deposition 
in muscles and the liver and a low-grade inflammatory state. The inflammation and 
elevated FFA concentrations reduced cellular glucose uptake, thereby inducing IR and a 
compensatory increase in pancreatic β-cell insulin secretion45. In a similar fashion in the liver 
excess fat accumulation and increased circulating FFA concentrations contributed to the 
development of NAFLD69-72. Thus, IR and NAFLD appear to reinforce one another, where IR 
is a driver for the development of NAFLD by contributing to hepatic steatosis, and NAFLD 
might exacerbate especially hepatic IR67-73.
Interestingly, previous studies have demonstrated that adolescents who were 
insulin resistant were less successful in decreasing BMI z-score during intervention than 
adolescents that were not insulin resistant, suggesting that the presence of comorbidities 
might affect outcomes of lifestyle interventions targeting adolescent obesity50,74-77. It is not 
yet known how NAFLD relates to IR and BMI z-score outcomes during lifestyle intervention 
in adolescents with overweight/obesity. With up to 52% of adolescents with overweight 
presenting with IR and approximately one third with signs of NAFLD, it is relevant to assess 
not only the effect of interventions on BMI z-score and obesity-related comorbidities, but 
also whether the presence of IR and NAFLD relates to intervention-related outcomes in 
adolescents with overweight/obesity40,78. 
Therefore a proof-of-principle substudy aiming to assess the prevalence and relationship 
between NAFLD and intervention-related outcomes on BMI z-score and HOMA-IR was 
conducted and included in this thesis. 
Treatment strategies for overweight, obesity and insulin resistance
Taken together, increased IR during puberty, especially in adolescents with overweight 
and obesity, poses a risk for pancreatic β-cell exhaustion, T2DM development and a myriad 
of comorbidities. Pubertal IR might thus pose a risk for T2DM development, but puberty 
might also be a window of opportunity to prevent T2DM development by monitoring 
and preventing further IR increase. Considering the high prevalence of IR and obesity 
in adolescents, it is important to identify adolescents with IR in an early stage so that 
development of further morbidity may be prevented. 
As of yet, no interventions in adolescents have been performed specifically aiming 
to decrease IR, although IR was often taken into account as a secondary intervention 
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outcome in childhood obesity studies. International recommendations for the treatment 
of childhood overweight, obesity and obesity-related comorbidities advise comprehensive, 
multidisciplinary lifestyle interventions including dietary and PA strategies79,80.  A meta-
analysis suggested that macronutrient composition could be tailored to target specific 
cardiometabolic risk factors, such as IR81. Previous studies have shown that dietary 
strategies aimed at increasing protein intake resulted in a significant reduction in obesity 
and improvement of HOMA-IR74,82-88. The DioGenes study combined high protein intake 
with decreased glycaemic index (GI) and observed a significant reduction in the percentage 
of adolescents with overweight/obesity in this group, compared to groups that followed 
different dietary strategies87. Other studies focussing on exercise strategies were shown 
to increase fat free mass and reduce fasting glucose concentration and HOMA-IR, with no 
exercise strategy resulting in more beneficial results than another89-92. Lifestyle interventions 
consisting of a combination of dietary, physical activity and behavioural strategies (such 
as counselling) were most effective in decreasing obesity status and cardiovascular risk 
parameters89.However, as of yet it is not known what the optimal combination is of dietary, 
exercise and behavioural strategies to decrease IR and BMI z-score in adolescents with 
overweight and obesity at high risk for T2DM development.
The PREVIEW study in adolescents: researching the effects of a lifestyle strategy 
combining higher protein intake, lower GI, and personalized PA recommendations for 
the prevention of diabetes in adolescents at risk 
The PREVention of diabetes through lifestyle Intervention and population studies in Europe 
and around the World (PREVIEW) study is a large, international randomized controlled trial 
in adults and adolescents that aimed to assess the effects of increasing dietary protein 
intake and reducing glycaemic index on T2DM prevention. In adolescents, the aim was to 
study the effects of a high-protein low-glycaemic index and moderate-protein moderate-
GI diet on IR in adolescents with overweight and obesity. Unique about the PREVIEW 
study in adolescents is that it was specifically targeted at adolescents with IR, as they were 
found to be at the highest risk for T2DM and possibly benefitted less from regular obesity 
interventions. 
Adolescents were randomized into either a high-protein low-GI diet (HP, 25/45/30 En% 
protein/carbohydrate/fat, GI >56) diet, or moderate-protein moderate-GI diet (MP, 15/55/30 
En% protein/carbohydrates/fat, GI <50), and instructed to increase physical activity. During 
the two years study duration participants had frequent clinical investigation days where 
measurements were taken, compliance assessed and individuals received personalized 
dietary and PA counselling. It was hypothesized that a high-protein low-GI diet would be 
superior in reducing IR increase during puberty, and decrease obesity status. 
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Outline of this dissertation
In conclusion, exaggerated insulin resistance is an important consequence of childhood 
obesity and increases the risk of developing T2DM. Understanding more about the pattern, 
determinants and consequences of especially pathological IR in puberty might aid in 
developing therapeutic strategies to prevent future T2DM development. The aim of this 
thesis was to provide an overview of current risk factors related to pubertal IR, identify 
possible new determinants of pubertal IR, and to evaluate the feasibility and effects of a 
new lifestyle intervention on the prevention of T2DM development in adolescents at risk. 
CHAPTER 2 presents an overview of risk factors for the development of pubertal insulin 
resistance, as well as associations of these risk factors with obesity status and IR in a 
population of adolescents with overweight or obesity. 
In CHAPTER 3 the design of the PREVIEW lifestyle intervention in adolescents, which 
studies the effects of increasing protein intake and physical activity on insulin resistance in 
adolescents with overweight and obesity, is described. In addition, this chapter presents the 
baseline participant characteristics and associations with obesity status and IR. The results 
and feasibility of the PREVIEW study in adolescents are presented in CHAPTER 4. 
CHAPTER 5 and 6 provide more insights in possible determinants of pubertal IR. CHAPTER 
5 presents a proof-of-principle substudy in which objectively and subjectively measured 
sleep parameters were related to IR, BMI z-score, and intervention-mediated changes 
herein. In CHAPTER 6, the possible role of NAFLD on insulin resistance in adolescents with 
overweight and obesity is studied. The findings of this thesis and future perspectives for 
the research and treatment of insulin resistance in adolescents are discussed in CHAPTER 7. 
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ABSTRACT 
Insulin resistance (IR) occurs in a transient manner during puberty. Obese adolescents 
may be at risk for persistent insulin resistance during puberty. The objective of the study 
is to review the literature on the association of anthropometric and lifestyle characteristics 
with insulin sensitivity in overweight and obese adolescents, and include data from a 
new study. Relevant papers were selected and reviewed. In addition 137 overweight and 
obese adolescents (42m/95f, age 14.4±2.3y, BMI z-score +3.3±0.7, HOMA-IR 3.4±1.8) from 
the Centre for Overweight Adolescent and Children’s Healthcare (MUMC+) were included 
in this study. Anthropometrics, Tanner stages, sleep characteristics, food intake behaviour, 
and physical activity were determined, and possible associations with homeostatic model 
assessment of insulin resistance (HOMA-IR) were tested. Adolescents with overweight and 
obesity with unfavourable fat partitioning and family history of non insulin-dependent 
diabetes mellitus (NIDDM) are at risk for persistent IR. Overweight and obese adolescents 
from the new cohort showed a higher HOMA-IR postpubertally. BMI z-score, age, pubertal 
stage and prepubertally total sleeping time (TST) and sleep efficiency (SE) were identified 
as significant contributors. Adolescents with overweight and obesity showed a persistently 
higher instead of transiently higher HOMA-IR during puberty, associated with BMI z-score, 
age, pubertal stage and prepubertally less TST and SE. 
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INTRODUCTION
During puberty, adolescents undergo a series of biological, cognitive and psychosocial 
changes. One of the hallmarks of puberty is a change in endocrine conditions and changes 
in anthropometric factors, such as height, body-weight, and body-composition. In parallel, 
behavioural changes, such as sleeping time, food intake behaviour and physical activity, 
driven both by biological processes or social and academic pressures occur1-9. Together, 
these factors pose an increased risk for the development of overweight and obesity, as well 
as for comorbidities such as insulin resistance, type 2 diabetes, cardiovascular disease, non-
alcoholic fatty liver disease and obstructive sleep apnoea syndrome9. 
This review discusses insulin insensitivity during puberty, reviewing the existing 
evidence for possibly related changes in body-weight, especially overweight and obesity, 
sleep characteristics, physical activity and food intake behaviour. In addition, data from a 
new, recent study on relationships between sleep-efficiency and insulin sensitivity in 
overweight and obese adolescents are reported. 
Transient insulin resistance at puberty
Puberty is associated with transient insulin resistance (IR) and hyperglycaemia, due to 
an impaired ability of insulin to stimulate glucose uptake10,11. In response, β-cells in the 
pancreas increase the production of insulin, leading to the clinical hallmark of high insulin 
concentrations in the presence of normal to high glucose concentrations. Insulin resistance, 
followed by impairment of insulin secretion can eventually lead to non-insulin dependent 
diabetes mellitus (NIDDM)10,11. 
Insulin resistance is a transient physiological stage of normal development. Healthy 
children with normal weight experience a stage of physiological insulin resistance that 
starts to rise some years before puberty, peaking at mid-puberty and resolving to near 
prepubertal levels by the end of puberty (Tanner stage 5)11-13. Girls however are more insulin 
resistant than boys at all Tanner stages11-13. In normal weight children the insulin resistance 
during puberty development is compensated by a sufficient pancreatic β-cell response to 
maintain glucose homeostasis12-14. Other metabolic characteristics of pubertal insensitivity 
to insulin are decreased glucose oxidation and increased free fatty acid oxidation.
It is well known that insulin resistance is strongly associated with BMI and body-
composition. Given that insulin resistance can occur during puberty in the absence of 
changes in BMI, and independent of changes in body fat, factors other than anthropometric 
changes have to be carefully examined in the onset of pubertal resistance11-13. 
Due to the considerable change in endocrinological parameters, hormones may play 
a crucial role in the association of puberty and transient insulin resistance. One of the 
most essential changes accompanying pubertal development is the rise in sex hormone 
concentrations, from barely detectable levels in early childhood towards adult levels in late 
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puberty. Insulin resistance, however, has not been shown to be associated with testosterone 
or estradiol levels. It has been hypothesized that the insulin resistance of normal puberty 
might be related to the GH/IGF-I axis. Plasma IGF-I levels are primarily regulated by GH, 
and GH is a counterregulatory hormone known to be a potent insulin antagonist. Indeed, 
strong evidence was found for the contribution of hormonal changes in growth hormone/
IGF-1 to pubertal insulin resistance. Moran et al. demonstrated that IGF-I levels in boys and 
girls rise and fall during the course of puberty in concert with the well-recognized rise and 
fall in insulin resistance7. Insulin-like growth factor-binding protein 3 (IGFBP-3), the primary 
carrier protein of IGF-I, correlates positively with insulin resistance, whereas IGFBP-1, which 
is inhibited by insulin, correlates inversely with insulin resistance7. The data suggest that 
physiological elevation of the IGF-I/GH axis contributes to the relative insulin resistance of 
normal puberty. 
Although pubertal insulin resistance is a normal physiological process compensated by 
a sufficient pancreatic β-cell response to maintain glucose homeostasis, it may contribute to 
pathology in the presence of pancreatic β-cell dysfunction in genetically/epigenetically at 
risk and obese children. Hyperglycaemia develops once the β-cell insulin secretion can no 
longer compensate for the level of IR. In children, the rate of passage from impaired glucose 
tolerance/impaired fasting glucose (IGT/IFG) to NIDDM happens faster compared to adults 
and can occur over the span of only 12–21 months. The majority of NIDDM in childhood 
concerns girls, consistent with their greater adiposity and IR. 
IGT is also increasingly common in adolescents. However as they complete puberty, 
insulin sensitivity often is restored and hyperglycaemia resolves as the pancreas is able to 
meet insulin demands again. Cree-green et al. suggest that it may be that the transient IGT 
seen in these teens is similar to that of gestational diabetes mellitus (GDM), implying that 
these teens will be at increased risk of NIDDM later in life, compared with obese teens with 
no IGT14. 
The divergence in the development of transient or persistent insulin resistance during 
puberty emphasizes the importance of longitudinal research. Goran et al. performed a 
longitudinal study in 60 children and examined at Tanner stage 1 and after 2.0±0.6 years 
of follow-up, by which time 29 children remained at Tanner stage 1 and 31 had progressed 
to Tanner stage 3 or 415. They report that in children progressing to Tanner stage 3, insulin 
sensitivity fell significantly by 32%, acute insulin response increased by 30%, the disposition 
index determined by an intravenous glucose tolerance test fell by 27%, with a significant 
increase in fasting glucose and insulin. In children remaining at Tanner stage 1 however, 
there was a slight increase in insulin sensitivity, with no significant change in acute insulin 
response or fasting glucose and insulin. The pubertal fall in insulin resistance was more 
consistent in African-Americans, remained significant after controlling for age, sex, and 
change in fat mass, visceral fat, and fat- free mass, and was similar in children with low, 
medium, and high body fat. The pubertal transition from Tanner stage 1 to Tanner stage 3 
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was associated with a 32% reduction in insulin sensitivity and increases in fasting glucose, 
insulin, and acute insulin response were similar across sex, ethnicity, and obesity. The 
significant fall in deposition index suggests conservation in β-cell function or an inadequate 
β-cell response to the fall in insulin sensitivity. The fall in insulin sensitivity was not associated 
with changes in body fat, visceral fat, IGF-I, androgens, or estradiol16. In addition, Goran 
et al. report on a longitudinal study on deterioration of insulin sensitivity and beta-cell 
function in overweight Hispanic children during pubertal transition15. They examined 1-year 
changes in insulin dynamics in overweight Hispanic children at high-risk of type 2 diabetes 
as a function of body composition and pubertal transition. They report an increase in fat 
mass increased by 13% (3.0 kg) and a decline of insulin sensitivity by 24%. The fall in insulin 
sensitivity over 1 year remained highly significant even after adjusting for baseline fat 
mass, age, gender and change in fat mass. The fall in insulin sensitivity was not significantly 
influenced by Tanner stage. However, subjects in earlier maturation showed compensatory 
appropriate β-cell compensation, whereas subjects in the latter stages of maturation did 
not. They conclude that failure to increase the acute insulin response in response to the fall 
in insulin sensitivity may be one factor in the pathogenesis of the progression of paediatric 
NIDDM. Taken together, interventions to prevent a persistent insulin resistance during 
puberty are necessary.
Development of overweight and obesity during puberty
Overweight and obesity are major components determining if insulin resistance will 
be transient or persistent after puberty. Therefore, it is necessary to start treatment and 
prevention of this chronic disease as early as possible during childhood and puberty. 
Possible determinants of overweight and obesity include a rapid catch-up growth after 
birth to the first birthday, as well as parental influences i.e. overweight of the father and 
dietary restrained eating behaviour of the mother17-19. Later in life, lifestyle factors of the 
adolescents themselves, such as restrained eating behaviour and physical activity habits 
become more important18-22. As for transient insulin resistance, hormonal changes during 
puberty may also imply a risk for overweight and obesity.
These changes encompass changes in gonadotropic hormone concentrations, but 
also leptin concentrations23. In girls, a peak in leptin concentrations, observed in Tanner 
stage 2, precedes a peak in lutein hormone (LH) and follicle stimulating hormone (FSH) 
concentrations in Tanner stage 323,24. Both in boys and girls, the leptin/FM ratio decreases 
from Tanner stage 2 onwards. In boys, this decrease continues throughout puberty, while in 
girls, this ratio rebounds again in Tanner stage 523,24. These observations imply that during 
puberty factors independent of fat mass become more important in the regulation of 
plasma leptin concentrations. The relationship between leptin and gonadotropic hormones 
during puberty is sex specific with respect to function and timing24. Leptin has been 
shown to be essential in reproductive functioning in both boys and girls24. In girls, leptin is 
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suggested to act as a permissive factor for the onset of puberty. Several studies have shown 
that a deficiency in leptin in anorexia nervosa, or hyperleptinaemia in morbid obesity 
during puberty and as evidenced by studies demonstrating a disturbance of onset as well 
as progression of puberty in leptin disturbant states like anorexia nervosa or obesity related 
hyperleptinaemia24. With regard to timing, an early leptin peak during puberty, especially in 
girls, was suggested to contribute to the risk of overweight and obesity23. 
Changes in sleep duration in relation to overweight and obesity during puberty
In addition to the sex differences in anthropometric and endocrinological variables seen in 
the transition from Tanner stage 1 to 5, a significant reduction in sleep duration is observed25-27. 
Pubertal status appears to be inversely associated with sleep duration25-27. Studies on the 
relationship between sleep duration and body-weight in adolescents report a consistent 
inverse association between habitual sleep duration and body-weight development25,27-29. 
This relationship remains independent of baseline BMI at the start of puberty, fat mass and 
obesity-associated (FTO) allele genotype (rs9939609), parent BMI, as well as changes in 
Baecke scores and hours television viewing during the progressive Tanner stages. However, 
due to the parallel development it is impossible to disentangle cause and consequence 
between the variables. Puberty is initiated through pulsatile gonadotropin-releasing 
hormone (GnRH) release from the hypothalamus and activation of the gonadal axis30,31. The 
subsequent development of secondary sex characteristics originate from shared neuronal 
systems, with the hypothalamus as integration point32. The hypothalamus regulates the 
sleep–wake and feeding circuits32,33. Circuits are connected through the hypocretin-1 
hormone that regulates feeding and locomotor activity via the nucleus accumbens, as well 
as signal transduction on the light–dark cycle to the suprachiasmatic nucleus. Changes in 
hypothalamic functioning, such as disturbed hypocretin-1 signalling, are associated with 
disturbance of the circadian cycle and feeding behaviour, affecting energy balance and 
body composition32,33. Consequently, changes in hypothalamic functioning may explain 
the relationship between the changes in BMI and in sleep duration during puberty. This 
hypothesis is underscored by altered hormone concentrations, such as lower leptin 
concentrations, diminished insulin sensitivity and altered cortisol concentrations in short 
sleeping adolescents, with the latter significantly contributing to lipogenesis. 
Integration of determinants of insulin resistance during puberty
Thus far we can state that puberty is a vulnerable period in life to develop insulin resistance 
and obesity. Specific determinants may include sleep characteristics, food intake behaviour, 
and physical activity. 
Sleep is an important factor for normal growth and development during childhood34-39. 
Especially TST (Total Sleeping Time) and QS (Quality Sleep: (Slow Wave Sleep + Rapid Eye 
Movement sleep)/TST) are crucial sleep factors associated with outcomes on physical, 
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cognitive, emotional, and social development in children38. Sleep deprivation and poor 
quality sleep have been identified as independent risk factors for the development of insulin 
resistance34-37. Until now, a limited number of studies on sleep in relation to insulin resistance 
have been conducted in adolescents40-42. For instance, when effects of partial sleep 
deprivation on markers of glucose metabolism was assessed during 3 consecutive nights 
of short sleep, acute sleep restriction appeared to reduce insulin sensitivity in adolescent 
boys41. Also, observations on sleep duration and insulin resistance assessed in healthy black 
and white adolescents show reduced sleep duration associated with increased HOMA-IR. It 
is suggested that interventions to extend sleep duration may reduce diabetes and obesity 
risk in youth42. A cross-sectional analysis from two examinations conducted in the Cleveland 
Children’s Sleep and Health Cohort (n = 387; 43% minorities) shows that sleep duration had 
a quadratic “U-shape” association between sleep duration and HOMA-IR. When adjusted 
for age, sex, race, preterm status, and activity, adolescents who slept 7.75 hours had the 
lowest predicted HOMA-IR, while adolescents who slept 5.0 hours or 10.5 hours had HOMA-
IR indices that were approximately 20% higher. It was concluded that shorter and longer 
sleep durations are associated with decreased insulin sensitivity in adolescents40,43. 
A second target for improving insulin sensitivity directly as well as indirectly by its effects 
on sleep characteristics concerns the lifestyle factor physical activity. Multiple studies found 
that increasing physical exercise increased insulin sensitivity in overweight adolescents, 
even in the absence body weight or fat mass changes44,45. Physical exercise improves the 
insulin sensitivity of important insulin target tissues, such as skeletal muscle, even hours 
after the exercise has been completed, thereby increasing glucose uptake. Those results 
support the importance of exercise in all therapies targeting the improvement in insulin 
resistance and diabetes risk.
As a third component, food intake behaviour is generally accepted as one of the 
main causes for the development of obesity and metabolic syndrome, with energy intake 
exceeding energy expenditure leading to increased energy storage in the body. Therefore, 
treatment of obesity and insulin resistance aims to decrease energy intake and promote 
healthy food choices46. Eating behaviour and eating habits change during childhood, 
especially in puberty18,19,46. This is also the time that many eating disorders, such as binge 
eating disorder, become apparent, possibly due to issues related to self-esteem and body 
image. Many studies have found an association between sleep deprivation and food 
choices47-52. Sleep-deprived individuals appear more prone to choose unhealthy foods high 
in energy and fat content47-52. Also, sleep-deprived individuals are reported to have more 
frequent meals or snacks between meals compared to individuals that had had sufficient 
sleep49. It has been presumed that sleep deprivation is associated with decreased leptin 
concentrations and increased ghrelin concentrations, thereby promoting the feeling of 
hunger and suppressing satiety53,54. A reduced sleep duration, quality sleep and rapid-
eye movement sleep, or fragmented sleep enhance a positive energy balance through 
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altered substrate oxidation, hormone concentrations, sleeping metabolic rate, appetitive 
behaviours and stress55. Circadian misalignment affects sleep architecture and the glucose-
insulin metabolism, substrate oxidation, the HOMA-IR index, leptin concentrations and 
HPA-axis activity55-58. 
Associations of sleep characteristics with insulin resistance
Since very few studies have assessed relationships between sleep duration and insulin 
resistance during childhood and adolescence, further research is needed to specify these 
relationships34-43. The following study was performed to specify the relationship between 
sleep characteristics and insulin resistance in overweight and obese adolescents, taking 
gender, puberty stage, BMI z-score, physical activity and food intake behaviour into account.
MATERIALS AND METHODS
1 Subjects 
Subjects were selected from the Centre for Overweight Adolescent and Children’s Healthcare 
(COACH) program in the Netherlands (Maastricht University Medical Centre (MUMC+)). 
Inclusion criteria were overweight or obesity and age between 10 and 18 years. Exclusion 
criteria were medical causes of overweight or obesity, such as hypothyroidism. Ethical 
approval was obtained from the medical ethics committee of the Maastricht University 
Medical Centre. All parents and children of 12 years and older gave informed consent for 
participation in COACH and use of study data for publication. 
2 Study design
Prior to body-weight treatment, the children and adolescents were subjected to extensive 
medical screening for causes, risk factors and comorbidities of overweight and obesity during 
a 24-hour admission at the paediatric ward of the MUMC+. Anthropometric measurements, 
and blood sampling for insulin sensitivity was performed. Questionnaires on food intake 
behaviour, physical activity and sleep were completed, and polysomnography took place 
during an overnight stay in the paediatric ward. 
3 Measurements 
3.1 Anthropometry
Body-weight (BW) was measured with the subject in the fasted state, barefoot and in 
underwear. Weight was determined to the nearest 0.1 kilogram using a calibrated scale 
(Seca, Chino, CA). Height was measured using a rigid wall-based digital stadiometer (De 
Grood Metaaltechniek, Nijmegen, the Netherlands) using the Frankfurt plane method59. BMI 
was calculated (BMI = body weight / height2). Due to considerable changes of BMI during 
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childhood and growth, the BMI was corrected for age and gender to obtain the BMI z-score60. 
BMI z-scores were calculated with the lambda, mu, sigma (LMS) method in Growth Analyser 
software (Growth Analyser VE, Rotterdam, the Netherlands). Furthermore, all children were 
classified as overweight, obese or morbid obese according to the International Obesity Task 
Force (IOTF) criteria61.
3.2 Puberty
Puberty stage was determined using the Tanner G/M stages62,63. Susman et al. showed that 
the 95% confidence interval of mean age in Tanner G/M stage 4 was 14.3 years for girls 
and 15.0 years for boys64. Tanner stages were subsequently divided in three subgroups: 
prepubertal (Tanner G/M stage 1), peripubertal (Tanner G/M stage 2-3) and postpubertal 
(Tanner G/M stage 4-5)64-67.
3.3 Insulin sensitivity  
Venous blood sampling was performed to analyse fasting glucose concentration (Cobas 8000 
modular analyser, Roche, 154 Woerden, the Netherlands) and fasting insulin concentration 
(fully automated HPLC Variant II 155 (Bio-Rad Laboratories, Veenendaal, the Netherlands). 
Insulin sensitivity was assessed by calculating the homeostatic model assessment of insulin 
resistance (HOMA-IR). HOMA-IR is calculated as glucose (mmol/L) x insulin (pmol/L)/ 22.568. 
3.4 Sleep characteristics 
Sleep was analysed using polysomnography. The polysomnograms yielded the following 
sleep stages: REM sleep, non-REM sleep stage N1, N2 and N369. A regular night of sleep 
consists of 4 to 5 cycles of these sleep stages, starting with n-REM stage N1 (drifting off to 
sleep), followed by N2 (light sleep), N3 (deep sleep) and REM sleep (dreaming sleep). Each 
sleep stage has a characteristic brain wave pattern, which makes it possible to differentiate 
each stage using polysomnography69.
Furthermore, total sleeping time (TST), defined as total time spent sleeping, was 
determined. Sleep efficiency (SE) is the total sleeping time divided by the total time spent 
in bed. REM is the total time spent in rapid eye movement sleep. Slow wave sleep (SWS) is 
the amount of time spent in non-REM sleep phase N3. Quality sleep (QS) is calculated as 
REM+SWS)/TST55-58.
3.5 Physical activity 
Physical activity was assessed using a validated Dutch translation of the Baecke questionnaire 
for children22,70. This questionnaire consists of 16 questions analysing three dimensions that 
were each scored on a five-point scale. The following dimensions were assessed: physical 
activity at school (school index), physical activity during performing sports (sport index) 
and physical activity during leisure time (leisure time index).
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3.6 Food intake behaviour
Food intake behaviour was assessed by a validated Dutch translation of the Three Factor 
Eating Questionnaire for children18,19. This questionnaire consists of the factors cognitive 
restraint, disinhibition and hunger. Cognitive restraint refers to the conscious control over 
food intake. Disinhibition indicates the loss of control in response to disinhibiting stimuli, 
e.g. stress. Hunger measures the feeling of hunger in general. 
4 Statistical analyses
Data were analysed using IBM SPSS statistics 19.0 software. Descriptive statistics were given 
as mean and standard deviation (SD). Factorial ANOVA was used for comparison of means 
between genders. 
Pearson’s correlation coefficients were calculated in order to determine associations 
between insulin sensitivity and sleep parameters, anthropometry, Baecke scores, and food 
intake behaviour. Significant correlations were further examined using multiple linear 
regression analysis. Significant results from the regression analyses were combined to 
assess the association for the combined model. Results were considered significant when 
p-values were smaller than 0.05. 
RESULTS
137 children (30.7% boys; 69.3% girls) were eligible for this study. Their characteristics are 
presented in Table 3.1. Fasting glucose concentration, insulin concentration and HOMA-IR 
are presented as factors of insulin sensitivity. The possible determinants of insulin sensitivity 
Total Sleeping Time (TST), Quality sleep (QS), Sleep Efficiency (SE), REM sleep and Slow Wave 
Sleep (SWS), as well as the three dimensions of the Baecke questionnaire (school index, sport 
index and leisure time index and three dimensions of the TFEQ questionnaire (cognitive 
restraint, disinhibition and hunger) are also included in Table 2.1. 
In the present cohort significant gender related effects were observed with respect 
to Tanner stages, insulin concentrations, HOMA-IR and scores on the sport index of the 
Baecke questionnaire (Table 2.1). Furthermore, significant differences were present between 
puberty stages. In girls, age, BMI z-score and IOTF classification differed significantly 
between puberty stages. In boys, significant differences between puberty stages were 
present for insulin concentrations and HOMA-IR. Since significant differences were found 
for gender and puberty, further multiple regression analyses are presented separately for 
gender and puberty stage. 
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Associations with insulin sensitivity
In the boys, including all puberty stages, age (r2=0.33, p<0.001) and puberty stage (r2=0.32, 
p<0.001) were identified as significant contributors to HOMA-IR (Table 2.2a). The older boys, 
and those in a later puberty stage, had a higher insulin resistance. There were trends for 
BMI z-score (r2=0.11, p=0.058) and Baecke total score (r2=0.12, p=0.078) to contribute to the 
explained variance of HOMA-IR, but this did not reach significance. The combination of age, 
BMI z-score, puberty stage, and Baecke total score explained 55% of the variance in HOMA-
IR in boys in this cohort. Age, BMI z-score, and puberty stage were positively, and Baecke 
score was inversely associated with HOMA-IR.
In the girls, including all puberty stages, BMI z-score was identified as an independent 
contributor to HOMA-IR (r2=0.07, p=0.018), explaining 7% of the variance in HOMA-IR (Table 
2.2b). The girls with a higher BMI z-score had a higher insulin resistance. None of the other 
variables were identified as significant predictors of HOMA-IR in girls in this cohort. 
In prepubertal girls, TST (r2=0.59, p=0.02) was identified as an independent contributor 
to HOMA-IR, explaining 59% of variance (Table 3.2c). Also, SE (r2=0.58, p=0.028) was identified 
as an independent contributor, explaining 58% of the variance in HOMA-IR in this group 
(Table 2.2c). Both were inversely associated with HOMA-IR. 
DISCUSSION
The main research question in this review is to assess the factors affecting insulin resistance 
during puberty, emphasizing a possible role of sleep characteristics. 
Cree-Green et al. showed that insulin resistance is related to an elevated BMI, pubertal 
hormones along with fat partitioning, elevated free fatty acids, inflammation, and mito-
chondrial dysfunction14. Insulin resistance varies with stage of pubertal development. 
Normally, adolescents reverse hyperglycaemia postpubertally, once the transient insulin 
resistance of puberty resolves. Cree-Green et al. propose 4 different phenotypes: in (i) lean 
children, and in (ii) obese children with no family history of NIDDM and minimal abnormalities 
in fat partitioning decreased insulin sensitivity is matched by up-regulation of pancreatic 
insulin secretion14. (iii) Obese children with altered fat partitioning do not match decreased 
insulin sensitivity by pancreatic insulin secretion, leading to IGT or IGF. However, their insulin 
sensitivity recovers and hyperglycaemia resolves in their postpubertal stage. The transient 
IGT however may imply that they will be at increased risk for diabetes later in life. (iv) Those 
children who develop NIDDM did show lower insulin sensitivity together with a decline in 
β-cell function resulting in permanent pancreatic insufficiency and hyperglycaemia. Thus, 
not all children with insulin resistance develop NIDDM. Identifying those early is of major 
importance for further prevention and treatment. 
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Data from the presented cross-sectional study in overweight and obese adolescent 
boys and girls at different puberty stages show no transient, yet persistent insulin resistance 
during the three distinguished puberty stages. In the selected cohort all children and 
adolescents were admitted based upon their BMI z-scores (Table 3.1). The results are 
considered separately for gender and puberty stage.            
In all girls together, HOMA-IR was positively related to BMI z-score, which is in 
accordance with present literature7,9,11. The postpubertal girls had a higher BMI z-score 
than the prepubertal and the peripubertal girls, and HOMA-IR remained persistently high 
postpubertally, in contrast with the usual conditions, where postpubertally HOMA-IR 
drops again14. In all boys together, age and puberty stage were positively associated with 
HOMA-IR, also confirming previous observations9,11. In the boys, postpubertal HOMA-IR 
was higher compared to the prepubertal figure14. We suggest that in the present cohort, 
the postpubertal boys and girls are at risk for NIDDM, since their postpubertal HOMA-IR is 
persistently at an elevated level.
The prepubertal girls showed inverse relations of HOMA-IR with total sleeping time and 
sleep efficiency. In acute studies, both SE and TST have been positively related to insulin 
sensitivity41,71. Longer TST may be a protective factor for glucose tolerance and/or pancreatic 
β-cell compensation capacity16. This finding is in accordance with published studies that also 
show that inadequate sleep duration, evaluated by sleep log or actigraphy, was significantly 
associated with a higher risk for insulin resistance40-42 and hyperglycaemia16 in children and 
adolescents. 
Strength of this study is the vast collection of measured observational data, including 
the polysomnography. A limitation is the relatively small cohort, resulting in rather small 
subgroups. The data of this cross-sectional study on overweight and obese children and 
adolescents indicate primarily associations of age, BMI z-score, and puberty stage with 
HOMA-IR, showing no transient, but rather a persistent insulin resistance during puberty. 
We presume that this is primarily due to the high BMI z-scores of the adolescents. Since most 
of the associations of insulin resistance with lifestyle factors per puberty stage appeared 
in the prepubertal girls, it is likely that a prepubertal intervention promoting increase of 
TST and SE, as well as a reduction of BMI z-score may reduce the risk for persistent insulin 
resistance. Since all these children and adolescents are at risk for insulin resistance during 
adulthood, this cohort will be followed up during an intervention aiming to reduce BMI 
z-score, and longitudinal data will be collected. Another interesting possibility for future 
research is to assess the effects of diet and physical activity on insulin resistance and sleep 
architecture in overweight and obese adolescents, with a relatively high HOMA-IR. This 
is currently being investigated in the ‘PREVIEW’ (PREVention of diabetes through lifestyle 
Intervention and population studies in Europe and around the World) study72. This study 
consists of a 3-year randomized control trial (RCT) in 2500 adults and 200 children, where 
the influence of medium and high protein diets and moderate and high intensity physical 
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activity on insulin resistance is being investigated. Furthermore, the PREVIEW study will 
perform data analyses in a large cohort of studies to assess the most successful combination 
of diet and physical activity to prevent NIDDM in pre-diabetic adolescents. 
In summary, the transient insulin resistance that normally occurs during puberty is 
at risk to become persistent insulin resistance, especially in obese adolescents with an 
unfavourable fat-partitioning, and with a family history of NIDDM. Determinants of insulin 
resistance in adolescents are suggested to be sleeping hours, physical activity and food 
intake behaviour. 
The data presented from a cohort of overweight and obese adolescents at Maastricht 
University Medical Centre, show an increased risk for NIDDM, indicated by a persistently 
higher HOMA-IR at each puberty stage. Then the main determinants of HOMA-IR are BMI 
z-score, age, pubertal stage, and prepubertal sleep efficiency and total sleeping time. 
The latter is an important clinical finding, as it not only suggests that sleep is a target for 
preventing insulin sensitivity in overweight youth, but that the sleep interventions should 
be staged early in puberty to assert maximum results. 
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ABSTRACT
Insulin resistance (IR) in adolescence is associated with T2DM. The PREVIEW study assesses the 
effectiveness of a high-protein, low-glycaemic index diet and moderate-protein, moderate-
glycaemic index diet to decrease IR in insulin resistant adolescents with overweight/
obesity. Inclusion criteria were age 10-17y, HOMA-IR≥2.0 and overweight/obesity. In 126 
adolescents (13.6±2.2y, BMI z-score 3.04±0.66, HOMA-IR 3.48±2.28) anthropometrics, fat 
mass percentage (FM%), metabolic parameters, physical activity, food intake and sleep 
were measured. Baseline characteristics did not differ between the groups. IR was higher 
in pubertal adolescents with morbid obesity than in prepubertal adolescents with morbid 
obesity (5.41±1.86 vs. 3.23±1.86, p=0.007) and prepubertal and pubertal adolescents with 
overweight/obesity (vs. 3.61±1.60, p=0.004 and vs. 3.40±1.50, p<0.001 respectively). IR was 
associated with sex, Tanner stage, BMI z-score, and FM%. Fasting glucose concentrations 
were negatively associated with Baecke Sport (r=-0.223, p=0.025) and positively with 
daytime sleepiness (r=0.280, p=0.016) independent of sex, Tanner stage, BMI z-score and 
FM%. In conclusion, IR was most severe in pubertal adolescents with morbid obesity. The 
relations between fasting glucose concentration with Baecke Sport and sleepiness suggest 
these might be possible targets for diabetes prevention. 
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INTRODUCTION
Up to 52% of children and adolescents with overweight present with insulin resistance 
(IR), a precursor of T2DM1. IR is defined as the inability of insulin to increase glucose uptake 
and utilization, leading to a compensatory increase in insulin secretion to maintain normal 
blood glucose values. IR is associated with metabolic disturbances, non-alcoholic fatty liver 
disease (NAFLD) and development of cardiovascular disorders. IR in adolescents is further 
complicated by a physiological transient insulin resistance during puberty, which seems to 
be more severe in adolescents with overweight and obesity2-4. Some adolescents appear 
to have insufficient β-cell insulin secretion to compensate for the increased IR, which puts 
them at risk for β-cell exhaustion and, ultimately, T2DM4. Thus, puberty may be a critical 
time for diabetes prevention in insulin resistant adolescents with overweight and obesity. 
Previous studies have shown that weight loss improves IR in children and adolescents 
with overweight and obesity8. Diets higher in protein, especially when combined with lower 
glycaemic index (GI), have shown to be protective for obesity in children9. However, it is 
not known which dietary strategy is most effective for IR reduction, independent of weight 
change, in high-risk insulin resistant adolescents. The PREVention of diabetes through 
Lifestyle Intervention and population studies in Europe and around the World (PREVIEW) 
study aims to assess the effectiveness of two dietary strategies on reducing IR, independent 
of weight change, in insulin resistant adolescents at high risk for T2DM. Participants were 
randomized into a moderate-protein, moderate-GI diet, following clinical standards for 
diabetes prevention, or a high-protein, low-GI diet in line with the most successful diet for 
adolescents in the DiOGenes study9. In this paper the study design, methods and baseline 
results are presented.
MATERIALS AND METHODS
Here we present a concise version of the methods. More information on the study protocol is 
presented in the Supplement. 
1. Participants 
The PREVIEW study in adolescents is a randomized trial conducted at three study sites 
(Maastricht University, the Netherlands; University of Navarra, Spain; and Swansea University, 
United Kingdom). Inclusion criteria included age 10-17 years, overweight or (morbid) obesity, 
IR (HOMA-IR≥2.0 for adolescents with Tanner stages ≥3 or any HOMA-IR for adolescents 
with Tanner stages 1-2), and written informed consent by both parents and adolescents 
aged ≥12 years. Adolescents were excluded from participation in the presence of medical 
conditions or medication use that might compromise study outcomes (e.g. T2DM, bariatric 
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surgery or metformin use) and issues leading to difficulty in compliance with the protocol 
(e.g. severe food intolerances). 
2. Design and intervention
The first 8 weeks of the study were aimed at weight stabilization in spite of growth. 
Participants received a personalized menu following the recommended guidelines of 
15/55/30 energy percentage (En%) protein/carbohydrate/fat. In the 96-weeks intervention 
phase adolescents were randomized into a moderate-protein moderate-GI arm (MP) 
consisting of a target macronutrient composition of 15/55/30En% protein/carbohydrate/
fat, and a GI≥56, or a high-protein, low-GI arm (HP) consisting of 25/45/30En% protein/
carbohydrate/fat and a GI≤50 (Supplementary Table 4.1). Adolescents received personalized 
menus and recipes in line with their randomization arm and energy needs. All participants 
received instructions on both high-intensity and moderate-intensity physical activity (PA) 
and exercise in general was encouraged. Nutritional and PA counselling was provided at 
each visit to improve compliance. The study protocol was approved by local Medical Ethics 
Committees and was compliant with the Declaration of Helsinki and the ICH-GCP. The trial 
was registered on ClinicalTrials.gov (number NCT01777893).
3 Measurements
Measurements were performed during standardized clinical investigation days (CIDs) 
(Supplementary Table 3.2). 
3.1 Anthropometric measurements and body composition
Height and weight were measured while adolescents were in fasted state, barefoot, and 
wearing only underwear. Subsequently body mass index (BMI), age- and sex-specific BMI 
z-scores and overweight classifications were calculated7. Body composition was measured 
using air-displacement plethysmography or bio-impedance measurements. Adolescents 
were classified as prepubertal (Tanner genital/mammae stages 1-2) or pubertal (Tanner 
stages 3-5)5,6. 
3.2 Parameters of glucose metabolism, lipids, inflammation, and liver parameters and blood 
pressure
After an overnight fast, a blood sample was taken to assess glucose metabolism parameters, 
lipids, markers of inflammation and liver parameters (Table 3.1 & Supplementary Table 3.2). 
Insulin sensitivity was assessed by Homeostatic Model Assessment of Insulin Resistance 
(HOMA-IR; glucose (mmol/L) * insulin (mU/L) / 22,5)10. Adolescents were defined as insulin 
resistant when HOMA-IR≥2.0 or any HOMA-IR for prepubertal adolescents due to a 
physiologically lower HOMA-IR in early puberty3. An average of three blood pressure 
measurements was used for analyses. 
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3.3 Lifestyle factors: food intake behaviour, physical activity and sleep
Adolescents completed a 4-day food record to assess energy intake, macronutrient 
composition, glycaemic index and glycaemic load (GL). The three Factor Eating Questionnaire 
(TFEQ) adapted for adolescents was used to assess food intake behaviour11. In a subcohort 
at UM 24h urinary nitrogen was obtained to calculate protein intake. PA was measured by 
7-day accelerometry using an Actigraph (Actigraph GT3X accelerometer) and by the Baecke 
questionnaire adapted for adolescents14. The Pittsburgh Sleep Quality Index (PSQI) and 
Epworth Sleepiness Scale (ESS) were used to assess self-reported sleep parameters12,13. In a 
subcohort sleep was measured using polysomnography. 
4 Statistical analyses
In future analyses, effects of the two dietary arms will be compared using ANOVA repeated 
measures with diet as a factor. Multiple regression analyses will be used to identify the 
contribution of different variables to HOMA-IR change. Baseline analyses in this paper were 
performed using the Statistical Package for the Social Sciences (SPSS) 24.0 (SPSS Inc, New 
York). ANOVA or Mann-Whitney-U test were used for assessing differences between the two 
intervention groups, depending on normality of data. Associations between parameters 
were assessed using Pearson’s or Spearman’s correlation coefficients, which were corrected 
for relevant variables. A p-value <0.05 was considered statistically significant. 
RESULTS
126 adolescents that completed screening and body composition measurement were 
included in baseline analyses (58.7% girls, age 13.6±2.2y, BMI z-score 3.04±0.66, HOMA-
IR 3.35±1.80, 31.0/46.0/23.0% overweight/obesity/morbid obesity, Figure 3.1 and Table 3.1). 
Participant characteristics were not significantly different between the HP and MP groups. 
HOMA-IR distribution in high-risk adolescents (HOMA-IR≥2.0) did not differ between 
adolescents in different Tanner stages or between the sexes (Supplementary Figure 3.1). IR 
was higher in pubertal adolescents with morbid obesity than in prepubertal adolescents 
with morbid obesity (5.41±1.86 vs. 3.23±1.86, p=0.007), and prepubertal and pubertal 
adolescents with overweight/obesity (vs. 3.61±1.60, p=0.004 and 3.40±1.50, p<0.001 
respectively). 
Parameters of glucose metabolism were positively associated with sex, Tanner stage, 
BMI z-score, fat mass index, fat free mass index and fat mass percentage. Independently 
of sex, Tanner stage, BMI z-score and FM%, Baecke Sport score was inversely (r= -0.223, 
p=0.025) and ESS daytime sleepiness positively (r=0.280, p=0.016) associated with fasting 
blood glucose concentrations (Supplementary Table 3.3). 
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Drop-out analyses showed no differences between adolescents that completed the PA 
and food intake questionnaires and adolescents that did not. Adolescents that completed 
sleep questionnaires had a higher fat free mass index (19.0±2.6 vs. 17.3±2.4kg/m2, p=0.001), 
lower FM% (37.1±9.3 vs. 40.4±7.1%, p=0.027) and higher fasting blood glucose concentration 
(4.8±0.7 vs. 4.4±0.7mmol/L, p=0.007) than adolescents that did not complete these 
questionnaires (Supplementary Table 3.4). 
Figure 3.1: Flowchart of participants in the PREVIEW study in adolescents
prescreened 
n=341 
screened 
n=142 
eligible & 
randomized 
n=131  
MP 
n=58 
HP 
n=68 
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did not meet inclusion criteria or met ≥ 1 
exclusion criterium 
excluded n=11  
 
- 2 HOMA-IR too low 
- 7 d id not continue participation 
- 2 exclusion due to medication 
eligible for 
analyses 
n= 126 
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DISCUSSION 
This paper describes the methods and baseline analyses of the PREVIEW study in adolescents. 
PREVIEW is the first international randomized trial to assess the effects of a high-protein, 
low-GI and moderate-protein, moderate-GI diet on IR in insulin resistant adolescents, 
independent of weight changes and puberty. In addition, the longitudinal follow-up (2y) 
in the PREVIEW study will help fill a gap in the knowledge of HOMA-IR development during 
puberty in at risk adolescents. 
It has been shown that a reduction in BMI is associated with IR reduction in adolescents 
with overweight and obesity8. The DiOGenes study showed that a diet with a higher protein 
content, especially when combined with a lower GI, significantly decreased the percentage 
of overweight and obesity in adolescents of all ages9. This study also found that the HP diet 
improved glucose metabolism even in the absence of BMI z-score changes15. Other studies 
focussing on IR in adolescents often included metformin prescription, which hinders 
evaluation of the independent effects of diet and physical activity on IR16. Unique about the 
PREVIEW study is that it studies the impact of a dietary intervention on IR, independent of 
weight changes, in an at-risk group of insulin resistant adolescents with overweight/obesity 
during puberty, without providing metformin. 
Baseline subject characteristics were not significantly different between the two 
intervention groups, demonstrating good randomization. No differences were found in 
HOMA-IR between adolescents in different Tanners stages or between the sexes, which is 
probably due to including only high-risk adolescents (HOMA-IR≥2.0) in these analyses. 
As expected, pubertal adolescents with morbid obesity had a significantly higher 
HOMA-IR than prepubertal adolescents or adolescents with overweight. High HOMA-
IR in adolescents with morbid obesity in this and previous studies indicates that these 
adolescents especially are at high risk for β-cell exhaustion, which can result in decreased 
and insufficient β-cell secretion and T2DM3,4,17. The PREVIEW study aims to provide more 
insight in longitudinal insulin resistance development during puberty in a 2y follow-up 
design.  
We confirmed that in insulin resistant adolescents with overweight and obesity, 
parameters of glucose metabolism are associated with increasing puberty stages and 
markers of adiposity (BMI z-score, FFMI, FMI and FM%)2. Physical activity, measured as Baecke 
Sport score, appeared to be inversely associated with fasting blood glucose concentrations, 
independent of sex, Tanner stage, BMI z-score and FM%. However, glucose concentrations 
and accelerometry counts were not related, and Baecke scores were not associated with 
accelerometry counts. Fasting blood glucose concentrations were positively related to ESS 
daytime sleepiness.
Strengths of the PREVIEW study are the assessment and monitoring of a wide range 
of targets associated with reduction of IR, i.e. diet, PA and sleep in adolescents at risk, and 
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the international setting. Limitations are the absence of a normal weight control group due 
to ethical considerations of research in children. Since the research was set in free-living 
conditions, compliance with the protocol may vary. Response to some lifestyle assessments 
using questionnaires was quite low due to refusal to answer questionnaires or incomplete 
questionnaires, limiting interpretation of lifestyle-related outcomes of the intervention. 
Drop-out analyses revealed some differences between adolescents that did and did not 
complete all assessments, which will be taken into account in future analyses (Supplementary 
Table 3.4). 
In conclusion, the PREVIEW study is a randomized trial aiming to assess the most 
effective diet for preventing IR increase, independent of weight change, and corrected for 
puberty stage, in at risk adolescents with overweight and obesity. Baseline characteristics 
did not differ between the HP and the MP intervention arms. In adolescents with overweight 
and obesity at risk for T2DM development, IR was most severe in pubertal adolescents with 
morbid obesity. IR was associated with sex, adiposity and Tanner stage. Fasting glucose 
concentrations were independently inversely related to Baecke sport and positively to 
sleepiness, indicating these might be possible tools for diabetes prevention.  
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SUPPLEMENTARY DATA FOR MANUSCRIPT 
DETAILED DESCRIPTION OF STUDY PROTOCOL AND METHODS 
1 Subjects
1.1 Inclusion/exclusion criteria
Inclusion criteria were 1) age 10-17 years, 2) overweight or obesity, defined as age- and 
sex-adjusted BMI≥25kg/m2 7, 3) IR (HOMA-IR≥2.0 for adolescents Tanner stages ≥3 or any 
HOMA-IR for adolescents Tanner stages 1-2), 4) written informed consent by both parents 
and adolescents aged ≥12 years, 5) proficiency of the local language and 6) willingness to be 
randomized and adhere to the study protocol. 
Exclusion criteria were 1) medical conditions that might compromise study outcomes 
or adherence (e.g. T2DM, malabsorption diseases, bariatric surgery, and chronic respiratory, 
neurological, musculoskeletal disorders), 2) medication use that potentially influenced 
body weight or glucose metabolism (e.g. metformin) ≤3 months prior to enrolment, 3) 
blood donation or transfusion ≤1 month prior to enrolment, 4) self-reported weight change 
≥5% 2 months prior to screening, 5) special diets 2 months before screening, 6) severe food 
intolerance, and 7) psychological or behavioural problems leading to difficulty in complying 
with the protocol.
1.2 Enrollment
Adolescents were pre-screened by telephone to assess inclusion and exclusion criteria, 
and subsequently they underwent a short screening at one of the intervention centres. 
Adolescents that were found to be eligible at the screening and agreed to continue study 
participation, were enrolled for baseline measurements and randomization (Figure 1).
2 Intervention and study protocol
2.1 Dietary intervention
All diets – regardless of intervention group – were aimed at weight stabilization in spite of 
growth, thus decreasing age- and sex-adjusted BMI z-score. Participants completed a four-
day food record at the start of the study, after which a dietician calculated the basal metabolic 
rate for each child using the WHO formula11. All adolescents received personalized sample 
menus constructed by dieticians, that were in line with their study allocation and energy 
needs with a maximum of 8700kJ/24 hours. During the first study phase, all adolescents 
received sample menus with the same target macronutrient composition of 15/55/30En% 
protein/carbohydrate/fat. During the following phase of 96 weeks adolescents received 
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personalized sample menus adhering to the targeted macronutrient composition of their 
randomization arm (Supplementary Table 3.1). In order increase compliance menus were 
kept as simple as possible and no instructions were given on micronutrient composition 
and dietary fibre. In addition, adolescents were provided with recipes which were in line 
with their randomization group and received dietary counselling at each study visit. The 
consumption of sugar-sweetened beverages and energy-dense foods between meals were 
discouraged, and the intake of fruits and vegetables stimulated. 
2.2 Physical activity 
Because of natural variability in physical activity in different age categories during childhood, 
all adolescents received instructions on both high-intensity (HI) and moderate-intensity (MI) 
PA of which they could choose exercises (Supplementary Table 3.1). Sports in general were 
encouraged. During each study visit, adolescents were counselled on physical activity. 
3 Measurements 
Measurements were performed during CIDs (Supplementary Table 3.2). 
3.1 Anthropometric measurements and BMI z-score calculation 
Height was measured to 0.1cm using a wall-mounted stadiometer (De Grood Metaaltechniek, 
Nijmegen, the Netherlands) and weight to 0.1kg on a digital scale (Seca, Chino, CA, USA). 
Because mean BMI in childhood is influenced by periods of growth, age- and sex-adjusted 
BMI z-scores were calculated to assess BMI deviation in respect to the mean BMI. Since mean 
BMI has increased during the childhood obesity epidemic, it was decided to calculate BMI 
z-scores to an older reference cohort as this represented a child’s true overweight status. 
As most of the cohort was Dutch, reference data of the Dutch National Growth Study of 
1980 was used to calculate BMI z-scores (Growth Analyser VE, Rotterdam, the Netherlands). 
Inter-cohort testing showed no difference in height between Dutch, Spanish and British 
adolescents, making this reference cohort suitable for all adolescents in the study.
3.2 Body composition
Body composition was measured using air-displacement plethysmography by the BodPod 
(Life Measurement Instrument, Concord, CA, USA) or bio-impedance measurements (BIA, 
Tanita SC-330, Tanita Corp, Tokyo, Japan), after which fat mass (FM), fat free mass (FFM) 
and fat mass percentage (FM%) were calculated. Subsequently, fat mass index (FMI) was 
calculated as fat mass (kg) / height (m)2, and fat free mass index (FFMI) as fat free mass (kg) / 
height (m)2. 
3.3 Parameters of glucose metabolism, lipids, inflammation, and liver parameters
Fasting blood glucose concentrations, total cholesterol, high-density lipoprotein (LDL) 
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cholesterol, low-density lipoprotein (HDL) cholesterol, triacylglycerides (TAG), C-reactive 
protein (CRP), alanine transaminase (ALT), and aspartate transaminase (AST) concentrations 
were measured with the COBAS 800 modular analyser (Roche, Woerden, the Netherlands). 
Fasting insulin and HbA1c concentrations were measured with the fully automated 
HPLC Variant II 155 (Bio-Rad Laboratories, Veenendaal, the Netherlands) and C-peptide 
concentration with Immulite XPI (Siemens, Eindhoven, the Netherlands). All laboratory 
measurements were performed in the Maastricht University Medical Centre laboratory. 
Insulin sensitivity was assessed by HOMA-IR, a commonly used marker for IR in children 
because its relatively non-invasive nature (glucose (mmol/L) * insulin (mU/L) / 22,5)10. In the 
absence of consensus on a HOMA-IR cut-off point for IR, we defined adolescents as insulin 
resistant when HOMA-IR≥2.0. Because HOMA-IR is physiologically lower in early pubertal 
stages while these adolescents still may be at risk of HOMA-IR increase during puberty, all 
HOMA-IR values were accepted in adolescents at Tanner stages 1-23. 
3.4 Blood pressure and heart rate
Blood pressure and heart rate were measured on the right arm, using the Mobil-O-
Graph (I.E.M., GmbH, Stolberg, Germany) and a cuff that corresponded with upper arm 
circumference. 
3.5 Food intake
Adolescents completed a 4-day food record on paper or through a food diary app to assess 
food intake and compliance to the study protocol. Food records were analysed at each 
site for energy intake, macronutrient composition, micronutrients, dietary fibre, GI and 
glycaemic load (GL). For the latter, local GI data for individual food items were used. As a 
biomarker, 24h urinary nitrogen was obtained to calculate protein intake in a subcohort at 
UM. 
3.6 Physical activity
PA was measured by 7-day accelerometry (Actigraph GT3X accelerometer, Actigraph Corp, 
USA). Wear time validation was performed with a minimum of 4 days >10 hours including 1 
weekend-day. 
3.7 Sleep
Self-assessed sleep parameters was assessed by the Pittsburgh Sleep Quality Index (PSQI) 
and Epworth Sleepiness Scale (ESS)12,13. In addition, a subcohort at UM underwent a 
polysomnography to obtain information on total sleeping time (TST), Rapid Eye Movement 
(REM) sleep, slow wave sleep (SWS), wake after sleep onset (WASO), and quality of sleep (QS, 
SWS+REM)/TST). 
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4 Primary and secondary endpoints
The primary endpoint of the PREVIEW study in adolescents was change in HOMA-IR, 
corrected for puberty, after two years of intervention. Secondary endpoints were changes 
in HbA1c, BMI z-score, FM%, FMI, cardiovascular risk factors, inflammation and liver 
transaminases, and their associations with HOMA-IR change. Further endpoints included 
changes in PA and dietary restraint. In a subgroup changes in sleep architecture and their 
associations with HOMA-IR changes were studied. 
5 Data management
Data was stored in a central project database at the University of Copenhagen19. 
Anthropometric data was entered in case report forms in the online Open Clinica database. 
Questionnaires were entered in an Questionnaire Delivery Platform (QDP, NetUnion, 
Lausanne, Switzerland) or on paper after which the questionnaire was entered in QDP 
by PREVIEW researchers. Laboratory analyses were centrally performed and entered in a 
database at UM. Accelerometry data was collected at each site and analysed at SU. Data 
cleaning was performed by independent researchers at UM and aberrant values checked 
with a paediatrician.
6 Statistical analyses
6.1 Power calculation
Considering an estimated 25% drop-out, α of 0.05 and sample size of 100, a power of 0.96 
will be achieved (G*power, Universität Düsseldorf, Düsseldorf, Germany).
6.2 Analysis for baseline results
Baseline analyses in this paper were performed using the Statistical Package for the Social 
Sciences (SPSS) 24.0 (SPSS Inc, IBM Corporation, Armonk, NY, USA). Normal distribution was 
tested with the Shapiro-Wilk test and outliers were assessed and removed if necessary. 
ANOVA or Mann-Whitney-U test were used to assess differences in baseline characteristics 
between the two intervention groups, depending on normality of data. Associations 
between parameters were assessed with Pearson’s or Spearman’s correlation coefficients, 
which were corrected for relevant variables. A p-value <0.05 was considered statistically 
significant. 
Drop-out analyses, consisting of ANOVA or Mann-Whitney-U tests depending on 
normality of data, were performed to assess differences in anthropometrics, body com-
position and glucose metabolism between adolescents that did and did not complete 
questionnaires. 
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6.3 Future analyses for comparing the two intervention groups
For comparing the two intervention groups in future analyses, the two dietary arms will 
be compared using intention-to-treat analyses. Changes over time in HOMA-IR and other 
outcome measures will be assessed using repeated measurement analyses, and multiple 
regression analyses will be used to identify the contribution of different variables to HOMA-
IR change. For comparisons between the two groups, a factorial ANOVA with repeated 
measures will be used.
7 Ethical considerations
Medical Ethics Committees at each study site approved the PREVIEW study protocol and 
amendments. The study protocol was compliant with the Declaration of Helsinki and the 
ICH-GCP and registered on ClinicalTrials.gov (number NCT01777893). All study data was 
handled according to local regulations and the European Directive 95/46/CE. Research 
staff was GCP trained and UM staff was also trained in clinical paediatrics. Signed informed 
consent was obtained of parents and adolescents ≥12 years. 
DISCUSSION POINTS 
1  HOMA-IR was significantly higher in pubertal adolescents with morbid obesity 
compared to prepubertal adolescents with morbid obesity and all adolescents with 
overweight
We found that pubertal adolescents with morbid obesity had significantly higher HOMA-
IR levels than pubertal adolescents with overweight/obesity, identifying this group of 
adolescents as having a particularly high risk for T2DM development (Supplementary Figure 
3.1). This finding confirms earlier studies in which especially adolescents with morbid obesity 
showed high HOMA-IR at the end of puberty, instead of decreasing HOMA-IR towards the 
end of puberty as is the pattern in lean adolescents4,17. Mechanistically, elevated IR in subjects 
with morbid obesity might be a direct result of increased ectopic fat storage, which results in 
increased free fatty acid (FFA) concentrations and inflammation, leading to reduced muscle 
glucose uptake and thereby maintenance of peripheral IR4. High HOMA-IR in late puberty 
in adolescents with morbid obesity in this and previous studies, demonstrates that these 
adolescents especially are at high risk for β-cell exhaustion and T2DM development3,4,17. 
2  Fasting blood glucose concentrations were negatively associated with Baecke Sport
Baecke Sport and fasting blood glucose concentrations were inversely related, independently 
of sex, Tanner stage, BMI z-score and FM% (Supplementary Table 3.3). This finding might 
suggest that higher self-reported PA was associated with better regulated blood glucose 
concentrations. During exercise, metabolism shifts from predominant reliance on free fatty 
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acids (FFA) in rest to carbohydrate oxidation. As glycogen stores in the muscle become 
deplete, insulin sensitivity of the muscle increases, thereby increasing fasting glucose uptake 
and muscle insulin sensitivity. Additionally, muscle contractions increase GLUT4 transporter 
protein translocation and thus enhanced muscle glucose uptake, even in IR12,13. However, 
glucose metabolism was not associated with accelerometry counts, and Baecke scores and 
accelerometry data were not interrelated. 
3  Fasting blood glucose concentrations were positively related to sleepiness
The positive association between fasting blood glucose concentrations and ESS daytime 
sleepiness scores indicates that adolescents that experienced more sleepiness had higher 
fasting blood glucose concentrations (Supplementary Table 3.3). This is consistent with an 
earlier study20. Obesity is associated with higher apnoea-hypopnea indexes and intermittent 
nocturnal hypoxemia, both of which are independently associated with sleepiness and IR. In 
addition, sleeping time declines during puberty. However, it should be noted that all fasting 
blood glucose concentrations in this cohort were within normal ranges. 
4 Missing data regarding lifestyle factors
For some questionnaires and food records, numbers of returned data are relatively low. 
This is caused by refusal to answer questionnaires, incomplete questionnaires or because 
questionnaires were not returned. For all questionnaires, a certain number of items have 
to be filled in to correctly calculate scores, incomplete questionnaires therefore sometimes 
led to exclusion of the questionnaire for that child for analyses. Food records were often 
incompletely filled out or not returned at all. Food records ≥2 days of adequate food 
composition were used for analyses, food records with fewer days or severely inadequately 
filled out records were excluded for this study.
Drop-out analyses found no differences in adolescents that completed the PA and TFEQ 
questionnaires and adolescents that did not complete these questionnaires (Supplementary 
Table 3.4). Adolescents that answered sleep questionnaires had a significantly higher FFMI 
and fasting glucose concentrations and lower FM% than adolescents that did not return the 
sleep questionnaires. These factors will be taken into consideration in future analyses. 
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Supplementary tables and figures 
Supplementary table 3.1 Description of the PREVIEW intervention in adolescents
 HP MP
Dietary 
intervention
High protein (25 En%)
Moderate carbohydrate (45 En%)
Low GI (≤50) diet
Food items with increased usea: 
• Whole-grain cereals with low GI
• Pasta
• Low-fat dairy products
• Poultry
• Fish
• Legumes 
Moderate protein (15 En%)
Higher carbohydrate (55 En%)
moderate GI (≥56) diet
Food items with increased usea: 
•  Whole-grain cereals with moderate/
high GI (e.g. bread)
•  Potatoes, sweet potatoes, couscous, rice
•  Bananas
Physical 
activity 
interventionb
High-intensity physical activity: ≥75 minutes per week of high intensity physical 
activity, such as vigorous bicycling, jogging >8km/h and strenuous ball games and 
moderate-intensity physical activity: ≥150 minutes per week of moderate intensity 
activity, such as moderate bicycling, brisk walking (4-6km/h), and swimming 
GI = Glycaemic Index; HP = high-protein low-GI diet; MP = moderate-protein moderate-GI diet; En% = Energy percentage. 
a. Increased use relative to the other intervention group
b. Both groups received instructions for both PA intensities
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Supplementary table 3.2: Overview of data collection at different Clinical Investigation Days 
(CID) in the PREVIEW adolescents intervention
Data collection Assessment time-points (week)
0
CID1
8
CID2
26
CID3
52
CID4
78
CID5
104
CID6
Randomization X
General information
Age (y)
Tanner G/M stage
X X X X X X
Anthropometric characteristics
• Body weight (kg)
• Height (cm)
• Sitting height (subgroup)
• BMI (kg/m2)
• BMI z-score (SD)
• IOTF class 
• Waist circumference (cm)
• Hip circumference (cm)
• Thigh circumference (cm)
X X X X X X
Body composition
• Fat free mass index (FFMI, kg/m2)
• Fat mass index (FMI, kg/m2)
• Fat mass (%)
X X X X X X
Parameters of glucose metabolism 
• Fasting glucose, fasting insulin, HOMA-IR, HbA1c, 
C-peptide
X X X X X X
Lipids
• Total cholesterol, HDL-cholesterol, LDL-cholesterol, TAG
X X X X X X
Inflammation
• CRP
X X X X X X
Liver parameters
• AST, ALT
X X X X X X
Blood pressure and heart rate
• Systolic and diastolic blood pressure
• Heart rate
X X X X X X
Physical activity
• 7-day accelerometry
• Baecke questionnaire
X X X X X
Food intake behaviour
• 4-day food record
• TFEQ questionnaire
• VAS appetite scores
X X X X
Protein intake
• Urinary nitrogen (subgroup)
X X X
Sleep assessment 
• Polysomnography (subgroup)
X X X
Sleep questionnaires 
• PSQI sleep questionnaire
• ESS Sleep questionnaire
X X X X X
CID = Clinical Investigation Day; Tanner G/M stage = Tanner stage for genitals (boys8) or mammae (girls9); BMI = Body Mass Index; 
IOTF = International Obesity Task Force overweight class1; HOMA-IR = Homeostatic Model Assessment of Insulin Resistance2; HDL-
cholesterol = high density lipoprotein-cholesterol; LDL-cholesterol = low density lipoprotein-cholesterol; TAG = triacylglycerides; 
CRP = c-reactive protein; AST = aspartate transaminase; ALT = alanine transaminase; TFEQ = Three Factor Eating Questionnaire10; 
PSQI = Pittsburgh Sleep Quality Index4; ESS = Epworth Sleep Scale questionnaire5.
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Supplementary table 3.3: Correlation coefficients for physical activity, food intake behaviour, 
and sleep with parameters of glucose metabolism, corrected for sex, Tanner stage, BMI z-score, 
and FM%
  Glucose 
(mmol/L)
Insulin 
(pmol/L)
HOMA-IR HbA1c 
(mmol/l)
C-peptide 
(nmol/L)
Physical activity
Baecke Work r 0.190 0.069 0.114 0.242 0.094
Baecke Sport r -0.223* -0.105 -0.157 -0.142 -0.140
Baecke Leisure r -0.118 -0.028 0.173 0.032 -0.046
Baecke total score r -0.096 0.059 0.073 0.068 -0.139
Counts (cpm) r -0.068 -0.088 -0.083 0.231 0.157
Food intake behaviour
TFEQ cognitive restraint 
of hunger
r -0.164 0.018 -0.067 0.010 -0.105
TFEQ disinhibition r 0.072 -0.112 -0.071 0.019 -0.150
TFEQ hunger r -0.039 0.024 0.015 0.149 -0.037
Sleep questionnaires
PSQI r -0.162 -0.216 -0.209 -0.361 -0.202
ESS r 0.280* -0.002 0.020 0.258 0.041
Sleep assessment
TST (min) r -0,065 0,082 0,115 -0,02 -0,063
SWS (min) r -0,093 -0,004 -0,026 -0,089 -0,050
REM (min) r -0,171 -0,031 -0,047 -0,002 -0,171
SE (%) r -0,039 0,047 0,103 0,037 0,042
QS (%) r -0,163 0,046 -0,014 -0,075 -0,024
WASO (min) r 0,034 -0,139 -0,163 -0,164 -0,179
HOMA-IR = Homeostatic Model Assessment of Insulin Resistance10; TFEQ = Three Factor Eating Questionnaire11; PSQI = Pittsburgh 
Sleep Quality Index12; ESS = Epworth Sleep Scale questionnaire13; TST = total sleep time; REM = Rapid Eye Movement Sleep; SWS = 
Slow Wave Sleep; WASO = Wake after Sleep Onset; QS = Quality of Sleep ((REM + SWS) / TST). * p<0.05
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Supplementary figure 3.3: HOMA-IR for different puberty stages
HOMA-IR at different puberty stages in adolescents with HOMA-IR ≥2.0 (n=94), presented as mean±SD.
A) HOMA-IR in adolescents in different Tanner stages. Mean HOMA-IR was not different between adolescents in 
the different puberty stages. B) HOMA-IR in prepubertal and pubertal boys and girls. No differences in HOMA-
IR were found between the groups. C) HOMA-IR in prepubertal and pubertal adolescents with overweight/
obesity and morbid obesity. Pubertal adolescents with morbid obesity had significant higher mean HOMA-
IR compared to the adolescents in the other groups. HOMA-IR = Homeostatic Model Assessment of Insulin 
Resistance10. Prepubertal: Tanner G/M stage 1-2. Pubertal: Tanner G/M stage 3-5. * p<0.01.
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ABSTRACT
Background
Pubertal insulin resistance (IR) is associated with increased risk of type 2 diabetes mellitus 
development in adolescents with overweight/obesity. 
Background
The PREVIEW study was a randomized parallel trial assessing the effect of increasing dietary 
protein intake on IR in adolescents with overweight/obesity. It was hypothesized that 
increase of protein intake would result in a relatively lower IR. 
Methods
Adolescents with overweight/obesity and IR from the Netherlands, UK and Spain were 
randomized into a moderate-protein-moderate-GI (15/55/30En% protein/carbohydrate/
fat, GI≥56) or high-protein-low-GI (25/45/30En% protein/carbohydrate/fat, GI<50) diet. 
Anthropometric and cardiometabolic parameters, puberty, dietary intake and physical 
activity (PA) were measured and related to changes in BMI z-score and HOMA-IR. 
Results
126 adolescents were included in this study (13.6±2.2y, BMI z-score 3.04±0.66, HOMA-IR 
3.48±2.28, HP n=68, MP n=58). Changes in protein intake were not significantly different 
between timepoints or intervention groups and no effects of the intervention on IR were 
observed. Post-hoc, BMI z-score decreased after 1y (-0.16(95%CI -0.24,-0.07), p<0.001) and 
2y (-0.19(-0.36,-0.02), p=0.028). HOMA-IR was positively associated with BMI z-score change 
(B=2.23(2.07;2.40), p<0.001). Cognitive restraint was increased (2.1(0.7,3.5), p=0.003); BMI 
z-score change was inversely related to dietary restraint change (B=-0.03(-0.05,-0.01), 
p=0.045), and positively to susceptibility to hunger (B=0.03(0.01;0.06), p=0.013).
Conclusions
The PREVIEW study observed no effect of a high-protein low-GI diet on insulin resistance 
in adolescents with overweight/obesity and insulin resistance because of lack of feasibility. 
Post-hoc, stabilization pubertal insulin resistance was associated with BMI z-score decrease. 
BMI z-score decrease was associated with increased dietary restraint.  
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INTRODUCTION 
The prevalence of childhood obesity has rapidly increased over the last decades and, 
without adequate management, is expected to rise to approximately 268 million children 
globally in 2025 with a subsequent increase in obesity-related comorbidities1-3. During 
puberty, transient insulin resistance (IR) is a common physiological phenomenon4-9. IR is 
defined as reduced ability of insulin to increase glucose uptake and utilization, resulting 
in a compensatory increase in insulin secretion to maintain normal blood glucose 
concentrations7. A transient increase in IR during puberty is considered to be a physiological 
phenomenon of growth, but especially adolescents with obesity show an exaggerated 
increase in IR. In addition, in adolescents with obesity, IR does not appear to decrease at the 
end of puberty as is observed in lean adolescents5,6,9. Particularly adolescents with obesity 
therefore may have increased risk for β-cell exhaustion and development of T2DM even 
at a young age5. Furthermore, it has been shown that both obesity and IR are associated 
with development of cardiovascular disease (CVD) e.g. dyslipidaemia and hypertension, and 
non-alcoholic fatty liver disease (NAFLD) even in childhood8,10. Moreover, insulin resistant 
adolescents were less successful in decreasing BMI z-score in response to interventions 
than adolescents that were not insulin resistant4,11. Thus, particularly in adolescents with 
overweight or obesity and increased IR, interventions should focus on decreasing BMI 
z-score and assess whether the increase of HOMA-IR during pubertal IR can be attenuated. 
Recommendations of the US Preventive Services Task Force and others include 
comprehensive, multidisciplinary lifestyle interventions for treatment of obesity in children, 
although there is no consensus on the most efficient and effective type of dietary and 
physical activity strategy11,12. Earlier observations reported that a relative increase of dietary 
protein, thereby reducing fat and carbohydrate intake, led to a significant reduction in 
obesity11-18. Two studies showed that a higher-protein diet reduced IR significantly12,17. 
One study that combined increased protein intake with decreased glycaemic index (GI) 
observed a significant reduction in percentage of children with overweight/obesity in 
this group compared to control diets17. Proposed underlying mechanisms for these effects 
might be the ability of protein to increase satiety, thermogenesis and fat-oxidation, thus 
reducing fat mass while maintaining fat free mass during energy restriction19. Lowering GI 
in diets has been suggested to promote satiety and reduces hunger, although few long-
term studies have been performed in adolescents to confirm these effects20. In addition, 
physical activity (PA) alone and in combination with a dietary intervention, has been shown 
to change body composition by increasing fat free mass, and reducing fat mass, fasting 
glucose concentrations and IR21-23. Especially lifestyle interventions combining diet, PA, 
and behavioural strategies have been effective in decreasing obesity and reducing IR and 
cardiovascular risk parameters in youths22. Studies researching the effects of combined 
lifestyle intervention in adolescents with overweight/obesity and increased IR are scarce. 
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Thus far three large community studies have been performed aiming to decrease insulin 
resistance parameters in adolescents with overweight/obesity, of which two showed 
significant favourable changes in glucose metabolism abnormalities and BMI z-score 
after short-term, intensive intervention24-26. Lifestyle interventions in adolescents in free-
living conditions often report problems with participants meeting dietary targets and 
maintaining physical activity (PA) levels26,27. Specifically studies aiming to increase relative 
protein intake reported difficulties in dietary compliance and participants meeting protein 
targets, and were mostly conducted under controlled settings (e.g. meal observation in 
in-centre settings)11,13-18. Therefore, the effect of a lifestyle intervention combining a high 
protein intake, low GI diet in adolescents with overweight/obesity and increased IR, should 
be addressed in real-life settings.  
The PREVention of diabetes through lifestyle Intervention and population studies in 
Europe and around the World (PREVIEW) study in adolescents was a randomized clinical 
study of the effect of a high-protein low-GI diet in adolescents with overweight or obesity 
and on IR. It was hypothesized that a high-protein low-GI diet would be superior in reducing 
IR compared to a medium-protein medium-GI diet, in insulin resistant adolescents with 
overweight or obesity.
MATERIALS AND METHODS
1 Study design
The PREVIEW study in adolescents was a multicentre, 104-week parallel-group, gender-
stratified block-randomized (10:10) trial between December 2013 and December 2018, as 
described previously28. The first eight weeks aimed at weight stabilization during growth. 
All participants received sample menus based on their estimated energy requirements, 
consisting of 15/55/30 energy percent (En%) protein/carbohydrate/fat29. In the second 
phase adolescents were randomized into a moderate-protein moderate-GI (MP) group or 
a high-protein low-GI (HP). Randomization was stratified by sex, age and centre in blocks of 
10 using a computerized randomization tool. The MP group received a sample menu with 
a macronutrient composition of 15/55/30 En% protein/carbohydrate/fat and a GI≥56. The 
HP group received a sample menu with a target macronutrient composition of 25/45/30 
En% protein/carbohydrate/fat and a GI≤50. All menus were tailored to the participant’s 
estimated energy requirements. Upon request, further personalized tips were given taking 
e.g. cultural traditions into account. Participants were instructed to increase PA (in organized 
sports and daily movement) and received booklets with exercises for high and medium 
intensity PA. Due to the personalized instructions for participants during the measurement 
meetings, participants and research staff could not be blinded. The study was designed 
as a 2y randomized clinical trial. The study protocol was approved by local Medical Ethics 
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Committees at all study sites. The study was compliant with the Declaration of Helsinki and 
ICH-GCP and published on ClinicalTrials.gov (no. NCT01777893).
2 Participants
Adolescents were recruited from three study sites (Maastricht University, the Netherlands; 
University of Navarra, Spain and Swansea University, United Kingdom) between December 
2013 and December 2016 by ED, NS and SNC. Inclusion criteria were overweight/obesity 
(BMI z-score >1.0 SDS), increased IR (defined as Homeostatic Model Assessment of Insulin 
Resistance (HOMA-IR) > 2.0 for adolescents at Tanner G/M stages ≥3 or any HOMA-IR for 
adolescents at Tanner stages 1-2) and signed informed consent from both parents and 
adolescents ≥12 years28. Exclusion criteria included medical conditions or use of medication 
that might influence study outcomes (e.g. T2DM, bariatric surgery, and use of metformin) or 
compromise study adherence (e.g. severe food intolerances or musculoskeletal diseases).
3 Measurements 
3.1 Anthropometric characteristics and body composition
Height and weight were measured at baseline, after 1 and 2y while participants were 
barefoot, wearing only underwear and in a fasted state, and subsequently BMI was cal-
culated. Because BMI in adolescents is not a representative measure of obesity status due 
to periods of growth, age- and gender-adjusted BMI z-scores were calculated (TNO Growth 
Calculator, TNO, Den Haag, the Netherlands)30. Body composition was measured with air-
displacement plethysmography (at Maastricht University: BodPod, Life Measurement 
Instruments, Concord, CA, USA) using the Lohman algorithm, bio-impedance measurements 
(at University of Navarra: BIA, Tanita SC-330. Tanita Corp, Tokyo, Japan), or dual energy x-ray 
absorptiometry (at Swansea University: DEXA, Stratos dR, Medimaging UK)31. Pubertal stage 
was determined with the Tanner genital (boys) or mammary (girls) scale32,33.
3.2  Glucose metabolism, lipid spectrum, inflammation, liver parameters and blood pressure
Blood samples were obtained by venepuncture after an overnight fast by trained 
healthcare professionals. All samples were centrifuged and frozen locally, and subsequently 
analysed at the laboratory for clinical chemistry at Maastricht University. Concentrations of 
fasting blood glucose, total cholesterol, high-density lipoprotein (HDL) cholesterol, low-
density lipoprotein (LDL) cholesterol, triglycerides (TAG), C-reactive protein (CRP), alanine 
transaminase (ALT), and aspartate transaminase (AST) were analysed with the COBAS 
800 modular analyser (Roche, Woerden, the Netherlands). Fasting insulin and HbA1c 
concentrations were determined using the fully automated HPLC Variant II 155 (Bio-Rad 
Laboratories, Veenendaal, the Netherlands) and C-peptide concentrations with the Immulite 
XPI (Siemens, Eindhoven, the Netherlands). An index for insulin resistance was calculated 
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using HOMA-IR (fasting glucose concentration (mmol/L) * fasting insulin concentration (mU/L) / 
22.5)34. Blood pressure and heart rate were measured while seated, on the right upper arm 
using a matching cuff size (Mobil-O-Graph, I.E.M., GmbH, Stolberg, Germany or Omron M6 
comfort HEM-7221-E8, Omron Corp., Kyoto, Japan). 
3.3 Compliance: food intake and physical activity 
Compliance to the dietary instructions was assessed using four-day food records, provided 
at each measurement visit, and which were subsequently analysed for energy intake, 
macronutrient composition including protein content (both g/d as En%), fibre content, GI 
and glycaemic load (GL) using the Eetmeter food diary & analysis tool (Voedingscentrum, 
Den Haag, the Netherlands). In addition, participants answered the Three Factor Eating 
Questionnaire (TFEQ), consisting of the three factors cognitive restraint of eating, disinhibition 
and hunger35. To assess underreporting, reported total energy intake was compared to 
the daily energy requirements for children and adolescents using the WHO formula to 
assess underreporting (total energy expenditure (MJ/day)=1.298+0.265kg–0.0011kg2 (boys) 
or 1.102+0.273kg–0.0019kg2 (girls))29. PA was assessed with 7-day accelerometry (Actigraph 
GT3X accelerometer, Actigraph Corp, USA) and the Baecke Questionnaire36. Participants 
were instructed to wear the accelerometer on the right hip during 7 full days and nights, 
only removing the accelerometer during showering, swimming or contact sports. Wear 
time validation was performed with a minimum of 4 days >10 hours including 1 weekend-
day. Epochs were measured with the length of 10 seconds and Evenson cut-off points were 
used to assess moderate, light and vigorous activity37,38. 
4 Statistical analyses
Power calculations were performed using G*power (Dusseldorf University, Dusseldorf, 
Germany) and adjusted for an estimated 25% drop-out. With an α of 0.05, effect size of 0.37 
for HOMA-IR and sample size of 100, a power of 0.96 could be achieved28. To remain sufficient 
power for analyses at 1 and 2y despite drop-out, intention-to-treat analyses were performed 
on the complete dataset after multiple imputation. For this 50 datasets were created (MICE 
Package in R, v3.2.3, Vienna, Austria). The maximum number of iterations was set to 20, 
where convergence was checked by inspecting the trace lines. The following predictors 
were used to impute missing values: gender, age, Tanner stage and BMI z-score at baseline 
and at 1 or 2y, and the baseline value of the imputed variable. For blood pressure, height 
at baseline and at 1 or 2y were added as predictors. Estimated effect changes over time in 
the intention-to-treat analyses were pooled from the multiple imputed datasets, analysed 
using factorial ANOVA’s with repeated measures and presented as mean (95% confidence 
interval). As this was an exploratory study, no corrections for multiple comparisons have 
been made. 
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Measured data from the adolescents who stayed in the study were analysed for changes 
over time, using ANOVA repeated measures. All statistical analyses were performed using 
IBM SPSS Statistics for Windows version 24 (IBM Corp., Armonk, NY, USA). For differences 
between the two intervention groups at baseline and comparing those who dropped out 
to completers, T-tests and factorial ANOVA and Mann-Whitney-U test were used. Factorial 
ANOVA’s with repeated measures were used for assessing differences over time in the 
completers group. Post-hoc associations for dietary and PA variables with changes in BMI 
z-score were performed using multiple linear regression analyses, with change in Tanner 
stage as a covariate. Post hoc associations for dietary and PA variables with HOMA-IR were 
performed with multiple linear regression analyses, with change in BMI z-score and Tanner 
stage as covariates. A two-sided p-value smaller than 0.05 was considered statistically 
significant. 
RESULTS
Characteristics of participants
In total, 126 adolescents were included in the baseline analyses between December 2013 
and December 2016, as described previously26. After 1y of intervention 83 adolescents (66%) 
were still participating, and after 2y 49 participants (39%) completed the study (Figure 4.1). 
Reasons for drop-out were discontinuation of the study due to personal reasons (n=4) and 
loss to follow-up (n=77). Baseline characteristics of adolescents who dropped out were 
not significantly different from adolescents that remained in the study. No serious adverse 
events (SAE) were reported. 
Baseline descriptives of the HP and MP group are presented in Tables 4.1A+B. No sig-
nificant differences between the groups were observed in gender, BMI z-score, HOMA-IR or 
other cardiometabolic or lifestyle parameters. Baseline descriptives of the adolescents that 
completed analyses at 1y and 2y are presented in Tables 4.2A+B. Here, too, no significant 
differences between the groups were observed in baseline demographics, cardiovascular 
or lifestyle variables. 
Compliance to dietary instructions
Absolute and relative reported protein intake, as a percentage of total energy intake, were 
not significantly changed after 1y and 2y of intervention in the HP and MP group (Tables 
4.1A & 4.2A). No significant differences were observed between the two intervention groups 
regarding dietary intake.
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341 Assessed for eligibility  
215 Excluded   
   199 did not meet inclusion criteria 
or declined to participate  
   2 HOMA-IR too low participate  
   7 discontinued participation  
   2 exclusion due to medication  
   5 no body composition available 
24 Drop-out at 1 year of intervention (35%) 
     4 discontinuation due to personal reasons 
     20 lost to follow-up 
68 Allocated to HPLGI intervention  
     68 Received allocated intervention  
19 Drop-out at 1 year of intervention (33%) 
     19 lost to follow up 
58 Allocated to MPMGI intervention  
     58 Received allocated intervention  
68 Included in estimated effect change analyses  
     65% (44/68) data available 
     35% (24/68) drop-out 
 
44 Included in 1y follow-up analyses  
58 Included in estimated effect change analyses  
     67% (39/58) data available 
     33% (19/58) drop-out 
 
39 Included in 1y follow-up analyses  
68 Included in estimated effect change 
analyses  
     37% (25/68) data available 
     63% (43/68) drop-out 
 
25 Completed the 2y study 
58 Included in estimated effect change 
analyses  
     41% (24/58) data available 
     59% (34/58) drop-out 
 
24 Completed the 2y study  
 
2y analysis 
126 Included for analyses 
Figure 4.1: Study flowchart. 
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Effects of the dietary intervention on IR, metabolic and anthropometric parameters
No significant differences were observed between the two intervention groups regarding 
insulin resistance, parameters of glucose metabolism, lipid metabolism, inflammation, liver 
enzymes, anthropometric characteristics, or lifestyle factors at any timepoint. 
Post-hoc observations
Regarding dietary observations, the total energy requirements for adolescents with cor-
responding ages, heights and weights to the study participants is 10.7-15.7 MJ/d for girls 
and boys (WHO-formula), the reported total energy intake was 5.9-7.0 MJ/d in this study27. 
Intention-to-treat analyses showed a significant decrease in GI and GL after 2y, but not 1y, 
of study participation (Table 4.1A). Cognitive dietary restraint scores on the TFEQ increased 
significantly after 1y in the completers subset, and after 2y in the ITT analyses (Tables 4.1A & 
4.2A). 
With respect to physical activity (PA), expressed as accelerometry counts per minute, 
and minutes spent in moderate, vigorous and moderate-to-vigorous, a significant increase 
at 1 and 2y, was observed, while sedentary time decreased (Tables 4.1A & 2A).
Considering anthropometric changes, mean age- and sex-corrected BMI z-score was 
significantly reduced, while pubertal stage, height, weight, BMI, fat free mass and fat mass 
increased (Tables 4.1B & 4.2B).
Regarding insulin resistance and further metabolic changes, fasting blood glucose 
concentration increased. And at 2y, but not after 1y, HOMA-IR was significantly higher than 
at baseline. After 1y mean heart rate was decreased. Differently from the set of adolescents 
that completed the intervention, the intention-to-treat analyses showed a significant 
increase in ALT concentration. 
Post-hoc associations with changes in BMI z-score 
Change in BMI z-score was negatively associated with change in cognitive restraint and 
positively with susceptibility to hunger on the TFEQ, after correcting for change in Tanner 
stage (Table 4.3). HOMA-IR was positively related to change in GI (Table 4.3). Change in 
BMI z-score was positively related to change in HOMA-IR after correcting for changes in 
Tanner G/M stage and BMI z-score at baseline (Figure 4.2). Other lifestyle variables were 
not significantly associated with change in BMI z-score or HOMA-IR, nor with changes in 
anthropometric characteristics or cardiovascular health parameters, after correcting for 
relevant confounders.
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TABLE 4.1A: Estimated effect changes in food intake, physical activity and sleep parameters after 
1 and 2 years of intervention
Baseline
Estimated effect changes  
after 1y (after multiple imputation)
Estimated effect changes 
after 2y (after multiple imputation)
Whole group
(n=126)
HP 
(n=68)
MP 
(n=58)
Whole group  
(n=126)
HP 
(n=68)
MP 
(n=58)
Whole group  
(n=126)
HP 
(n=68)
MP 
(n=58)
Outcome mean ± SD mean ± SD mean ± SD Δ (95% CI) Δ (95% CI) Δ (95% CI) Δ (95% CI) Δ (95% CI) Δ (95% CI)
Food intake
Glycaemic Index 52.4 ± 8.2 50.9 ± 7.7 54.3 ± 8.7 -1.2 (-4.7, 2.3) 0 (-4.6, 4.6) -2.7 (-7.9, 2.6) -2.0 (-3.7, -0.3)* -1.4 (-3.5, 0.6) -2.8 (-5.4, -0.2)*
Glycaemic Load 97.9 ± 35.4 93.4 ± 30.9 103.0 ± 32.8 -13.6 (-27.1, 0.0) -8.2 (-24.7, 8.2) -20.3 (-41.8, 1.1) -10.1 (-19.4, -0.8)* -6.8 (-17.2, 3.7) -14.5 (-30.1, 1.0)
Energy intake (MJ/d) 7.0 ± 2.0 6.7 ± 1.6 7.3 ± 2.3 -1.0 (-1.6, -0.4)** -0.9 (-1.7, -0.1)* -1.2 (-2.1, -0.3)* -0.2 (-0.6, 0.2) 0.0 (-0.5, 0.5) -0.6 (-1.6, 0.1)
Protein (g/d) 71.0 ± 18.2 70.0 ± 19.2 70.9 ± 17.4 -5.3 (-10.7, 0.2) -6.0 (-13.7, -1.8) -4.4 (-11.7, 2.8) -2.8 (-6.8, 1.1) -1.7 (-6.5, 3.0) -4.3 (-10.9, 2.2)
Protein (En%) 17.2 ± 3.0 17.5 ± 2.4 16.9 ± 3.7 1.8 (-0.2, 3.9) 1.8 (-1.1, 4.7) 1.8 (-0.7, 4.4) -0.2 (-1.4, 1.1) -0.5 (-2.2, 1.2) 0.3 (-1.7, 2.2)
Fat (g/d) 67.8 ± 26.1 65.9 ± 23.5 70.2 ± 29.3 -10.7 (-19.1, -2.4)* -9.4 (-20.3, 1.5) -12.4 (-25.0, 0.1) 0.1 (-5.1, 5.2) 2.3 (-3.4, 8.1) -2.9 (-11.2, 5.3)
Fat (En%) 35.7 ± 7.4 35.9 ± 7.8 35.4 ± 6.9 0.8 (-4.6, 6.2) 0.8 (-6.6, 8.2) 0.8 (-6.2, 7.8) 1.3 (-1.8, 4.4) 1.4 (-2.5, 5.2) 1.2 (-3.4, 5.9)
Carbohydrate (g/d) 187.2 ± 60.7 176.3 ± 46.0 200.9 ± 74.2 -29.1 (-49.4, -8.7)** -25.2 (-48.8, -1.6) -34.0 (-68.3, 0.4) -10.1 (-24.6, 4.4) -4.0 (-21.1, 13.2) -18.4 (-41.3, 4.5)
Carbohydrate (En%) 45.1 ± 7.1 44.7 ± 7.8 45.6 ± 6.1 0.9 (-5.1, 6.8) 0.9 (-7.0, 8.9) 0.8 (-6.7, 8.3) -0.5 (-4.4, 3.5) -0.8 (-5.7, 4.1) 0.0 (-5.9, 6.0)
Fibre (g/d) 14.0 ± 5.5 13.9 ± 5.0 14.1 ± 6.2 0.3 (-1.4, 1.9) 1.0 (-1.1, 3.2) -0.7 (-2.9, 1.4) 0.1 (-1.7, 1.9) -0.1 (-2.4, 2.1) 0.4 (-2.5, 3.3)
Food intake parameters
TFEQ cognitive restraint of eating 11.0 ± 3.8 10.6 ± 3.6 11.5 ± 4.1 0.9 (-0.5, 2.3) 1.2 (-0.6, 3.0) 0.6 (-1.5, 2.6) 2.1 (0.7, 3.5)** 2.4 (0.6, 4.1)** 1.8 (-0.3, 3.9)
TFEQ disinhibition 6.2 ± 3.3 6.7 ± 3.5 5.4 ± 3.0 0.2 (-0.8, 1.2) -0.1 (-1.5, 1.3) 0.6 (-0.9, 2.0) 1.5 (-0.2, 3.2) 0.7 (-1.4, 2.7) 2.7 (0.3, 5.1)*
TFEQ hunger 5.4 ± 3.3 5.8 ± 3.7 4.9 ± 2.5 -0.5 (-2.0, 0.9) -1.0 (-3.1, 1.0 0.1 (-1.5, 1.8) 1.4 (-0.5, 3.4) 0.8 (-1.5, 3.1) 2.3 (-0.4, 5.0)
Physical activity parameters
Baecke School 2.5 ± 0.4 2.4 ± 0.3 2.6 ± 0.4 0.0 (-0.1, 0.1) 0.1 (0.0, 0.2) -0.1 (-0.2, 0.1) -0.1 (-0.3, 0.0) -0.0 (-0.2, 0.1) -0.2 (-0.4, -0.0)*
Baecke Sport 2.8 ± 0.5 2.7 ± 0.5 2.8 ± 0.5 0.1 (-0.1, 0.2) 0.1 (-0.1, 0.3) 0.1 (-0.1, 0.3) -0.1 (-0.3, 0.1) -0.1 (-0.3, 0.1) -0.2 (-0.4, 0.1)
Baecke Leisure 2.8 ± 0.7 2.9 ± 0.6 2.8 ± 0.7 0.0 (-0.1, 0.2) 0.0 (-0.2, 0.2) 0.0 (-0.2, 0.3) -0.0 (-0.2, 0.1) -0.1 (-0.3, 0.2) -0.0 (-0.3, 0.2)
Baecke total score 8.1 ± 1.0 8.0 ± 1.0 8.2 ± 1.1 0.1 (-0.1, 0.4) 0.2 (-0.2, 0.5) 0.1 (-0.3, 0.4) -0.3 (-0.5, -0.0) -0.1 (-0.5, 0.2) -0.4 (-0.8, -0.0)
Accelerometry counts (kcpd) 297.5 ± 101.5 309.4 ± 99.9 279.4 ± 103.1 33.0 (5.3, 60.7)** 27.7 (-10.5, 65.9) 39.5 (-0.3, 79.4) 29.6 (-11.8, 71.1) 4.2 (-46.4, 54.8) 60.9 (5.7, 116.0)*
Accelerometry counts (cpm) 306.7 ± 108.5 316.6 ± 101.9 291.0 ± 118.7 106.5 (71.2, 141.7)** 104.2 (60.2, 148.3)** 109.2 (58.3, 160.1)** 76.5 (33.6, 119.5)** 51.7 (1.1, 102.3)* 107.1 (48.2, 166.0)**
Sedentary behaviour (min/d) 631.6 ± 114.4 617.0 ± 105.8 653.4 ± 125.0 -177.2 (-211.4, -143.0)** -165.3 (-210.1,-120.6)** -191.8 (-241.7,-141.9)** -156.7 (-190.1, -123.3)** -138.9 (-180.7, -97.1)** -178.5 (-224.1,-132.9)**
Light PA (min/d) 323.7 ± 71.0 335.0 ± 7.8 306.7 ± 69.1 -35.7 (-58.0, -13.3)** -40.6 (69.9, -11.3)** -29.6 (-59.9, 0.8) -19.0 (-48.8, 10.9) -37.1 (-71.8, -2.4)* 3.4 (-37.9, 44.6)
Moderate PA (min/d) 21.4 ± 14.7 22.2 ± 13.3 20.3 ± 16.9 7.3 (3.9, 10.7)** 6.7 (2.3, 11.1)** 8.0 (2.8, 13.1)** 5.0 (0.1, 9.9)* 3.0 (-2.7, 8.7) 7.4 (0.8, 14.)*
Vigorous PA (min/d) 4.7 ± 5.0 4.7 ± 4.8 4.7 ± 5.4 5.3 (2.8, 7.8)** 5.7 (2.3, 9.1)** 4.8 (1.5, 8.2)** 3.3 (1.1, 5.5)** 2.8 (0.0, 5.6)* 3.8 ( 0.8, 6.9)*
Moderate-to-vigorous PA (min/d) 26.1 ± 17.5 26.9 ± 16.4 25.1 ± 19.2 12.5 (8.0, 16.9)** 12.3 (6.4, 18.2)** 12.6 (5.9, 19.4)** 8.2 (3.1, 13.4)** 5.7 (3.7, 12.1) 11.4 (4.0, 18.8)**
HP: High-Protein Low-Glycaemic Index; MP: Medium-Protein Medium-Glycaemic Index; BMI = Body Mass Index; FFM = fat free mass; FM = fat mass; 
SBP = systolic blood pressure; DBP = diastolic blood pressure; HR = heart rate; HOMA-IR = Homeostatic Model Assessment of Insulin Resistance (glucose 
(mmol/L)/ insulin (mU/L) * 22,534; HDL cholesterol = high-density lipoprotein cholesterol; LDL cholesterol = low-density lipoprotein cholesterol; TG = 
triacylglycerides; CRP = C-reactive protein; AST = aspartate aminotransferase; ALT = alanine aminotransferase; En% = percentage of total energy intake; 
TFEQ = Three Factor Eating Questionnaire35; cpd = counts per day ; cpm = counts per minute; PA = Physical Activity. Estimated effect changes are based 
upon imputated datasets. P-values are based upon comparison with baseline values. *p<0.05 ; ** p<0.01.
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TABLE 4.1A: Estimated effect changes in food intake, physical activity and sleep parameters after 
1 and 2 years of intervention
Baseline
Estimated effect changes  
after 1y (after multiple imputation)
Estimated effect changes 
after 2y (after multiple imputation)
Whole group
(n=126)
HP 
(n=68)
MP 
(n=58)
Whole group  
(n=126)
HP 
(n=68)
MP 
(n=58)
Whole group  
(n=126)
HP 
(n=68)
MP 
(n=58)
Outcome mean ± SD mean ± SD mean ± SD Δ (95% CI) Δ (95% CI) Δ (95% CI) Δ (95% CI) Δ (95% CI) Δ (95% CI)
Food intake
Glycaemic Index 52.4 ± 8.2 50.9 ± 7.7 54.3 ± 8.7 -1.2 (-4.7, 2.3) 0 (-4.6, 4.6) -2.7 (-7.9, 2.6) -2.0 (-3.7, -0.3)* -1.4 (-3.5, 0.6) -2.8 (-5.4, -0.2)*
Glycaemic Load 97.9 ± 35.4 93.4 ± 30.9 103.0 ± 32.8 -13.6 (-27.1, 0.0) -8.2 (-24.7, 8.2) -20.3 (-41.8, 1.1) -10.1 (-19.4, -0.8)* -6.8 (-17.2, 3.7) -14.5 (-30.1, 1.0)
Energy intake (MJ/d) 7.0 ± 2.0 6.7 ± 1.6 7.3 ± 2.3 -1.0 (-1.6, -0.4)** -0.9 (-1.7, -0.1)* -1.2 (-2.1, -0.3)* -0.2 (-0.6, 0.2) 0.0 (-0.5, 0.5) -0.6 (-1.6, 0.1)
Protein (g/d) 71.0 ± 18.2 70.0 ± 19.2 70.9 ± 17.4 -5.3 (-10.7, 0.2) -6.0 (-13.7, -1.8) -4.4 (-11.7, 2.8) -2.8 (-6.8, 1.1) -1.7 (-6.5, 3.0) -4.3 (-10.9, 2.2)
Protein (En%) 17.2 ± 3.0 17.5 ± 2.4 16.9 ± 3.7 1.8 (-0.2, 3.9) 1.8 (-1.1, 4.7) 1.8 (-0.7, 4.4) -0.2 (-1.4, 1.1) -0.5 (-2.2, 1.2) 0.3 (-1.7, 2.2)
Fat (g/d) 67.8 ± 26.1 65.9 ± 23.5 70.2 ± 29.3 -10.7 (-19.1, -2.4)* -9.4 (-20.3, 1.5) -12.4 (-25.0, 0.1) 0.1 (-5.1, 5.2) 2.3 (-3.4, 8.1) -2.9 (-11.2, 5.3)
Fat (En%) 35.7 ± 7.4 35.9 ± 7.8 35.4 ± 6.9 0.8 (-4.6, 6.2) 0.8 (-6.6, 8.2) 0.8 (-6.2, 7.8) 1.3 (-1.8, 4.4) 1.4 (-2.5, 5.2) 1.2 (-3.4, 5.9)
Carbohydrate (g/d) 187.2 ± 60.7 176.3 ± 46.0 200.9 ± 74.2 -29.1 (-49.4, -8.7)** -25.2 (-48.8, -1.6) -34.0 (-68.3, 0.4) -10.1 (-24.6, 4.4) -4.0 (-21.1, 13.2) -18.4 (-41.3, 4.5)
Carbohydrate (En%) 45.1 ± 7.1 44.7 ± 7.8 45.6 ± 6.1 0.9 (-5.1, 6.8) 0.9 (-7.0, 8.9) 0.8 (-6.7, 8.3) -0.5 (-4.4, 3.5) -0.8 (-5.7, 4.1) 0.0 (-5.9, 6.0)
Fibre (g/d) 14.0 ± 5.5 13.9 ± 5.0 14.1 ± 6.2 0.3 (-1.4, 1.9) 1.0 (-1.1, 3.2) -0.7 (-2.9, 1.4) 0.1 (-1.7, 1.9) -0.1 (-2.4, 2.1) 0.4 (-2.5, 3.3)
Food intake parameters
TFEQ cognitive restraint of eating 11.0 ± 3.8 10.6 ± 3.6 11.5 ± 4.1 0.9 (-0.5, 2.3) 1.2 (-0.6, 3.0) 0.6 (-1.5, 2.6) 2.1 (0.7, 3.5)** 2.4 (0.6, 4.1)** 1.8 (-0.3, 3.9)
TFEQ disinhibition 6.2 ± 3.3 6.7 ± 3.5 5.4 ± 3.0 0.2 (-0.8, 1.2) -0.1 (-1.5, 1.3) 0.6 (-0.9, 2.0) 1.5 (-0.2, 3.2) 0.7 (-1.4, 2.7) 2.7 (0.3, 5.1)*
TFEQ hunger 5.4 ± 3.3 5.8 ± 3.7 4.9 ± 2.5 -0.5 (-2.0, 0.9) -1.0 (-3.1, 1.0 0.1 (-1.5, 1.8) 1.4 (-0.5, 3.4) 0.8 (-1.5, 3.1) 2.3 (-0.4, 5.0)
Physical activity parameters
Baecke School 2.5 ± 0.4 2.4 ± 0.3 2.6 ± 0.4 0.0 (-0.1, 0.1) 0.1 (0.0, 0.2) -0.1 (-0.2, 0.1) -0.1 (-0.3, 0.0) -0.0 (-0.2, 0.1) -0.2 (-0.4, -0.0)*
Baecke Sport 2.8 ± 0.5 2.7 ± 0.5 2.8 ± 0.5 0.1 (-0.1, 0.2) 0.1 (-0.1, 0.3) 0.1 (-0.1, 0.3) -0.1 (-0.3, 0.1) -0.1 (-0.3, 0.1) -0.2 (-0.4, 0.1)
Baecke Leisure 2.8 ± 0.7 2.9 ± 0.6 2.8 ± 0.7 0.0 (-0.1, 0.2) 0.0 (-0.2, 0.2) 0.0 (-0.2, 0.3) -0.0 (-0.2, 0.1) -0.1 (-0.3, 0.2) -0.0 (-0.3, 0.2)
Baecke total score 8.1 ± 1.0 8.0 ± 1.0 8.2 ± 1.1 0.1 (-0.1, 0.4) 0.2 (-0.2, 0.5) 0.1 (-0.3, 0.4) -0.3 (-0.5, -0.0) -0.1 (-0.5, 0.2) -0.4 (-0.8, -0.0)
Accelerometry counts (kcpd) 297.5 ± 101.5 309.4 ± 99.9 279.4 ± 103.1 33.0 (5.3, 60.7)** 27.7 (-10.5, 65.9) 39.5 (-0.3, 79.4) 29.6 (-11.8, 71.1) 4.2 (-46.4, 54.8) 60.9 (5.7, 116.0)*
Accelerometry counts (cpm) 306.7 ± 108.5 316.6 ± 101.9 291.0 ± 118.7 106.5 (71.2, 141.7)** 104.2 (60.2, 148.3)** 109.2 (58.3, 160.1)** 76.5 (33.6, 119.5)** 51.7 (1.1, 102.3)* 107.1 (48.2, 166.0)**
Sedentary behaviour (min/d) 631.6 ± 114.4 617.0 ± 105.8 653.4 ± 125.0 -177.2 (-211.4, -143.0)** -165.3 (-210.1,-120.6)** -191.8 (-241.7,-141.9)** -156.7 (-190.1, -123.3)** -138.9 (-180.7, -97.1)** -178.5 (-224.1,-132.9)**
Light PA (min/d) 323.7 ± 71.0 335.0 ± 7.8 306.7 ± 69.1 -35.7 (-58.0, -13.3)** -40.6 (69.9, -11.3)** -29.6 (-59.9, 0.8) -19.0 (-48.8, 10.9) -37.1 (-71.8, -2.4)* 3.4 (-37.9, 44.6)
Moderate PA (min/d) 21.4 ± 14.7 22.2 ± 13.3 20.3 ± 16.9 7.3 (3.9, 10.7)** 6.7 (2.3, 11.1)** 8.0 (2.8, 13.1)** 5.0 (0.1, 9.9)* 3.0 (-2.7, 8.7) 7.4 (0.8, 14.)*
Vigorous PA (min/d) 4.7 ± 5.0 4.7 ± 4.8 4.7 ± 5.4 5.3 (2.8, 7.8)** 5.7 (2.3, 9.1)** 4.8 (1.5, 8.2)** 3.3 (1.1, 5.5)** 2.8 (0.0, 5.6)* 3.8 ( 0.8, 6.9)*
Moderate-to-vigorous PA (min/d) 26.1 ± 17.5 26.9 ± 16.4 25.1 ± 19.2 12.5 (8.0, 16.9)** 12.3 (6.4, 18.2)** 12.6 (5.9, 19.4)** 8.2 (3.1, 13.4)** 5.7 (3.7, 12.1) 11.4 (4.0, 18.8)**
HP: High-Protein Low-Glycaemic Index; MP: Medium-Protein Medium-Glycaemic Index; BMI = Body Mass Index; FFM = fat free mass; FM = fat mass; 
SBP = systolic blood pressure; DBP = diastolic blood pressure; HR = heart rate; HOMA-IR = Homeostatic Model Assessment of Insulin Resistance (glucose 
(mmol/L)/ insulin (mU/L) * 22,534; HDL cholesterol = high-density lipoprotein cholesterol; LDL cholesterol = low-density lipoprotein cholesterol; TG = 
triacylglycerides; CRP = C-reactive protein; AST = aspartate aminotransferase; ALT = alanine aminotransferase; En% = percentage of total energy intake; 
TFEQ = Three Factor Eating Questionnaire35; cpd = counts per day ; cpm = counts per minute; PA = Physical Activity. Estimated effect changes are based 
upon imputated datasets. P-values are based upon comparison with baseline values. *p<0.05 ; ** p<0.01.
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TABLE 4.1B: Estimated effect changes in anthropometric characteristics, body composition, 
blood pressure, and parameters of glucose metabolism, lipids, liver enzymes and inflammation 
and blood pressure after 1 and 2 years of intervention
Baseline
Estimated effect changes  
after 1y (after multiple imputation)
Estimated effect changes 
after 2y (after multiple imputation)
Whole group
(n=126)
HP 
(n=68)
MP 
(n=58)
Whole group 
(n=126)
HP 
(n=68)
MP 
(n=58)
Whole group 
(n=126)
HP 
(n=68)
MP 
(n=58)
Outcome mean ± SD mean ± SD mean ± SD Δ (95% CI) Δ (95% CI) Δ (95% CI) Δ (95% CI) Δ (95% CI) Δ (95% CI)
General characteristics
Girls n (%) 74 (58.7%) 39 (57.4%) 35 (60.3%)
Age (yr) 13.6 ± 2.2 13.7 ± 2.4 13.4 ± 2.0 1.1 (1.1, 1.2)** 1.1 (1.1, 1.2)** 1.1 (1.1, 1.2)** 2.2 (2.1, 2.3)** 2.2 (2.0, 2.3)** 2.2 (2.0, 2.3)**
Tanner stage 3 (2 - 4) 3 (2 - 5) 3 (2 - 4) 0.5 (0.4, 0.7)** 0.6 (0.3, 0.8)** 0.5 (0.3, 0.8)** 0.7 (0.5, 1.0)** 0.8 (0.4, 1.2)** 0.7 (0.3, 1.1)**
Anthropometric characteristics
Height (m) 1.61 ± 0.11 1.61 ± 0.11 1.60 ± 0.10 0.05 (0.04, 0.06)** 0.05 (0.04, 0.06)** 0.05 (0.04, 0.07)** 0.08 (0.06, 0.10)** 0.08 (0.05, 0.11)** 0.09 (0.06, 0.11)**
Weight (kg) 78.0 ± 19.7 80.0 ± 20.9 75.7 ± 18.2 9.3 (4.2, 14.5)** 8.3 (1.1, 15.5)* 10.6 (3.6, 17.6)** 3,8 (-0.4, 8.0) 4.4 (-1.5, 10.4) 3.0 (-2.9, 8.9)
BMI (kg/m2) 29.8 ± 4.9 30.1 ± 5.1 29.3 ± 4.6 1.7 (0.0, 3.5) 1.3 (-1.1, 3.6) 2.3 (-0.3, 4.9) -0.4 (-1.4, 0.6) -0.33 (-1.8, 1.2) -0.5 (-1.8, 0.8)
BMI z-score (SD) 3.04 ± 0.66 3.10 ± 0.69 2.97 ± 0.63 -0.16 (-0.24, -0.07)** -0.22 (-0.33, -0.10)** -0.09 (-0.21, 0.03) -0.19 (-0.36, -0.02)* -0.16 (-0.36, 0.04) -0.22 (-0.46, 0.01)
Fat free mass (kg) 46.9 ± 11.5 47.5 ± 12.3 46.2 ± 10.5 3.3 (2.2, 4.4)** 3.0 (1.5, 4.5)** 3.6 (2.0, 5.3)** 6.4 (4.2, 8.7)** 6.8 (3.7, 9.9)** 6.0 (3.3, 8.7)**
Fat mass (kg) 31.0 ± 11.8 32.4 ± 12.3 29.3 ± 11.0 1.8 (0.4, 3.2)* 1.0 (-0.9, 3.0) 2.7 (0.7, 4.7)** 4.6 (1.5, 7.6)** 5.0 (1.4, 8.6)** 4.0 (-0.3, 8.4)
Fat mass (%) 39.2 ± 8.11 40.0 ± 7.4 38.2 ± 8.9 -0.8 (-3.3, 1.7) -1.1 (-4.7, 2.5) -0.5 (-3.8, 2.9) 1.6 (-0.2, 3.5) 1.4 (-0.9, 3.7) 2.0 (-0.8, 4.8)
Blood pressure
SBP (mmHg) 116,5 ± 12.4 116.8 ± 12.9 116.0 ± 11.9 1.3 (-1.5, 1.3) 0.7 (-3.1, 4.5) 2.0 (-2.1, 6.1) 3.2 (-0.7, 7.3) 4.2 (-0.9, 9.2) 2.3 (-3.0, 7.5)
DBP (mmHg) 66.6 ± 7.6 67.3 ± 8.0 65.7 ± 7.1 -0.8 (-2.6, 1.1) -0.7 (-3.2, 1.8) -0.8 (-3.2, 1.5) 2.0 (-0.8, 4.7) 2.4 (-1.2, 6.0) 1.4 (-2.3, 5.1)
HR (bpm) 75.3 ± 11.7 76.1 ± 13.3 74.4 ± 9.5 -2.3 (-4.4, -0.3)* -3.0 (-5.9, -0.2)* -1.5 (-4.3, 1.3) -0.5 (-4.7, 3.8) -1.2 (-6.3, 3.9) 0.4 (-4.9, 5.8)
Parameters of glucose metabolism, lipids, inflammation and liver enzymes
Glucose (mmol/L) 4.6 ± 0.7 4.6 ± 0.7 4.5 ± 0.7 0.2 (0.0, 0.4)* 0.2 (-0.1, 0.4) 0.2 (-0.0, 0.5) 0.4 (0.2, 0.6)** 0.3 (0.1, 0.6)* 0.4 (0.1, 0.7)**
Insulin (pmol/L) 109.6 ± 74.2 107.2 ± 51.5 112.4 ± 94.6 -0.2 (-18.5, 14.4) -5.8 (-25.6, 13.8) 2.5 (-22.6, 27.6) 21.2 (-10.1, 52.5) 28.1 (-11.4, 67.6) 13.2 (-25.5, 51.9)
HOMA-IR 3.35 ± 1.80 3.44 ± 1.66 3.24 ± 1.96 0.31 (-0.30, 0.92) 0.19 (-0.55, 0.94) 0.45 (-0.47, 1.37) 0.87 (0.23, 1.52)** 0.85 (-0.00, 1.72) 0.89 (-0.00, 1.78)
HbA1c (mmol/mol) 32.7 ± 2.7 32.7 ± 2.9 32.8 ± 2.5 0.3 (-0.4, 1.0) 0.1 (-0.8, 1.0) 0.5 (-0.4, 1.5) 0.8 (-0.0, 1.6) 0.7 (-0.3, 1.7) 0.9 (-0.2, 2.0)
C-peptide (nmol/L) 0.9 ± 0.3 0.9 ± 0.3 0.9 ± 0.3 0.0 (-0.1, 0.1) 0.0 (-0.1, 0.1) 0.0 (-0.1, 0.1) 0.1 (-0.0, 1.6) 0.1 (-0.0, 0.2) 0.0 (-0.1, 0.2)
Total cholesterol (mmol/L) 4.1 ± 0.8 4.1 ± 0.7 4.2 ± 0.8 -0.1 (-0.2, 0.1) 0.0 (-0.2, 0.2) -0.1 (-0.3, 0.1) -0.1 (-0.3, 0.1) -0.0 (-0.3, 0.2) -0.1 (-0.3, 0.1)
HDL cholesterol (mmol/L) 1.3 ± 0.3 1.3 ± 0.3 1.3 ± 0.3 0.0 (-0.1, 0.0) 0.0 (-0.1, 0.1) 0.0 (-0.1, 0.1) -0.0 (-0.1, 0.1) -0.0 (-0.2, 0.1) 0.0 (-0.1, 0.1)
LDL cholesterol (mmol/L) 2.4 ± 0.6 2.4 ± 0.6 2.4 ± 0.7 0.0 (-0.2, 0.1) 0.0 (-0.2, 0.1) -0.1 (-0.2, 0.1) -0.1 (-0.3, 0.1) -0.0 (-0.3, 0.2) -0.1 (-0.4, 0.1)
TG (mmol/L) 1.1 ± 0.5 1.1 ± 0.5 1.1 ± 0.6 0.0 (-1.9, 0.5) 0.0 (-0.1, 0.1) 0.0 (-0.2, 0.1) -0.0 (-0.2, 0.1) 0.0 (-0.1, 0.2) -0.1 (-0.2, 0.1)
CRP (mg/L) 2.9 ± 3.1 2.9 ± 2.7 3.0 ± 3.5 -0.7 (-1.9, 0.5) -0.5 (-2.1, 1.0) -0.9 (-2.5, 0.8) 1.1 (-0.6, 2.7) 1.4 (-0.6, 3.4) 0.6 (-1.7, 2.9)
AST (U/L) 25.1 ± 8.1 23.9 ± 7.4 26.6 ± 8.8 2.3 (-2.5, 7.1) 1.4 (-4.2, 7.1) 3.4 (-4.6, 11.4) -0.1 (2.7, 2.6) 0.6 (-2.6, 3.8) -0.9 (-4.6, 2.8)
ALT (U/L) 24.7 ± 14.6 23.5 ± 13.8 26.2 ± 15.5 4.1 (0.3, 7.8)* 5.3 (0.5, 10.1)* 2.6 (-2.8, 8.0) 3.7 (-1.1, 8.6) 5.7 (-0.3, 11.6) 1.4 (-4.9, 7.8)
HP: High-Protein Low-Glycaemic Index; MP: Medium-Protein Medium-Glycaemic Index; BMI = Body Mass Index; FFM = fat free mass; FM = fat mass; 
SBP = systolic blood pressure; DBP = diastolic blood pressure; HR = heart rate; HOMA-IR = Homeostatic Model Assessment of Insulin Resistance (glucose 
(mmol/L)/ insulin (mU/L) * 22,534; HDL cholesterol = high-density lipoprotein cholesterol; LDL cholesterol = low-density lipoprotein cholesterol; TG = 
triacylglycerides; CRP = C-reactive protein; AST = aspartate aminotransferase; ALT = alanine aminotransferase; En% = percentage of total energy intake; 
TFEQ = Three Factor Eating Questionnaire35; cpd = counts per day; cpm = counts per minute; PA = Physical Activity. Estimated effect changes are based 
upon imputated datasets. P-values are based upon comparison with baseline values. *p<0.05 ; ** p<0.01.
PSM 20200422 Proefschrift Elke Dorenbos (11246).indd   82 14-08-20   09:30
83
Effect of a high-protein low-GI diet on insulin resistance in adolescents overweight/obesity | Chapter 4
4
TABLE 4.1B: Estimated effect changes in anthropometric characteristics, body composition, 
blood pressure, and parameters of glucose metabolism, lipids, liver enzymes and inflammation 
and blood pressure after 1 and 2 years of intervention
Baseline
Estimated effect changes  
after 1y (after multiple imputation)
Estimated effect changes 
after 2y (after multiple imputation)
Whole group
(n=126)
HP 
(n=68)
MP 
(n=58)
Whole group 
(n=126)
HP 
(n=68)
MP 
(n=58)
Whole group 
(n=126)
HP 
(n=68)
MP 
(n=58)
Outcome mean ± SD mean ± SD mean ± SD Δ (95% CI) Δ (95% CI) Δ (95% CI) Δ (95% CI) Δ (95% CI) Δ (95% CI)
General characteristics
Girls n (%) 74 (58.7%) 39 (57.4%) 35 (60.3%)
Age (yr) 13.6 ± 2.2 13.7 ± 2.4 13.4 ± 2.0 1.1 (1.1, 1.2)** 1.1 (1.1, 1.2)** 1.1 (1.1, 1.2)** 2.2 (2.1, 2.3)** 2.2 (2.0, 2.3)** 2.2 (2.0, 2.3)**
Tanner stage 3 (2 - 4) 3 (2 - 5) 3 (2 - 4) 0.5 (0.4, 0.7)** 0.6 (0.3, 0.8)** 0.5 (0.3, 0.8)** 0.7 (0.5, 1.0)** 0.8 (0.4, 1.2)** 0.7 (0.3, 1.1)**
Anthropometric characteristics
Height (m) 1.61 ± 0.11 1.61 ± 0.11 1.60 ± 0.10 0.05 (0.04, 0.06)** 0.05 (0.04, 0.06)** 0.05 (0.04, 0.07)** 0.08 (0.06, 0.10)** 0.08 (0.05, 0.11)** 0.09 (0.06, 0.11)**
Weight (kg) 78.0 ± 19.7 80.0 ± 20.9 75.7 ± 18.2 9.3 (4.2, 14.5)** 8.3 (1.1, 15.5)* 10.6 (3.6, 17.6)** 3,8 (-0.4, 8.0) 4.4 (-1.5, 10.4) 3.0 (-2.9, 8.9)
BMI (kg/m2) 29.8 ± 4.9 30.1 ± 5.1 29.3 ± 4.6 1.7 (0.0, 3.5) 1.3 (-1.1, 3.6) 2.3 (-0.3, 4.9) -0.4 (-1.4, 0.6) -0.33 (-1.8, 1.2) -0.5 (-1.8, 0.8)
BMI z-score (SD) 3.04 ± 0.66 3.10 ± 0.69 2.97 ± 0.63 -0.16 (-0.24, -0.07)** -0.22 (-0.33, -0.10)** -0.09 (-0.21, 0.03) -0.19 (-0.36, -0.02)* -0.16 (-0.36, 0.04) -0.22 (-0.46, 0.01)
Fat free mass (kg) 46.9 ± 11.5 47.5 ± 12.3 46.2 ± 10.5 3.3 (2.2, 4.4)** 3.0 (1.5, 4.5)** 3.6 (2.0, 5.3)** 6.4 (4.2, 8.7)** 6.8 (3.7, 9.9)** 6.0 (3.3, 8.7)**
Fat mass (kg) 31.0 ± 11.8 32.4 ± 12.3 29.3 ± 11.0 1.8 (0.4, 3.2)* 1.0 (-0.9, 3.0) 2.7 (0.7, 4.7)** 4.6 (1.5, 7.6)** 5.0 (1.4, 8.6)** 4.0 (-0.3, 8.4)
Fat mass (%) 39.2 ± 8.11 40.0 ± 7.4 38.2 ± 8.9 -0.8 (-3.3, 1.7) -1.1 (-4.7, 2.5) -0.5 (-3.8, 2.9) 1.6 (-0.2, 3.5) 1.4 (-0.9, 3.7) 2.0 (-0.8, 4.8)
Blood pressure
SBP (mmHg) 116,5 ± 12.4 116.8 ± 12.9 116.0 ± 11.9 1.3 (-1.5, 1.3) 0.7 (-3.1, 4.5) 2.0 (-2.1, 6.1) 3.2 (-0.7, 7.3) 4.2 (-0.9, 9.2) 2.3 (-3.0, 7.5)
DBP (mmHg) 66.6 ± 7.6 67.3 ± 8.0 65.7 ± 7.1 -0.8 (-2.6, 1.1) -0.7 (-3.2, 1.8) -0.8 (-3.2, 1.5) 2.0 (-0.8, 4.7) 2.4 (-1.2, 6.0) 1.4 (-2.3, 5.1)
HR (bpm) 75.3 ± 11.7 76.1 ± 13.3 74.4 ± 9.5 -2.3 (-4.4, -0.3)* -3.0 (-5.9, -0.2)* -1.5 (-4.3, 1.3) -0.5 (-4.7, 3.8) -1.2 (-6.3, 3.9) 0.4 (-4.9, 5.8)
Parameters of glucose metabolism, lipids, inflammation and liver enzymes
Glucose (mmol/L) 4.6 ± 0.7 4.6 ± 0.7 4.5 ± 0.7 0.2 (0.0, 0.4)* 0.2 (-0.1, 0.4) 0.2 (-0.0, 0.5) 0.4 (0.2, 0.6)** 0.3 (0.1, 0.6)* 0.4 (0.1, 0.7)**
Insulin (pmol/L) 109.6 ± 74.2 107.2 ± 51.5 112.4 ± 94.6 -0.2 (-18.5, 14.4) -5.8 (-25.6, 13.8) 2.5 (-22.6, 27.6) 21.2 (-10.1, 52.5) 28.1 (-11.4, 67.6) 13.2 (-25.5, 51.9)
HOMA-IR 3.35 ± 1.80 3.44 ± 1.66 3.24 ± 1.96 0.31 (-0.30, 0.92) 0.19 (-0.55, 0.94) 0.45 (-0.47, 1.37) 0.87 (0.23, 1.52)** 0.85 (-0.00, 1.72) 0.89 (-0.00, 1.78)
HbA1c (mmol/mol) 32.7 ± 2.7 32.7 ± 2.9 32.8 ± 2.5 0.3 (-0.4, 1.0) 0.1 (-0.8, 1.0) 0.5 (-0.4, 1.5) 0.8 (-0.0, 1.6) 0.7 (-0.3, 1.7) 0.9 (-0.2, 2.0)
C-peptide (nmol/L) 0.9 ± 0.3 0.9 ± 0.3 0.9 ± 0.3 0.0 (-0.1, 0.1) 0.0 (-0.1, 0.1) 0.0 (-0.1, 0.1) 0.1 (-0.0, 1.6) 0.1 (-0.0, 0.2) 0.0 (-0.1, 0.2)
Total cholesterol (mmol/L) 4.1 ± 0.8 4.1 ± 0.7 4.2 ± 0.8 -0.1 (-0.2, 0.1) 0.0 (-0.2, 0.2) -0.1 (-0.3, 0.1) -0.1 (-0.3, 0.1) -0.0 (-0.3, 0.2) -0.1 (-0.3, 0.1)
HDL cholesterol (mmol/L) 1.3 ± 0.3 1.3 ± 0.3 1.3 ± 0.3 0.0 (-0.1, 0.0) 0.0 (-0.1, 0.1) 0.0 (-0.1, 0.1) -0.0 (-0.1, 0.1) -0.0 (-0.2, 0.1) 0.0 (-0.1, 0.1)
LDL cholesterol (mmol/L) 2.4 ± 0.6 2.4 ± 0.6 2.4 ± 0.7 0.0 (-0.2, 0.1) 0.0 (-0.2, 0.1) -0.1 (-0.2, 0.1) -0.1 (-0.3, 0.1) -0.0 (-0.3, 0.2) -0.1 (-0.4, 0.1)
TG (mmol/L) 1.1 ± 0.5 1.1 ± 0.5 1.1 ± 0.6 0.0 (-1.9, 0.5) 0.0 (-0.1, 0.1) 0.0 (-0.2, 0.1) -0.0 (-0.2, 0.1) 0.0 (-0.1, 0.2) -0.1 (-0.2, 0.1)
CRP (mg/L) 2.9 ± 3.1 2.9 ± 2.7 3.0 ± 3.5 -0.7 (-1.9, 0.5) -0.5 (-2.1, 1.0) -0.9 (-2.5, 0.8) 1.1 (-0.6, 2.7) 1.4 (-0.6, 3.4) 0.6 (-1.7, 2.9)
AST (U/L) 25.1 ± 8.1 23.9 ± 7.4 26.6 ± 8.8 2.3 (-2.5, 7.1) 1.4 (-4.2, 7.1) 3.4 (-4.6, 11.4) -0.1 (2.7, 2.6) 0.6 (-2.6, 3.8) -0.9 (-4.6, 2.8)
ALT (U/L) 24.7 ± 14.6 23.5 ± 13.8 26.2 ± 15.5 4.1 (0.3, 7.8)* 5.3 (0.5, 10.1)* 2.6 (-2.8, 8.0) 3.7 (-1.1, 8.6) 5.7 (-0.3, 11.6) 1.4 (-4.9, 7.8)
HP: High-Protein Low-Glycaemic Index; MP: Medium-Protein Medium-Glycaemic Index; BMI = Body Mass Index; FFM = fat free mass; FM = fat mass; 
SBP = systolic blood pressure; DBP = diastolic blood pressure; HR = heart rate; HOMA-IR = Homeostatic Model Assessment of Insulin Resistance (glucose 
(mmol/L)/ insulin (mU/L) * 22,534; HDL cholesterol = high-density lipoprotein cholesterol; LDL cholesterol = low-density lipoprotein cholesterol; TG = 
triacylglycerides; CRP = C-reactive protein; AST = aspartate aminotransferase; ALT = alanine aminotransferase; En% = percentage of total energy intake; 
TFEQ = Three Factor Eating Questionnaire35; cpd = counts per day; cpm = counts per minute; PA = Physical Activity. Estimated effect changes are based 
upon imputated datasets. P-values are based upon comparison with baseline values. *p<0.05 ; ** p<0.01.
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TABLE 4.2A: Food intake and physical activity parameters at baseline and after one year of 
PREVIEW intervention (n=83) 
Baseline 1y follow-up
Whole group 
(n=83)
HP 
(n=44)
MP 
(n=39)
Whole group 
(n=83)
HP 
(n=44)
MP 
(n=39)
Outcome mean ± SD mean ± SD mean ± SD mean ± SD mean ± SD mean ± SD
Food intake 
Glycaemic Index 51.9 ± 8.9 50.2 ± 8.7 54.3 ± 8.7 52.4 ± 7.0 52.7 ± 6.1 52.2 ± 7.9
Glycaemic Load 96.4 ± 36.2 87.0 ± 28.3 109.1 ± 42.1 84.1 ± 24.7 72.8 ± 18.0 92.9 ± 26.2
Energy intake (MJ/d) 6.8 ± 0.1 6.5 ± 1.9 7.3 ± 2.3 5.9 ± 1.3** 5.4 ± 1.2 6.4 ± 1.2*
Protein (g/d) 73.9 ± 24.9 76.2 ± 27.9 70.9 ± 17.4 65.0 ± 12.8 61.1 ± 12.1 67.9 ± 13.0
Protein (En%) 17.9 ± 14.0 19.1 ± 18.0 16.4 ± 3.8 18.9 ± 3.1 19.4 ± 2.8 18.4 ± 3.4
Fat (g/d) 68.9 ± 26.5 68.0 ± 24.7 70.2 ± 29.3 55.0 ± 18.6** 51.8 ± 21.8 57.4 ± 16.2**
Fat (En%) 37.6 ± 19.3 38.4 ± 24.5 36.7 ± 6.8 33.6 ± 7.5 34.1 ± 9.6 33.2 ± 5.8
Carbohydrate (g/d) 183.0 ± 63.4 169.7 ± 51.4 200.9 ± 74.2 158.6 ± 37.9* 137.9 ± 25.2* 174.6 ± 39.0
Carbohydrate (En%) 44.4 ± 7.1 42.5 ± 7.7 46.7 ± 6.2 45.7 ± 7.7 44.4 ± 8.8 46.7 ± 6.8
Fibre (g/d) 15.4 ± 6.5 14.9 ± 7.2 16.1 ± 5.4 14.7 ± 4.1 14.2 ± 3.8 15.2 ± 4.4
Food intake parameters
TFEQ cognitive restraint of eating 10.99 ±  3.795 10.6 ± 3.573 11.53 ± 4.091 12.2 ± 3.6* 11.6 ± 3.7 12.8 ± 3.6*
TFEQ disinhibition 6.15 ± 3.319 6.7 ± 3.475 5.37 ± 2.965 5.9 ± 3.6 6.1 ± 3.7 5.7 ± 3.5
TFEQ hunger 5.41 ± 3.286 5.77 ± 3.721 4.90 ± 2.51 4.7 ± 3.9 4.3 ± 4.2 5.0 ± 3.7
Physical activity parameters
Baecke School 2.5 ± 0.4 2.4 ± 0.3 2.6 ± 0.4 2.5 ± 0.4 2.5 ± 0.4 2.5 ± 0.3
Baecke Sport 2.8 ± 0.5 2.7 ± 0.5 2.8 ± 0.5 2.8 ± 0.5 2.8 ± 0.4 2.9 ± 0.5
Baecke Leisure 2.9 ± 0.6 2.9 ± 0.6 2.8 ± 0.7 2.9 ± 0.6 2.8 ± 0.6 2.9 ± 0.6
Baecke total score 8.2 ± 1.0 8.0 ± 1.0 8.2 ± 1.1 8.2 ± 0.9 8.1 ± 0.9 8.3 ± 0.8
Accelerometry counts (kcpd) 279.5 ± 107.8 309.4 ± 99.9 279.4 ± 103.1 296.8 ± 79.3 285.6 ± 90.1 297.0 ± 74.7
Accelerometry counts (cpm) 285.5 ± 113.1 318.0 ± 101.1 291.2 ± 116.8 368.8 ± 103.7** 351.6 ± 116.9* 369.0 ± 103.0
Sedentary behaviour (min) 652.7 ± 116.4 617.0 ± 105.8 653.4 ± 125.0 479.9 ± 82.1** 500.6 ± 88.4** 487.9 ± 80.3**
Light PA (min) 314.3 ± 65.6 335.0 ± 70.8 306.7 ± 69.1 294.0 ± 63.1 291.5 ± 60.7 284.6 ± 67.3
Moderate PA (min) 17.6 ± 11.4 22.2 ± 13.3 20.3 ± 16.9 24.8 ± 11.4* 21.3 ± 11.6 24.2 ± 11.0
Vigorous PA (min) 4.1 ± 5.4 4.7 ± 4.8 4.7 ± 5.4 6.3 ± 7.3 6.0 ± 7.0 7.9 ± 8.2
Moderate-to-vigorous PA (min) 21.7 ± 14.5 26.9 ± 16.4 25.1 ± 19.2 31.0 ± 16.7* 27.4 ± 16.3 32.1 ± 15.9
HP: High-Protein Low-Glycaemic Index; MP: Medium-Protein Medium-Glycaemic Index; BMI = Body Mass Index; FFM = fat free 
mass; FM = fat mass; SBP = systolic blood pressure; DBP = diastolic blood pressure; HR = heart rate; HOMA-IR = Homeostatic Model 
Assessment of Insulin Resistance (glucose (mmol/L)/ insulin (mU/L) * 22,534; HDL cholesterol = high-density lipoprotein cholesterol; LDL 
cholesterol = low-density lipoprotein cholesterol; TG = triacylglycerides; CRP = C-reactive protein; AST = aspartate aminotransferase; 
ALT = alanine aminotransferase; En% = percentage of total energy intake; TFEQ = Three Factor Eating Questionnaire35; cpd = counts 
per day ; cpm = counts per minute; PA = Physical Activity. Estimated effect changes are based upon imputated datasets. P-values are 
based upon comparison with baseline values. *p<0.05 ; ** p<0.01.
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TABLE 4.2A: Food intake and physical activity parameters at baseline and after one year of 
PREVIEW intervention (n=83) 
Baseline 1y follow-up
Whole group 
(n=83)
HP 
(n=44)
MP 
(n=39)
Whole group 
(n=83)
HP 
(n=44)
MP 
(n=39)
Outcome mean ± SD mean ± SD mean ± SD mean ± SD mean ± SD mean ± SD
Food intake 
Glycaemic Index 51.9 ± 8.9 50.2 ± 8.7 54.3 ± 8.7 52.4 ± 7.0 52.7 ± 6.1 52.2 ± 7.9
Glycaemic Load 96.4 ± 36.2 87.0 ± 28.3 109.1 ± 42.1 84.1 ± 24.7 72.8 ± 18.0 92.9 ± 26.2
Energy intake (MJ/d) 6.8 ± 0.1 6.5 ± 1.9 7.3 ± 2.3 5.9 ± 1.3** 5.4 ± 1.2 6.4 ± 1.2*
Protein (g/d) 73.9 ± 24.9 76.2 ± 27.9 70.9 ± 17.4 65.0 ± 12.8 61.1 ± 12.1 67.9 ± 13.0
Protein (En%) 17.9 ± 14.0 19.1 ± 18.0 16.4 ± 3.8 18.9 ± 3.1 19.4 ± 2.8 18.4 ± 3.4
Fat (g/d) 68.9 ± 26.5 68.0 ± 24.7 70.2 ± 29.3 55.0 ± 18.6** 51.8 ± 21.8 57.4 ± 16.2**
Fat (En%) 37.6 ± 19.3 38.4 ± 24.5 36.7 ± 6.8 33.6 ± 7.5 34.1 ± 9.6 33.2 ± 5.8
Carbohydrate (g/d) 183.0 ± 63.4 169.7 ± 51.4 200.9 ± 74.2 158.6 ± 37.9* 137.9 ± 25.2* 174.6 ± 39.0
Carbohydrate (En%) 44.4 ± 7.1 42.5 ± 7.7 46.7 ± 6.2 45.7 ± 7.7 44.4 ± 8.8 46.7 ± 6.8
Fibre (g/d) 15.4 ± 6.5 14.9 ± 7.2 16.1 ± 5.4 14.7 ± 4.1 14.2 ± 3.8 15.2 ± 4.4
Food intake parameters
TFEQ cognitive restraint of eating 10.99 ±  3.795 10.6 ± 3.573 11.53 ± 4.091 12.2 ± 3.6* 11.6 ± 3.7 12.8 ± 3.6*
TFEQ disinhibition 6.15 ± 3.319 6.7 ± 3.475 5.37 ± 2.965 5.9 ± 3.6 6.1 ± 3.7 5.7 ± 3.5
TFEQ hunger 5.41 ± 3.286 5.77 ± 3.721 4.90 ± 2.51 4.7 ± 3.9 4.3 ± 4.2 5.0 ± 3.7
Physical activity parameters
Baecke School 2.5 ± 0.4 2.4 ± 0.3 2.6 ± 0.4 2.5 ± 0.4 2.5 ± 0.4 2.5 ± 0.3
Baecke Sport 2.8 ± 0.5 2.7 ± 0.5 2.8 ± 0.5 2.8 ± 0.5 2.8 ± 0.4 2.9 ± 0.5
Baecke Leisure 2.9 ± 0.6 2.9 ± 0.6 2.8 ± 0.7 2.9 ± 0.6 2.8 ± 0.6 2.9 ± 0.6
Baecke total score 8.2 ± 1.0 8.0 ± 1.0 8.2 ± 1.1 8.2 ± 0.9 8.1 ± 0.9 8.3 ± 0.8
Accelerometry counts (kcpd) 279.5 ± 107.8 309.4 ± 99.9 279.4 ± 103.1 296.8 ± 79.3 285.6 ± 90.1 297.0 ± 74.7
Accelerometry counts (cpm) 285.5 ± 113.1 318.0 ± 101.1 291.2 ± 116.8 368.8 ± 103.7** 351.6 ± 116.9* 369.0 ± 103.0
Sedentary behaviour (min) 652.7 ± 116.4 617.0 ± 105.8 653.4 ± 125.0 479.9 ± 82.1** 500.6 ± 88.4** 487.9 ± 80.3**
Light PA (min) 314.3 ± 65.6 335.0 ± 70.8 306.7 ± 69.1 294.0 ± 63.1 291.5 ± 60.7 284.6 ± 67.3
Moderate PA (min) 17.6 ± 11.4 22.2 ± 13.3 20.3 ± 16.9 24.8 ± 11.4* 21.3 ± 11.6 24.2 ± 11.0
Vigorous PA (min) 4.1 ± 5.4 4.7 ± 4.8 4.7 ± 5.4 6.3 ± 7.3 6.0 ± 7.0 7.9 ± 8.2
Moderate-to-vigorous PA (min) 21.7 ± 14.5 26.9 ± 16.4 25.1 ± 19.2 31.0 ± 16.7* 27.4 ± 16.3 32.1 ± 15.9
HP: High-Protein Low-Glycaemic Index; MP: Medium-Protein Medium-Glycaemic Index; BMI = Body Mass Index; FFM = fat free 
mass; FM = fat mass; SBP = systolic blood pressure; DBP = diastolic blood pressure; HR = heart rate; HOMA-IR = Homeostatic Model 
Assessment of Insulin Resistance (glucose (mmol/L)/ insulin (mU/L) * 22,534; HDL cholesterol = high-density lipoprotein cholesterol; LDL 
cholesterol = low-density lipoprotein cholesterol; TG = triacylglycerides; CRP = C-reactive protein; AST = aspartate aminotransferase; 
ALT = alanine aminotransferase; En% = percentage of total energy intake; TFEQ = Three Factor Eating Questionnaire35; cpd = counts 
per day ; cpm = counts per minute; PA = Physical Activity. Estimated effect changes are based upon imputated datasets. P-values are 
based upon comparison with baseline values. *p<0.05 ; ** p<0.01.
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TABLE 4.2B: Anthropometric characteristics, body composition, blood pressure, and parameters 
of glucose metabolism, lipids, liver function and inflammation at baseline and after one year of 
intervention (n=83)
Baseline (n=83) 1y follow-up
 Whole group 
(n=83)
HP 
(n=44)
MP 
(n=39)
Whole group 
(n=83)
HP 
(n=44)
MP 
(n=39)
Outcome mean ± SD mean ± SD mean ± SD mean ± SD mean ± SD mean ± SD
General characteristics
Girls n(%)  
Age (yr) 13.3 ± 2.2 13.7 ± 2.4 13.5 ± 2.0 14.5 ± 2.2** 14.7 ± 2.5** 14.3 ± 1.9
Tanner stage 3 (2 - 4) 3 (2 - 5) 3 (2 - 4) 4 (3 - 5)** 4 (3 - 5)** 3 (3 - 4)
Anthropometric characteristics
Height (m) 1.61 ± 0.11 1.61 ± 0.10 1.60 ± 0.1 1.66 ± 0.10** 1.67 ± 0.10** 1.65 ± 0.10
Weight (kg) 77.5 ± 20.3 80.0 ± 20.9 75.7 ± 18.2 82.8 ± 20.9** 83.7 ± 21.9** 81.8 ± 20.0
BMI (kg/m2) 29.4 ± 4.9 30.2 ± 5.1 29.3 ± 4.6 29.7 ± 5.7 29.6 ± 5.9 29.9 ± 5.6
BMI z-score (SD) 3.04 ± 0.66 3.10 ± 0.69 2.97 ± 0.62 2.87 ± 0.81** 2.82 ± 0.86** 2.92 ± 0.75
Fat free mass (kg) 47.5 ± 11.6 47.5 ± 12.3 46.2 ± 10.5 51.0 ± 11.9** 52.8 ± 12.8** 48.7 ± 10.6
Fat mass (kg) 31.0 ± 11.8 32.4 ± 12.3 29.3 ± 11.0 32.7 ± 13.4* 34.0 ± 14.1 31.2 ± 12.6
Fat mass (%) 38.8 ± 8.7 40.0 ± 7.4 38.2 ± 8.9 38.2 ± 9.0 38.4 ± 8.8 38.1 ± 9.5
Blood pressure
SBP (mmHg) 116.8 ± 12.6 116.8 ± 12.9 116.0 ± 11.9 117.8 ± 11.2 118.1 ± 12.7 117.5 ± 9.3
DBP (mmHg) 65.9 ± 8.4 67.3 ± 8.0 65.7 ± 7.1 65.8 ± 7.9 67.1 ± 8.4 64.3 ± 7.1
HR (bpm) 76.3 ± 12.3 76.1 ± 13.3 74.4 ± 9.5 73.6 ± 10.2* 73.7 ± 11.8* 73.5 ± 8.0
Laboratory parameters
Glucose (mmol/L) 4.5 ± 0.7 4.6 ± 0.7 4.5 ± 0.7 4.7 ± 0.7* 4.8 ± 0.7 4.6 ± 0.7
Insulin (pmol/L) 114.3 ± 87.6 107.2 ± 51.5 112.4 ± 94.6 106.2 ± 74.7 95.4 ± 60.5 119.4 ± 88.3
HOMA-IR 3.57 ± 2.62 3.44 ± 1.66 3.52 ± 2.87 3.70 ± 2.62 3.45 ± 2.42 4.01 ± 2.85
HbA1c (mmol/mol) 32.6 ± 2.6 32.7 ± 2.9 32.8 ± 2.5 33.1 ± 3.2 32.8 ± 3.5 0.8 ± 2.8
C-peptide (nmol/L) 0.9 ± 0.3 0.9 ± 0.3 0.9 ± 0.3 0.8 ± 0.3 0.8 ± 0.3 3.9 ± 0.4
Total cholesterol (mmol/L) 4.0 ± 0.7 4.1 ± 0.7 4.2 ± 0.8 4.0 ± 0.7 4.2 ± 0.7 1.3 ± 0.7
HDL cholesterol (mmol/L) 1.2 ± 0.3 1.3 ± 0.3 1.3 ± 0.3 1.3 ± 0.3 1.3 ± 0.3 2.3 ± 0.3
LDL cholesterol (mmol/L) 2.3 ± 0.6 2.4 ± 0.6 2.4 ± 0.7 2.3 ± 0.6 2.3 ± 0.6 0.9 ± 0.6
TG (mmol/L) 1.1 ± 0.5 1.1 ± 0.5 1.1 ± 0.6 1.0 ± 0.5 1.1 ± 0.6 1.9 ± 0.5
CRP (mg/L) 2.9 ± 3.1 2.9 ± 2.7 3.0 ± 3.5 2.4 ± 3.0 2.7 ± 3.7 1.9 ± 1.6
AST (U/L) 25.2 ± 8.6 23.9 ± 7.4 26.6 ± 8.8 27.4 ± 23.1 23.3 ± 6.4 32.8 ± 34.1
ALT (U/L) 25.5 ± 17.4 23.5 ± 13.8 26.2 ± 15.5 28.0 ± 19.4 28.4 ± 20.4* 27.6 ± 18.3
HP: High-Protein Low-Glycaemic Index; MP: Medium-Protein Medium-Glycaemic Index; BMI = Body Mass Index; FFM = fat free 
mass; FM = fat mass; SBP = systolic blood pressure; DBP = diastolic blood pressure; HR = heart rate; HOMA-IR = Homeostatic Model 
Assessment of Insulin Resistance (glucose (mmol/L)/ insulin (mU/L) * 22,534; HDL cholesterol = high-density lipoprotein cholesterol; LDL 
cholesterol = low-density lipoprotein cholesterol; TG = triacylglycerides; CRP = C-reactive protein; AST = aspartate aminotransferase; 
ALT = alanine aminotransferase; En% = percentage of total energy intake; TFEQ = Three Factor Eating Questionnaire35; cpd = counts 
per day; cpm = counts per minute; PA = Physical Activity. Estimated effect changes are based upon imputated datasets. P-values are 
based upon comparison with baseline values. *p<0.05 ; ** p<0.01.
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TABLE 4.2B: Anthropometric characteristics, body composition, blood pressure, and parameters 
of glucose metabolism, lipids, liver function and inflammation at baseline and after one year of 
intervention (n=83)
Baseline (n=83) 1y follow-up
 Whole group 
(n=83)
HP 
(n=44)
MP 
(n=39)
Whole group 
(n=83)
HP 
(n=44)
MP 
(n=39)
Outcome mean ± SD mean ± SD mean ± SD mean ± SD mean ± SD mean ± SD
General characteristics
Girls n(%)  
Age (yr) 13.3 ± 2.2 13.7 ± 2.4 13.5 ± 2.0 14.5 ± 2.2** 14.7 ± 2.5** 14.3 ± 1.9
Tanner stage 3 (2 - 4) 3 (2 - 5) 3 (2 - 4) 4 (3 - 5)** 4 (3 - 5)** 3 (3 - 4)
Anthropometric characteristics
Height (m) 1.61 ± 0.11 1.61 ± 0.10 1.60 ± 0.1 1.66 ± 0.10** 1.67 ± 0.10** 1.65 ± 0.10
Weight (kg) 77.5 ± 20.3 80.0 ± 20.9 75.7 ± 18.2 82.8 ± 20.9** 83.7 ± 21.9** 81.8 ± 20.0
BMI (kg/m2) 29.4 ± 4.9 30.2 ± 5.1 29.3 ± 4.6 29.7 ± 5.7 29.6 ± 5.9 29.9 ± 5.6
BMI z-score (SD) 3.04 ± 0.66 3.10 ± 0.69 2.97 ± 0.62 2.87 ± 0.81** 2.82 ± 0.86** 2.92 ± 0.75
Fat free mass (kg) 47.5 ± 11.6 47.5 ± 12.3 46.2 ± 10.5 51.0 ± 11.9** 52.8 ± 12.8** 48.7 ± 10.6
Fat mass (kg) 31.0 ± 11.8 32.4 ± 12.3 29.3 ± 11.0 32.7 ± 13.4* 34.0 ± 14.1 31.2 ± 12.6
Fat mass (%) 38.8 ± 8.7 40.0 ± 7.4 38.2 ± 8.9 38.2 ± 9.0 38.4 ± 8.8 38.1 ± 9.5
Blood pressure
SBP (mmHg) 116.8 ± 12.6 116.8 ± 12.9 116.0 ± 11.9 117.8 ± 11.2 118.1 ± 12.7 117.5 ± 9.3
DBP (mmHg) 65.9 ± 8.4 67.3 ± 8.0 65.7 ± 7.1 65.8 ± 7.9 67.1 ± 8.4 64.3 ± 7.1
HR (bpm) 76.3 ± 12.3 76.1 ± 13.3 74.4 ± 9.5 73.6 ± 10.2* 73.7 ± 11.8* 73.5 ± 8.0
Laboratory parameters
Glucose (mmol/L) 4.5 ± 0.7 4.6 ± 0.7 4.5 ± 0.7 4.7 ± 0.7* 4.8 ± 0.7 4.6 ± 0.7
Insulin (pmol/L) 114.3 ± 87.6 107.2 ± 51.5 112.4 ± 94.6 106.2 ± 74.7 95.4 ± 60.5 119.4 ± 88.3
HOMA-IR 3.57 ± 2.62 3.44 ± 1.66 3.52 ± 2.87 3.70 ± 2.62 3.45 ± 2.42 4.01 ± 2.85
HbA1c (mmol/mol) 32.6 ± 2.6 32.7 ± 2.9 32.8 ± 2.5 33.1 ± 3.2 32.8 ± 3.5 0.8 ± 2.8
C-peptide (nmol/L) 0.9 ± 0.3 0.9 ± 0.3 0.9 ± 0.3 0.8 ± 0.3 0.8 ± 0.3 3.9 ± 0.4
Total cholesterol (mmol/L) 4.0 ± 0.7 4.1 ± 0.7 4.2 ± 0.8 4.0 ± 0.7 4.2 ± 0.7 1.3 ± 0.7
HDL cholesterol (mmol/L) 1.2 ± 0.3 1.3 ± 0.3 1.3 ± 0.3 1.3 ± 0.3 1.3 ± 0.3 2.3 ± 0.3
LDL cholesterol (mmol/L) 2.3 ± 0.6 2.4 ± 0.6 2.4 ± 0.7 2.3 ± 0.6 2.3 ± 0.6 0.9 ± 0.6
TG (mmol/L) 1.1 ± 0.5 1.1 ± 0.5 1.1 ± 0.6 1.0 ± 0.5 1.1 ± 0.6 1.9 ± 0.5
CRP (mg/L) 2.9 ± 3.1 2.9 ± 2.7 3.0 ± 3.5 2.4 ± 3.0 2.7 ± 3.7 1.9 ± 1.6
AST (U/L) 25.2 ± 8.6 23.9 ± 7.4 26.6 ± 8.8 27.4 ± 23.1 23.3 ± 6.4 32.8 ± 34.1
ALT (U/L) 25.5 ± 17.4 23.5 ± 13.8 26.2 ± 15.5 28.0 ± 19.4 28.4 ± 20.4* 27.6 ± 18.3
HP: High-Protein Low-Glycaemic Index; MP: Medium-Protein Medium-Glycaemic Index; BMI = Body Mass Index; FFM = fat free 
mass; FM = fat mass; SBP = systolic blood pressure; DBP = diastolic blood pressure; HR = heart rate; HOMA-IR = Homeostatic Model 
Assessment of Insulin Resistance (glucose (mmol/L)/ insulin (mU/L) * 22,534; HDL cholesterol = high-density lipoprotein cholesterol; LDL 
cholesterol = low-density lipoprotein cholesterol; TG = triacylglycerides; CRP = C-reactive protein; AST = aspartate aminotransferase; 
ALT = alanine aminotransferase; En% = percentage of total energy intake; TFEQ = Three Factor Eating Questionnaire35; cpd = counts 
per day; cpm = counts per minute; PA = Physical Activity. Estimated effect changes are based upon imputated datasets. P-values are 
based upon comparison with baseline values. *p<0.05 ; ** p<0.01.
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TABLE 4.3: Post-hoc associations of ΔBMI z-score and ΔHOMA-IR with lifestyle parameters (n=126). 
  ΔGI ΔGL
ΔEnergy 
intake 
(kJ)
ΔProtein 
(En%)
ΔTFEQ 
F1
ΔTFEQ 
F2
ΔTFEQ 
F3
ΔBMI z-score‡ B (95% CI) 0.001 
(-0.013; 
0.015)
0.002 
(-0.001; 
0.005)
0.000 
(0.000; 
0.000)
-0.026 
(-0.060; 
0.007)
-0.027 
(-0.054; 
-0.001)
0.034 
(0.000; 
0.068)
0.034 
(0.008; 
0.060)
 p-value 0.891 0.279 0.010* 0.118 0.045* 0.052 0.013*
ΔHOMA-IR$ B (95% CI) 0.134 
(0.014; 
0.254)
0.014 
(-0.014; 
0.042)
0.000 
(-0.001; 
0.001)
-0.167 
(-0.481; 
0.147)
-0.144 
(-0.363; 
0.074)
0.138 
(-0.128; 
0.403)
0.034 
(-0.190; 
0.258)
 p-value 0.031* 0.306 0.963 0.277 0.189 0.299 0.759
Post-hoc associations of change in BMI z-score and HOMA-IR with changes in food intake. En% = energy percentage ; TFEQ = Three 
Factor Eating Questionnaire35. Associations are based upon the pooled imputed dataset. ^ Corrected for gender, age, Tanner G/M 
stage at baseline and ΔTanner G/M stage. ‡ Corrected for gender, age, Tanner G/M stage at baseline and ΔTanner stage. * p<0.05 ; 
** p<0.01
β=2.234 (2.070; 2.399), p<0.001** 
Figure 4.2: Association of change in BMI z-score with change in HOMA-IR.
 
63 
 
 
Scatterplot for changes of BMI z-score with changes in HOMA-IR 
after one year of PREVIEW intervention 
 
 
 
 
 
Figure 4.2. Association of change in BMI z-score with change in HOMA-IR.  
β=2.234 (2.070; 2.399), p<0.001**  
 
  
Scatterplot for changes of BMI z-score with changes in HOMA-IR after 
one year of PREVIEW intervention
PSM 20200422 Proefschrift Elke Dorenbos (11246).indd   88 14-08-20   09:30
89
Effect of a high-protein low-GI diet on insulin resistance in adolescents overweight/obesity | Chapter 4
4
DISCUSSION
This PREVIEW study aimed to assess the effects of a high-protein low-GI vs. a medium- 
protein medium-GI diet on insulin resistance in adolescents with overweight and obesity 
and insulin resistance. No significant differences were found in reported protein intake 
and GI between the two intervention groups, despite groups receiving different dietary 
instructions. No significant differences were observed between the two intervention groups 
regarding IR, parameters of glucose metabolism, lipid metabolism, inflammation, liver 
enzymes, anthropometric characteristics, or lifestyle factors at any timepoint. We conclude 
that the study as it was designed was not feasible.
Lack of feasibility was due to poor retention rates and lack of dietary compliance. 
Retention rates were 66% after 1y and 39% after 2y. The HP group did not achieve the protein 
target of 25En% and reported protein intake was not significantly different between the two 
intervention groups. One possible explanation might be that the protein intake estimates 
were based upon self-reported food diaries, which are known to be underreported39. 
Reported energy intake was 32.6-62.1% lower than the energy requirements according 
to the WHO formula for adolescents of corresponding ages and weights29. The unmet 
protein target might partly be explained by reduced reward mechanisms in the brain or 
costs of high-protein foods40. Previous studies aiming to increase relative protein intake in 
adolescents also reported difficulties in dietary compliance11,13-18. Only half of them observed 
a difference in protein En% between the higher-protein and the control group, which was 
often lower than the targets set between 22.5 and 25.0 En%14,16,18. None of the studies 
observed a difference in BMI z-score decrease between intervention groups. The results 
from this study imply that achieving and maintaining a high-protein low-GI diet during 1y 
or 2y is not feasible with instructions alone. Achieving and maintaining an energy target of 
25En% protein might only be feasible with vouchers/subsidies for foods high in protein, the 
use of protein supplements or meal replacements. 
Post-hoc observations showed that in the complete group of adolescents with 
overweight/obesity and increased IR, a significant decrease in BMI z-score was observed 
while dietary restraint and MVPA were increased after 1y and 2y. The reduction in BMI 
z-score was inversely related to change in dietary restraint and positively to change in 
hunger susceptibility and HOMA-IR change. 
Furthermore, HOMA-IR stabilized after 1y of lifestyle intervention, despite progression 
in pubertal stage, but increased after 2y. As described previously, transient pubertal IR 
typically nadirs at mid-puberty, which might explain the increase of HOMA-IR after 2y of 
study participation even though BMI z-score decreased5,6. Change in HOMA-IR at 1y was 
positively related to changes in BMI z-score after correcting for relevant confounders. Half 
of the previously performed studies where reported protein intake did increase significantly 
observed a reduction in HOMA-IR in adolescents with an increased-protein diet11,12,14. 
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However, these studies did not take pubertal stage into account. None of the studies found 
a significant effect of change in GI on anthropometric or cardiometabolic outcomes. 
After both 1y and 2y age- and sex-corrected BMI z-score was significantly reduced in these 
adolescents at high risk for T2DM development. After correcting for relevant confounders 
change in BMI z-score at 1y was negatively related to change in cognitive restraint of the 
TFEQ, which was increased significantly, and positively to change in susceptibility to hunger. 
Change in HOMA-IR at 1y was positively associated with change in BMI z-score independent 
of change in Tanner stage. This reduction of age- and sex-corrected BMI z-score of 0.17 SD 
is considered to be of clinical relevance, since a BMI z-score reduction of ≥0.15 has been 
associated with significant increases in insulin sensitivity, decrease of total cholesterol and 
LDL-cholesterol concentrations, and normalization of blood pressure41,42. 
TFEQ cognitive restraint scores were significantly higher after dietary instructions. 
Previous studies have shown that adolescents that have dieted in the past showed higher 
cognitive restraint and disinhibition scores on the TFEQ, compared to children without a 
history of dieting43. Moreover, a study in a similar cohort of Dutch adolescents showed an 
increase in dietary restraint scores during adolescence, especially in those with overweight/
obesity, indicating an increase in awareness of food intake and body-weight44,45. The 
observed reduction in BMI z-score was related to increased cognitive restraint scores, 
possibly as a result of more conscious eating behaviour after the dietary guidance, while 
supported by the positive relationship of change in BMI z-score with change in hunger 
susceptibility.
After 1y and 2y of personalized dietary and PA instructions, an increase in PA counts and 
moderate and vigorous intensity PA was observed, while sedentary behaviour decreased 
at all timepoints in both the completer as ITT-analyses, yet these observations were not 
associated with changes in HOMA-IR or BMI z-score. 
By including all adolescents at increased risk of T2DM, regardless of age or specific 
obesity status, the study design was placed in a real life setting. Thus, the results of the 
PREVIEW study are representative of results that can be expected in out-centre treatments 
of all adolescents with overweight and obesity. Limitations were the use of HOMA-IR as a 
proxy of IR, and absence of an untreated control group due to ethical considerations of 
performing research in adolescents. In addition, no qualitative data was required on why 
participants did not meet the protein target and costs of diets was not considered in this 
study. 
In conclusion, the PREVIEW study observed no effect of a high-protein low-GI diet on 
insulin resistance in adolescents with overweight/obesity and insulin resistance because of 
lack of feasibility. Post-hoc, attenuating pubertal insulin resistance was associated with BMI 
z-score decrease. BMI z-score decrease was associated with increased dietary restraint.
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ABSTRACT  
Background
Inadequate sleep duration and quality are associated with increased risk of developing 
obesity, insulin resistance and cardiovascular risk in adolescents.
Objectives
To identify associations of sleep characteristics with anthropometric and cardiometabolic 
parameters and changes herein during the PREVIEW lifestyle intervention in adolescents 
with overweight/obesity. 
Methods
67 adolescents (13.4±2.2y, BMI z-score 3.06±0.69) received measurements for sleep 
architecture (using polysomnography), habitual sleep (using actigraphy) and self-reported 
sleep (PSQI questionnaire) at baseline and after one year of intervention. Sleep parameters 
were related to anthropometric and cardiometabolic characteristics. 
Results
Baseline habitual total sleeping time (TST) was negatively associated with BMI z-score, 
corrected for Tanner stage and sex. N2 sleep duration was independently negatively 
associated with diastolic blood pressure. While BMI z-score decreased significantly after 1y, 
none of the sleep parameters had changed and were not related to outcome variables. PSQI 
(poor) sleep quality scores were inversely related to polysomnography-measured Quality 
Sleep, habitual TST, and positively with N2 sleep and Wake-After-Sleep-Onset duration. 
Habitual sleep duration and polysomnography-measured sleep duration were not related. 
Conclusions
In adolescents with overweight/obesity habitual sleep duration was inversely related to BMI 
z-score, but not to cardiometabolic parameters. N2 sleep duration was negatively related 
to diastolic blood pressure. We recommend the combination of objective and self-reported 
sleep measurement methods. 
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INTRODUCTION 
As the prevalence of childhood obesity and obesity-related comorbidities increases, more 
research is performed to identify possible targets for obesity prevention and therapy1. 
Lifestyle interventions, mainly focussing on increasing physical activity and control of 
food intake, are currently the cornerstone of prevention and treatment of overweight 
and obesity-related comorbidities2. Recently more evidence is emerging that sleep may 
be a third modifiable contributor to energy balance, and consequently to obesity and 
related comorbidities. Identifying the relationship of sleep with obesity status might aid in 
optimizing treatment strategies and prevent development of morbidities for adolescents 
with overweight and obesity. 
Puberty is associated with weight gain and a significant decline in sleep duration3-5. 
A growing body of evidence identified inadequate sleep duration and quality as an 
independent risk factor for weight gain in lean children, even after correcting for contributing 
factors such as BMI at the start of puberty or screentime3,6,7. In addition, decreased sleep 
duration and changes in sleep architecture, especially decrease of slow wave sleep 
(SWS), seem to be related to increased insulin resistance, hypertension, dyslipidaemia, 
and inflammatory factors6,8-11. Although the exact mechanism linking inadequate sleep 
with obesity and obesity-related comorbidities is not yet known, the most important 
mechanisms appear to be related to endocrine stress regulation. Sleep is a refractory period 
for stress hormones such as cortisol, norepinephrine and epinephrine. Loss of sleep or 
decrease of sleep quality may lead to increased endocrine stress. Experimental studies in 
children found that both increased cortisol concentrations and sympathetic nervous system 
activity were associated with unfavourable changes in glucose metabolism10. In addition, 
short sleep duration is associated with higher levels of the orexigenic hormone ghrelin and 
lower concentrations of the anorexigenic hormone leptin, which promotes hunger and 
food intake12. One experimental study found increased food intake after sleep restriction, 
and several observational studies reported increased intake of specifically high-energy and 
sugar rich foods11. Reduced sleep and subsequent daytime tiredness may also contribute to 
decreased PA and exercise in general8.
Although the majority of studies point to an inverse relation between sleep duration 
and the development of cardiometabolic risk, including obesity, evidence in children is 
still limited and often conflicting. Most studies have been performed in lean children or in 
general paediatric populations, but no research has yet been performed on the influence 
of sleep duration and architecture in children in whom overweight and obesity is already 
present. Also, the relationship between sleep characteristics and cardiometabolic risk 
parameters in adolescents has not yet been researched in longitudinal designs. Earlier 
studies were performed with different methods of sleep assessment e.g. polysomnography, 
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actigraphy, self-reporting with questionnaires and/or parental sleep assessment, which 
limits the possibility for comparison of studies. Lastly, many studies did not correct for 
variables like pubertal stage, sex and obesity status, all of which are known to be related to 
sleep and cardiometabolic risk factors8. 
The PREVIEW study in adolescents aimed to assess the effect of a lifestyle intervention on 
BMI z-score and insulin resistance in adolescents with overweight/obesity13. The aim of the 
present study was to identify possible associations between sleep duration and architecture 
with anthropometric characteristics, parameters of glucose metabolism, cardiovascular risk, 
and inflammation in adolescents with overweight or obesity in a longitudinal design. In 
addition, this study aimed to compare the association between objective and subjective 
sleep assessment outcomes in adolescents with overweight and obesity. We hypothesized 
that sleep duration was negatively associated with BMI z-score and HOMA-IR, and that 
change in sleep duration would be inversely related to change in BMI z-score after one year. 
MATERIALS AND METHODS
1 Design and intervention
The PREVIEW study in adolescents was a randomized controlled trial assessing the effects 
of increasing protein intake on obesity status and insulin resistance in adolescents with 
overweight/obesity and at increased risk of developing type 2 diabetes mellitus (T2DM), as 
described before18. Participants from three study sites (Maastricht University Medical Centre, 
the Netherlands; University of Navarra, Spain and Swansea University, United Kingdom) were 
instructed to increase dietary protein content and physical activity, and reduce glycaemic 
index of foods. At baseline and after one year of lifestyle intervention participants were 
subjected to regular measurements of anthropometric characteristics, blood sampling and 
questionnaires assessing lifestyle variables18. Adolescents recruited at Maastricht UMC were 
offered additional polysomnographies as part of their medical screening at baseline and 
after one year of study participation. Ethical approval was obtained from all sites and the 
trial was registered at Clinicaltrials.gov (NCT01777893). 
2 Participants
Inclusion criteria for this study were an age between 10 and 17 years, overweight or 
(morbid) obesity defined as BMI z-score ≥1.0 SD, increased risk of developing T2DM (defined 
as homeostatic model assessment of insulin resistance (HOMA-IR) ≥2.0 for adolescents 
at Tanner stages ≥3 or any HOMA-IR for adolescents at Tanner stages 1-2), availability of 
polysomnography data, and written informed consent from caregivers and adolescents 
aged 12y or over18. Exclusion criteria included diagnosis of medical conditions or use of 
medications that might compromise study outcomes (e.g. diabetes, bariatric surgery or 
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metformin use), and issues that might limit study compliance (e.g. severe food intolerances). 
A total of 67 adolescents recruited at Maastricht University participated in this study for 
which additional polysomnographies were performed. Participant characteristics are 
presented in Table 5.1. 
3 Measurements
3.1 Anthropometric measurements, body composition and pubertal stage
Height and weight were measured while adolescents were in fasted state, barefoot, and 
wearing only underwear, using a calibrated scale (Seca, Chino, CA, USA) and wall-based 
stadiometer (De Grood Metaaltechniek, Nijmegen, the Netherlands). Because body mass 
index (BMI) in childhood is affected by periods of accelerated growth, age- and sex-adjusted 
BMI z-scores were calculated (Growth Analyzer VE, Rotterdam, the Netherlands) and obesity 
status using international obesity cut-off points14. Body composition was assessed using 
air displacement plethysmography (BodPod, Life Measurement Instruments, Concord, CA, 
USA)15. Pubertal stage was assessed according to the Tanner stadia for boys and girls16,17. 
3.2 Parameters of glucose metabolism, lipids, inflammation and blood pressure
After an overnight fast, blood samples were taken to measure concentrations of fasting 
blood glucose, total cholesterol, high-density lipoprotein (HDL) cholesterol, low-density 
lipoprotein (LDL) cholesterol, and C-reactive protein (CRP, COBAS 800 modular analyser, 
Roche, Woerden, the Netherlands). Fasting insulin and HbA1c concentrations were 
measured with the fully automated HPLC Variant II 15 (Bio-Rad Laboratories, Veenendaal, 
the Netherlands). HOMA-IR (calculated as fasting glucose concentration (mmol/L) * fasting 
insulin concentration (mU/L) / 22.5) was used as a proxy of insulin resistance18. Blood pressure 
and heart rate were measured three times on the right arm (Mobil-O-Graph, I.E.M., GmbH, 
Stolberg, Germany). An average of 3 measurements was used for analyses. 
3.3 Sleep 
Sleep was objectively measured using polysomnography during an overnight stay at the 
paediatric intensive care unit of Maastricht UMC. Analyses with BrainRT (v2.1, OSG, Rumst, 
Belgium) assessed duration of Total Sleeping Time (TST), Wake After Sleep Onset (WASO), 
and the different sleep stages Rapid Eye Movement (REM) sleep, and non-REM sleep 
phases N1, N2 and N3 (also known as Slow Wave Sleep (SWS)). In addition, Quality Sleep 
(QS, calculated as (REM+SWS)/TST) was determined19. Habitual TST was measured during 4 
consecutive nights at home with the Actisleep GT3X (Actigraph Corp., Pensacola, FL, USA), 
applying a fully automated algorithm developed for use in 24-h waist worn accelerometer 
protocols. The algorithm produces estimates of a nocturnal sleep period that are compared 
with an expert visual inspection of accelerometer trace20. Subjectively experienced sleep 
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was assessed using the Pittsburgh Sleep Quality Index (PSQI), where higher scores indicate 
poorer sleep quality and which for clarity will be formulated as PSQI (poor) sleep quality in 
this paper21. 
4 Statistical analyses
A sample size of 40 adolescents at 1y follow-up was required to demonstrate an association 
of changes in sleep duration with HOMA-IR with an alpha of 0.05 and a power of 0.809. 
Analyses were performed with IBM SPSS Statistics for Windows (v24, IBM Corp., Armonk, 
NY, USA). Comparison of drop-outs with study completers were assessed with independent 
Student’s T-tests and Mann-Whitney-U tests, as appropriate. Changes over time were 
determined with repeated measures ANOVA or Wilcoxon signed rank analyses in the group 
that had a follow-up polysomnography assessment. Associations between (change in) 
sleep parameters and (change in) outcome parameters were assessed using Pearson’s or 
Spearman’s correlation coefficients, as appropriate. Associations at baseline were corrected 
for sex, Tanner stage and BMI z-score. A two-sided p-value of 0.05 or less was considered to 
be statistically significant. 
RESULTS 
Sixty-seven participants from PREVIEW were eligible for this sleep study (Figure 5.1). After 
one year of study participation, a second polysomnography was performed in 29 subjects 
(43.3%). Reasons for not participating in the follow-up polysomnography were drop-out of 
the PREVIEW study (n=18) or refusal of a second polysomnography measurement (n=20). 
Baseline characteristics are presented in Table 5.1. 
At baseline, actigraphy-measured habitual TST was negatively associated with age, BMI 
z-score, absolute fat mass, and fat mass as a percentage of body weight, and was associated 
with sex (Table 5.2). Polysomnography-measured SWS and QS were negatively related to 
age, Tanner stage, FFM and FM. Time spent in phase N2 sleep was positively related to age, 
Tanner stage and FFM. After correcting for Tanner stage and sex, only inverse associations 
of habitual TST with BMI z-score, FFM and FM remained significant. No associations were 
observed between the outcome of the sleep questionnaire and anthropometric character-
istics. 
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Associations of sleep parameters with glucose metabolism, cardiovascular risk and 
inflammation were corrected for Tanner stage, BMI z-score and sex (Table 5.2). Phase N2 
sleep was inversely related to diastolic blood pressure, independent of the correction factors 
mentioned (Table 5.3). No other associations were found between sleep duration or sleep 
architecture parameters and glucose metabolism, cardiovascular risk, or inflammation. 
Twenty-nine subjects (43.3%) participated in the sleep assessment after one year. 
No significant differences in anthropometric characteristics, cardiovascular risk or sleep 
parameters were observed between the study completers and drop-outs (data not shown). 
The characteristics of the 29 adolescents participating in both baseline and follow-up 
polysomnography are presented in Table 5.1. After one year mean BMI z-score decreased 
significantly while height, weight, FFM and FM increased (Dorenbos et al. submitted). Changes 
were observed in neither sleep duration or sleep phases, nor in self-reported sleep quality 
using the PSQI questionnaire (Table 5.1). 
Comparison of the different sleep assessment methods was made to identify 
possible associations between objective and subjective sleep characteristics (Table 5.4). 
No associations were found between habitual TST, measured by actigraphy at home, and 
polysomnography-measured TST assessed during hospital admission. PSG-measured 
Quality Sleep was negatively correlated with PSQI (poor) sleep quality, while phase N2 sleep 
was positively associated with PSQI (poor) sleep quality. WASO was positively related to 
daytime dysfunction on the PSQI questionnaire. Habitual TST, measured by actigraphy, was 
negatively correlated with PSQI (shorter) sleep duration.
 
 
Figure 5.2 Flowchart 
 
 
 
 
 
 67 eligible for baseline 
polysomnography analyses 
38 drop-out 
* 18 drop-out within 1y 
* 20 refused 2nd polysomnography 
29 included for polysomnography 
follow-up analyses at 1y  
Figure 5.1: Flowchart 
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5
DISCUSSION 
This is the first study to assess the relationship of objective and subjective sleep characteristics 
with anthropometric and cardiometabolic parameters and changes herein in adolescents 
with overweight and obesity. After correcting for pubertal stage and sex, habitual sleep 
duration was negatively related to BMI z-score. Phase N2 sleep was negatively related to 
diastolic blood pressure, independent of puberty, BMI z-score and sex, but no other sleep 
parameters were associated with anthropometry or cardiometabolic risk. PSQI (poor) sleep 
quality scores were inversely associated with PSG-measured Quality Sleep, habitual TST, 
and positively with phase N2 sleep and WASO (wake-up after sleep onset). Habitual sleep 
duration (measured by actigraphy) and polysomnography measured sleep durations were 
not related.
At baseline, the inverse relation between habitual TST with BMI z-score, absolute fat 
mass and fat free mass remained significant after correction for pubertal stage and sex, 
indicating that adolescents with overweight/obesity with a higher BMI z-score had shorter 
sleep duration, independent of pubertal stage. Earlier studies have already shown an 
inverse association between sleep duration and obesity in adolescents and adults of all 
weight classes6-8. These results suggest that in adolescents with overweight/obesity, sleep 
duration but not parameters of sleep architecture, were related to severity of overweight 
and body composition. 
Associations between sleep variables and parameters of glucose metabolism, cardio-
vascular risk and inflammation were corrected for Tanner stage, BMI z-score and sex to 
eliminate confounding effects of obesity status and puberty. Phase N2 sleep duration was 
negatively related to diastolic blood pressure at baseline, suggesting that adolescents who 
had less phase N2 sleep had higher diastolic blood pressure. A weak negative association 
between sleep duration and DBP has been observed before, and is speculated to be 
related to nocturnal non-dipping in adolescents with obesity and increased sympathetic 
nervous system activity8,10,22. No associations were observed between total sleep duration, 
duration of the different sleep stages, and self-reported sleep, with parameters of insulin 
resistance, cardiovascular risk and inflammation after correction for confounders. A recent 
meta-analysis of studies found no overall association between sleep duration and HOMA-
IR8. Although some studies reported positive associations between SWS sleep duration and 
measures of insulin sensitivity23-25, those findings could not be confirmed in this study. It 
should however be noted that these studies were performed in mixed groups of lean and 
overweight adolescents, whereas in this cohort all adolescents were overweight/obese and 
had relatively high HOMA-IR concentrations at baseline. In line with our findings, studies in 
lean and obese adolescents observed no overall associations between sleep duration and 
phases with dyslipidaemia and CRP8,26. 
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To this date, only one study in adolescents has been performed in a longitudinal 
design27. In this cohort 29 adolescents (43.3%) participated in a second polysomnography. 
Drop-out or refusal to undergo a second polysomnography might be due to the intensive 
nature of the measurement (polysomnography required an overnight stay at the paediatric 
ward). None of the measured parameters of sleep duration and architecture at baseline were 
significantly different between adolescents that participated in a second polysomnography 
and drop-outs. Both objectively measured and self-reported sleep parameters did not 
change significantly during 1-year study participation. We speculate that the reduction in 
BMI z-score may have counteracted the reduction in sleep duration as was earlier reported 
by progressing age and Tanner stage3. 
Polysomnography is the gold standard for assessment of sleep architecture but requires 
overnight hospital admission, making it an invasive and costly procedure. In adolescents 
mainly actigraphy to assess daily sleep during multiple nights, or sleep questionnaires to 
assess experienced sleep quality (PSQI) are used. In this study both objective and subjective 
sleep measurement methods were combined to assess a full range of objectively measured 
and experienced sleep parameters. Self-reported poor sleep duration was negatively 
associated with actigraph-measured TST, and higher self-assessed sleep quality was related 
to higher percentages of SWS and REM sleep. Similarly, higher WASO was positively related 
with higher self-reported daytime dysfunction scores. These relationships suggest that 
PSQI scores are indicative for polysomnography outcomes. On the other hand, associations 
of sleeping duration with anthropometric characteristics were different for actigraph-
measured TST and polysomnography-measured TST, and these two were not interrelated 
(r=-0.112, p=0.090). This might be explained by measurements during different nights: 
actigraph-measured habitual TST was measured during 4 consecutive nights at home 
while polysomnography-TST was measured during one night at an in-hospital setting. In 
conclusion, PSQI (poor) sleep quality scores were indicative of polysomnography outcomes, 
while actigraphy and polysomnography measured sleep duration were not related28. The 
use of both field and self-assessed sleep measurement methods may complement each 
other when combined. 
As far as we know, this is the first exploratory study to assess the relationship of sleep 
parameters with anthropometric characteristics and cardiometabolic parameters and 
changes herein over time, in adolescents with overweight and obesity. Moreover, this is 
the first study to use longitudinal PSG measurements and one of the first to use multiple 
actigraph-measurements over time in adolescents without sleep syndromes9,29-31. Strengths 
of this study are the longitudinal design where adolescents were measured during one year 
follow-up, as well as the correction for confounders puberty, sex and BMI z-score. Also novel 
is the combination of both objective and subjective sleep measures in an adolescent cohort. 
A limitation is the large drop-out for a second polysomnography measurement resulting in 
a small sample of adolescents eligible for longitudinal assessments. 
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In conclusion, the inverse association of sleep duration with BMI z-score in adolescents 
with overweight/obesity confirms earlier observations of sleep duration with risk of 
obesity. Previously reported relationships with insulin resistance, cardiometabolic risk 
or inflammation were not confirmed in adolescents with overweight/obesity. Phase N2 
sleep duration was inversely associated with diastolic blood pressure. PSQI (poor) sleep 
quality scores were indicative of polysomnography outcomes, while actigraph- and 
polysomnography-measured sleep duration were not related. More studies are needed 
to assess changes in sleep duration and architecture parameters, and the effects of sleep 
hygiene interventions, on cardiometabolic health in adolescents without sleep syndromes. 
We would recommend future sleep studies to include both objective as well as self-reported 
sleep measurement methods. 
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ABSTRACT 
Introduction
Non-alcoholic fatty liver disease (NAFLD) and insulin resistance (IR) often co-develop with 
obesity. This study assessed associations between NAFLD activity, IR and BMI z-score in 
adolescents with overweight/obesity during lifestyle intervention. 
Methods 
126 participants from the PREVIEW study (59% girls, BMI z-score 3.04±0.66) were guided 
to increase protein intake and physical activity. Changes in BMI z-score and HOMA-IR were 
assessed in participants with aminotransferase (ALT) concentrations below and above the 
upper limit of normal (ULN), indicative of NAFLD. 
Results
32.5% of adolescents presented with ALT concentrations>ULN. Change in BMI z-score was 
significantly less in subjects with ALT concentrations>ULN after 1y intervention, compared 
to subjects with ALT concentration<ULN. NAFLD was positively related to BMI z-score and 
change herein after 1y. Baseline ALT concentration was positively associated with HOMA-IR. 
Conclusions
Increased ALT concentration, indicative of NAFLD, was positively associated with baseline 
BMI z-score, and associated with less BMI z-score change after 1y lifestyle intervention. 
Baseline ALT concentration was positively related to IR. These associations should be 
confirmed in larger studies.
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INTRODUCTION 
One of the major concerns of the obesity epidemic is the surge in obesity-related comor-
bidities in adolescents, such as insulin resistance (IR), dyslipidaemia and non-alcoholic 
fatty liver disease (NAFLD)1. IR has been shown to be a risk factor for developing type 2 
diabetes mellitus, and previously we and others have shown IR to be related to BMI 
z-score in adolescents with overweight/obesity2-8. NAFLD encompasses a spectrum of liver 
diseases in the absence of excessive alcohol consumption, ranging from hepatic steatosis to 
steatohepatitis, liver fibrosis and cirrhosis, and has been related to obesity9,10. Measurement 
of serum aminotransferase (ALT) concentrations are commonly used as a proxy for NAFLD 
in children11. Interestingly, IR and NAFLD frequently co-develop in adolescents with 
overweight/obesity and appear to affect each other negatively. It has been proposed that 
their pathophysiological mechanisms are largely similar9,10,12,13. Increased circulating free fatty 
acids (FFA) are related to ectopic lipid deposition in muscles and in the liver, thus contributing 
to liver steatosis, as well as promoting a low-grade inflammatory state9,10,12,13. Inflammation 
and elevated FFA concentrations reduce cellular glucose uptake, thereby inducing IR and a 
compensatory increase in pancreatic β-cell insulin secretion14. Thus, IR and NAFLD reinforce 
one another, where IR is a driver for the development of NAFLD by contributing to hepatic 
steatosis, and NAFLD might exacerbate especially hepatic IR9,10,12,13,15,16. 
Recent studies demonstrated that adolescents who were insulin resistant were less 
successful in decreasing BMI z-score during intervention than adolescents that were not 
insulin resistant, suggesting that the presence of comorbidities might relate to outcomes 
of lifestyle interventions targeting adolescent obesity17,18. Considering the closely related 
pathophysiological mechanisms of IR and NAFLD, it is relevant to assess the effect and 
associations of NAFLD activity with BMI z-score, IR and intervention-induced changes 
thereof2,19. 
The PREVIEW study in adolescents aimed to assess the effect of lifestyle intervention to 
decrease IR and BMI z-score in adolescents with overweight/obesity20. The purpose of this 
substudy was to assess the possible contribution of NAFLD, indicated by increased serum 
ALT concentrations, to BMI z-score, glucose metabolism and changes herein in adolescents 
with overweight/obesity during lifestyle intervention. 
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MATERIALS AND METHODS  
1 Study design
The PREVIEW study in adolescents was a lifestyle intervention designed to assess the role 
of lifestyle interventions on anthropometric characteristics and parameters of glucose 
metabolism and liver transaminases in adolescents with overweight/obesity and IR20. As 
previously published, participants received instructions to increase dietary protein intake 
while reducing glycaemic index, and to increase physical activity (PA)20. The study was 
approved by local Medical Ethics Committees, compliant with the Declaration of Helsinki 
and ICH-GCP and published on ClinicalTrials.gov (no. NCT01777893). 
2 Participants 
126 Adolescents were recruited at Maastricht University (Maastricht, the Netherlands), 
University of Navarra (Pamplona, Spain) and Swansea University (Swansea, United Kingdom). 
Inclusion criteria were overweight or obesity (defined as BMI z-score >1.0 SD), increased 
IR (defined as Homeostatic Model Assessment of Insulin Resistance (HOMA-IR) >2.0 for 
adolescents Tanner stages ≥3 or any HOMA-IR at Tanner stages 1-2) and signed informed 
consent from parents and adolescents ≥12y. Exclusion criteria included medical conditions 
or medication use that could influence study outcomes (e.g. bariatric surgery, T2DM, 
metformin use)20, or secondary causes of elevated ALT concentrations (e.g. viral hepatitis). 
3 Measurements 
Height and weight were measured using a wall-mounted stadiometer (De Grood 
Metaaltechniek, Nijmegen, the Netherlands) and digital scale (Seca, Chino, CA, USA) while 
adolescents were in a fasted state, barefoot, and wearing only underwear. Age- and sex-
corrected BMI z-scores were calculated to assess overweight and obesity (TNO Growth 
Calculator, Den Haag, the Netherlands)21.
Blood samples were obtained after an overnight fast. Glucose and ALT concentrations 
were analysed using the COBAS 800 modular analyser (Roche, Woerden, the Netherlands). 
Concentrations of insulin and HbA1c were measured with the fully automated HPLC Variant 
II 155 (Bio-Rad Laboratories, Veenendaal, the Netherlands) and C-peptide concentration 
with Immulite XPI (Siemens, Eindhoven, the Netherlands). NAFLD was defined as ALT 
concentration above the upper limit of normal (ULN), corresponding to ALT>22.1 U/L for 
girls and ALT>25.8U/L for boys11. HOMA-IR was assessed using the formula: fasting glucose 
concentration (mmol/L) * fasting insulin concentration (mU/L) / 22.522. 
4 Statistical analyses
Statistical analyses were performed using IBM SPSS Statistics for Windows version 24 (IBM 
Corp., Armonk, NY, USA). Subjects were divided into group 1 (ALT concentrations <ULN) 
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and group 2 (ALT concentrations >ULN), and compared using factorial ANOVA’s and Mann-
Whitney-U tests. Changes over time were analysed with repeated measures ANOVAs. 
To assess the effect of NAFLD activity in the whole group, the binary variable “NAFLD 
activity” was made in which subjects with concentrations below the ULN were numbered 
as “0” and those with ALT concentrations >ULN as “1”. A multi-step regression model was 
used where sex, Tanner stage and BMI z-score were added as co-variates to observe their 
effect on the overall model, as they have been associated with IR previously9,10. A two-sided 
p-value smaller <0.05 was considered statistically significant. 
RESULTS  
One hundred twenty-six adolescents were eligible for baseline measurements, and 83 
(65.9%) adolescents participated in follow-up measurements after 1y intervention. Drop-
outs and study completers did not differ in any of the variables measured at baseline 
(Dorenbos et al. unpublished results). 
Differences in intervention outcomes between subjects with ALT concentrations above 
the ULN, indicating active NAFLD, and those with ALT concentrations below the ULN 
Participant characteristics are presented in Table 6.1. Fourty-one adolescents (32.5%) 
presented with ALT concentrations >ULN, of which 43.9% were girls (compared to 65.9% in 
the group with ALT concentration <ULN). In group 2 (ALT concentrations >ULN) 43.9% were 
girls while in group 1 (ALT concentrations >ULN) 65.9% were girls, although this was not 
significant. Age and Tanner stage were not different between the two groups. 
After 1y lifestyle intervention Tanner stage increased in both groups. Treatment*time 
analyses indicated that weight had increased significantly more in group 2 (ALT 
concentrations above ULN), compared to group 1 (p<0.05, Table 1). BMI z-score decreased 
only in group 1 (p<0.01) but not in group 2, and change in BMI z-score was statistically 
significantly different between the two groups (p<0.05). ALT concentration increased in 
group 1 (ALT concentrations >ULN) while this remained stable in group 2 (ALT concentrations 
above ULN), and the change in ALT concentrations between the groups was statistically 
significant (treatment*time; p<0.01). Other changes in anthropometric characteristics and 
parameters of glucose metabolism were not significantly different between the two groups.
Associations of ALT concentration, and ALT concentration above the ULN, with BMI 
z-score and HOMA-IR at study onset and after one year of intervention
In a multivariate regression model in the whole group in which multiple co-variates (ALT 
concentration, BMI z-score, sex and Tanner stage) were entered, ALT concentration, sex and 
BMI z-score were identified as independent contributors to baseline HOMA-IR (Table 6.2A). 
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6
HOMA-IR and sex were associated with baseline BMI z-score. ALT concentration at baseline 
was not related to BMI z-score. 
Associations of NAFLD activity with BMI z-score and HOMA-IR at baseline and after 1y 
intervention was assessed in multiple-step regression models (Table 6.2B). ALT concentration 
>ULN, compared to ALT concentration <ULN, was positively associated with baseline BMI 
z-score although this disappeared after adding sex and Tanner stage as covariates. In 
addition, NAFLD activity was positively related to BMI z-score change after 1y. After adding 
sex and Tanner stage as co-variates the positive association of NAFLD with change in BMI 
z-score remained, although the overall model was no longer significant. NAFLD activity was 
not related to HOMA-IR at baseline, 1y or change herein. No collinearity was found between 
the factors included in these models. 
DISCUSSION
This PREVIEW study aimed to assess the role of ALT concentration as a marker of NAFLD 
on outcomes of a combined lifestyle intervention, in particular BMI z-score and HOMA-
IR, in adolescents with overweight/obesity. ALT concentrations >ULN, indicating NAFLD, 
were present in 1/3 of adolescents with overweight/obesity. Baseline ALT concentration 
was positively related to IR, although ALT concentration >ULN was not. After 1y PREVIEW 
intervention BMI z-score decreased significantly in the group of subjects with ALT 
concentrations <ULN, but not in those with abnormal ALT concentrations. NAFLD activity 
at baseline, compared to normal ALT concentration, was identified as a contributor to BMI 
z-score and change herein after 1 year lifestyle intervention.
A total of 32.5% of adolescents with overweight/obesity in this cohort presented with 
ALT concentrations >ULN. Prevalence of NAFLD was recently estimated to be ~34% in 
children with obesity19, confirming this result of the present study. The golden standard for 
NAFLD diagnosis is liver biopsy, but due to the invasiveness of this procedure evaluation 
of ALT concentrations are more commonly used in paediatric practice. The ALT cut-
off values used in this study have previously been shown to have a high sensitivity and 
specificity in both boys and girls and are widely used as a marker for NAFLD11. There were 
more boys in the group with elevated ALT concentrations compared to the group with 
normal ALT concentrations, although this was not statistically significant. Interestingly, ALT 
concentrations increased significantly in the group with normal baseline ALT, although 
mean ALT concentration at 1y did not surpass the ULN. 
Baseline BMI z-score was not different between the group with normal ALT concentrations 
and those with ALT concentrations >ULN. Adolescents with overweight/obesity and elevated 
ALT concentrations showed no change in BMI z-score after one year lifestyle intervention, 
while adolescents with normal ALT concentrations significantly decreased BMI z-score. The 
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change in BMI z-score after 1y was statistically significant between both groups, and NAFLD 
activity was positively associated with baseline BMI z-score and change herein. At baseline 
this association was no longer significant after adding sex and Tanner stage as covariates, 
indicating that sex and puberty mediated this relationship. However, the positive association 
between NAFLD activity and BMI z-score change remained significant after adding sex and 
Tanner as co-variates into the regression analyses. These results indicate that NAFLD at 
onset was a risk factor for less BMI z-score decrease during intervention. 
Although baseline ALT concentration was positively related to HOMA-IR, no significant 
associations were observed between ALT concentrations >ULN and HOMA-IR or change 
herein. It is possible that the relation between NAFLD and IR is only indirect as our and others 
data showed a significant association between NAFLD and baseline IR only after adding sex 
and Tanner stage, although this was not observed after 1y15,16,23. Furthermore, no change 
in HOMA-IR was observed in this study which may also have masked a possible effect of 
NAFLD activity on HOMA-IR. Since changes in HOMA-IR were shown to be primarily related 
to changes in BMI z-score (Dorenbos, submitted), similarly to previous observations, possible 
associations between NAFLD and IR may be indirect and depending on BMI z-score15. 
As far as we know this is the first study assessing the effects of NAFLD on lifestyle 
intervention outcomes in adolescents with overweight/obesity. Limitations are the use of 
ALT concentration as a proxy for NAFLD activity due to the invasiveness of repeated liver 
biopsies and the relatively small sample size. 
In conclusion, this study demonstrated that 1/3 of adolescents with overweight/obesity 
presented with ALT concentrations above the ULN, indicative of NAFLD. Adolescents with 
elevated ALT concentrations had significantly less BMI z-score reduction after 1y lifestyle 
intervention. NAFLD was positively related to BMI z-score and change herein after 1y, 
suggesting that NAFLD might be a factor that affects lifestyle intervention outcome and 
success in adolescents with overweight/obesity. NAFLD was not directly associated with 
baseline IR or change herein. Although these results will have to be confirmed in larger 
cohorts, we recommend to screen for markers of NAFLD in childhood obesity interventions.
TABLE 6.2A: Prediction models for baseline BMI z-score and HOMA-IR 
  B SE 95% CI p-value R2 p-value model
BMI z-score model ALT (U/L) 0.002 0.004 (-0.006; 0.010) 0.681 0.210 <0.001**
HOMA-IR 0.099 0.025 (0.049; 0.149) <0.001**
Tanner stage 0.050 0.040 (-0.030; 0.130) 0.215
Sex 0.300 0.117 (0.069; 0.531) 0.011*
HOMA-IR model ALT (U/L) 0.036 0.013 (0.010; 0.063) 0.007** 0.229 <0.001**
 BMI z-score 1.249 0.293 (0.568; 1.729) <0.001**  
 Tanner stage 0.058 0.138 (-0.216; 0.332) 0.675  
 Sex -0.942 0.400 (-1.734; -0.155) 0.020*  
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This thesis aimed to evaluate the effects of lifestyle intervention for the treatment of high 
pubertal insulin resistance in adolescents with overweight and obesity, and to gain new 
insights in determinants of pubertal insulin resistance, specifically insufficient duration and 
quality of sleep, and non-alcoholic fatty liver disease (NAFLD). 
The prevention of diabetes through lifestyle intervention and population studies 
in Europe and around the world (PREVIEW) study was a large, international randomized 
controlled trial assessing the most effective combination of dietary and physical activity 
strategies to prevent type 2 diabetes mellitus (T2DM) in adults and adolescents1. The aim of 
the PREVIEW study in adolescents was to assess the effects of a high-protein low-GI diet (HP, 
25/45/30 En% protein/carbohydrate/fat, GI >56) or moderate-protein moderate-GI diet (MP, 
15/55/30 En% protein/carbohydrates/fat, GI <50) on IR in adolescents with overweight and 
obesity at increased risk for developing T2DM. It was hypothesized that the HP diet would 
be superior in reducing IR compared to the MP diet. The second aim of the PREVIEW study 
was to assess the role of possible risk factors for T2DM development, specifically sleep and 
non-alcoholic fatty liver disease, on intervention-related outcomes. 
COMPLIANCE TO AND FEASIBILITY OF THE LONG-TERM COMBINED 
LIFESTYLE INTERVENTION
Attrition 
Motivation to complete the PREVIEW study was less than expected. Based upon general 
recommendations this study used an expected drop-out of 25% in power analyses to 
assess sample size2. In this study however retention rates were 66% after one year and 
39% after two years. In the sleep substudy 40% of participants were willing to participate 
in a second overnight hospital stay for polysomnography measurement after one year. 
The main reason for study discontinuation was loss to follow up. Although no qualitative 
research was performed and the real rationale for study discontinuation are therefore not 
known, problems with recruitment and retention are common in childhood obesity studies 
and some reasons can be learned from earlier trials2. Frequently mentioned arguments 
are misalignment of the research purpose and methods with the goals and lifestyle of 
adolescents that would have to adhere to them, as was also described in a qualitative survey 
of the MIKADO study performed under drop-outs (Willeboordse, unpublished data). In the 
Centre for Overweight Adolescent and Children’s Healthcare (COACH) cohort, from which a 
large part of the participants for the PREVIEW study were recruited, attrition was 10% after 
one year but increased to 30% and 50% after two and three years3 (and unpublished data). 
One of the most used reasons for discontinuation was that participants felt that they had 
learned sufficiently about healthy lifestyle. In this cohort, the main reason for drop-out was 
also the program not meeting the patient’s expectations, or the feeling that patients had 
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gained enough knowledge on healthy lifestyle. A meta-analysis reported that drop-out rates 
in other lifestyle intervention studies for children with overweight/obesity varied between 
2 and 51% at 12 months4. Considering the intensive, long-term nature of the PREVIEW study 
and that most of the PREVIEW participants had already participated in one or more years of 
COACH intervention, the attrition rates seem in line with those of previous studies. 
However, as high attrition is such a common problem in adolescent (obesity) research 
and was also an obstacle in the PREVIEW study, some recommendations can be made to 
help future adolescent obesity research2. A recent study assessed the effect of consumer 
involvement in an adolescent obesity study, and found that inclusion of fun games, 
practical activities, resistance training and forming new friendships with other participants 
resulted in an impressive 82% and 62% of participants completing measurements at one 
and two years, respectively5-7. Based upon our and previous studies’ experiences, it might 
be helpful to involve adolescents in the design of the study, use more age-appropriate 
tools (e.g. e-health), and plan regular contacts and fun social activities to enhance study 
completion and compliance2,6. Furthermore, if interim analyses show that study compliance 
or completion is severely affected, as was demonstrated by the PREVIEW study where 
attrition after two years was very low and therefore not suitable for completer analyses, 
small adjustments to the study protocol might be considered to enhance overall compliance 
and usability of the study data.
Compliance to dietary instructions
Dietary instructions were provided during individual meetings with adolescents and their 
parents, which took place during regular clinical investigation days. All adolescents were 
provided with sample menus in line with their randomization group and individual dietary 
needs. After one and two years of dietary instructions, no significant changes in protein 
intake were observed between different timepoints or between the HP and MP intervention 
groups, despite the groups receiving different dietary instructions. However, total reported 
energy intake, as well as the absolute intake of fat and carbohydrates decreased significantly 
after one year of personalized dietary counselling. Participants also reported an increase in 
dietary restraint on the Three-Factor Eating Questionnaire after one and two years of study 
participation, indicating a more conscious eating pattern8. 
Thus far, seven studies have been conducted assessing the effects of a high-protein 
diet on BMI z-score in adolescents with overweight and obesity9-15, of which five reported 
a significant increase in dietary protein intake at 12 weeks11,12, 26 weeks13,14 or 12 months15, 
and two did not observe a difference in protein intake. All of the studies set in free-living 
conditions reported difficulties in dietary compliance9-13,15,16. If an increase in protein intake 
was observed, protein intake was on average ~21En%, which was less than the targets set 
between 22.5 and 25En%. 
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There are a couple of reasons that might explain why an increase in protein intake could 
not be achieved in the PREVIEW study. Firstly, the method of assessing dietary compliance 
was different. The PREVIEW study assessed food intake using self-reported food diaries 
because they were easy to use, were available on an app, and allowed for quick and easy 
evaluation and feedback during measurement contacts. Although this is the most frequently 
used tool for dietary assessment in research settings, food diaries are known to often 
underreport actual food intake17,18. This might have been the case in the PREVIEW study, too, 
as adolescents reported a markedly lower total energy intake compared to their estimated 
energy requirements from the WHO formula19. Moreover, the increase in weight and BMI 
sec implicate that in reality, an increase in energy intake must have taken place. The data of 
this study therefore does not allow conclusions on whether the absence of differences in 
protein intake truly is a result of insufficient dietary compliance. Other methods that have 
been previously used in adolescent studies are meal observation in an in-centre design or 
a 3-pass 24h dietary recall, although the latter is self-reported and therefore also presents 
with problems in reliability9-11,13,15. While these methods may improve validity of the reported 
food intake, it might not be representative of normal eating behaviour. An alternative is the 
use of urine-nitrogen sampling as was performed by the PREVIEW study in adults, but this 
was not deemed to be safe for adolescents1.
Considering design, the PREVIEW study was set in free-living conditions as opposed to 
the in-centre design9-11 or supervised grocery shopping designs as used in the studies13,14. 
While this is more representative of normal living circumstances, a free-living design also 
allows participants more freedom to (not) adhere to the dietary guidelines. This study also 
differed from the other studies in that instructions were highly personalized and tailored on 
the needs of the adolescent, instead of focussed on the whole family, and had fewer contact 
moments than some other studies11-15. Although this made the PREVIEW study less intensive 
than some of the previous studies, it might have negatively affected dietary compliance. It 
should also be noted that Garnett et al. provided additional metformin medication, which is 
known to enhance BMI z-score reduction and might therefore have influenced motivation 
and study compliance15. 
One last important difference is that the study duration of the PREVIEW study was longer 
than in the previously conducted studies, where the intervention ranged from 12 weeks to 
12 months. Longer study duration might have compromised dietary compliance, as was 
also observed in the study by Mirza et al. where protein intake was significantly increased at 
12 weeks of active intervention, but not after 12 and 24 months when adolescents received 
ambulatory instructions11. One study in adults demonstrated that protein intake stimulated 
satiety centres in the brain but reduced reward mechanisms, which may explain difficulties 
in maintaining high protein diets for an extended period of time20.
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In conclusion, the dietary intervention of the study as it was designed was not feasible. 
The absence of a significant difference in protein intake in adolescents in this study may 
be attributable to under- or misreporting of actual food intake, the free-living design, the 
relatively long duration of the trial and the effects of protein on the brain reward system. 
The results of the PREVIEW study and previous protein studies in adolescents do however 
demonstrate that maintaining and achieving high protein intake for an extended period of 
time is not feasible in adolescent populations in free-living conditions. It is possible that this 
is only achievable long-term using vouchers or subsidies for products high in protein, meal 
replacement, or with protein supplements. 
Compliance to physical activity instructions
Physical activity instructions consisted of encouragement to increase physical activity of 
any sort. In the PREVIEW study in adolescents, physical activity was not a part of the RCT 
and therefore not protocolized. However, as physical activity is an important part of health 
recommendations for childhood obesity, PA recommendations were provided and exercise 
in general was encouraged on a regular basis. Instructions were highly personal and mainly 
focused on participants finding and continuing on a form of exercises they enjoyed to 
encourage long-term compliance. So, if a participant did already participate in sports, they 
were encouraged to maintain and expand on this. If they did not already participate in 
any form of exercise, they were invited to join weekly physical activity orientation classes 
especially designed for adolescents with overweight and obesity. In addition to these 
instructions, all adolescents received booklets specifically designed for the PREVIEW study, 
with tutorials and exercised they could perform at home. 
During the PREVIEW study, measurements after one and two years showed a significant 
increase in accelerometry counts, moderate, vigorous and moderate-to-vigorous activity 
while sedentary time was decreased. This is particularly encouraging since an earlier 
observational study found that PA generally decreased for each year that a child aged, 
mainly caused by a relative increase in time spent sedentary21. It should also be considered 
that although counts provide a quantification of the performed activity, it does not per 
se quantify energy expenditure. Indeed, earlier studies have indicated that in individuals 
with higher weight and BMI, PA counts may be lower but energy expenditure per activity 
is higher compared to lean individuals22,23. In our study it is likely that the increase in PA is 
attributable to the personalized coaching and the focus on making sports a habitual, fun 
activity. 
PSM 20200422 Proefschrift Elke Dorenbos (11246).indd   129 14-08-20   09:31
130
Chapter 7 | General discussion
OBSERVATIONS DURING THE PREVIEW INTERVENTION
HOMA-IR stabilized after one year of study participation, despite progression in 
pubertal status
Even though the incidence of T2DM in youth is increasing, the study of preventative 
strategies for T2DM would require very large cohorts and long follow-up time, which 
propels most studies in adolescents to use IR as a precursor for diabetes. As discussed in 
the introduction of this thesis pubertal IR is a complicated and challenging research area, 
as it is both a physiological process but also poses an increased risk for developing T2DM 
and other normally late-onset morbidities. It is therefore the question to what extend IR 
should be meddled with. Currently there is enough evidence to ascertain that IR during 
puberty is necessary to facilitate normal tissue proliferation and growth, but that increased 
IR – especially in the presence of other risk factors such as obesity – severely increases the 
risk of an adolescent to develop T2DM and related morbidity24-26. Therefore, especially the 
monitoring and prevention of further IR increase is important. 
One of the most important determinants of IR is obesity status. Cross-sectional studies 
have shown a comparable but enhanced pattern in adolescents with overweight and 
obesity, where HOMA-IR is higher than in lean peers at the onset of puberty, reaches higher 
values at mid-puberty, and does not always decrease as adolescents enter adulthood25,27-33. 
A similar effect was observed in two studies described in this thesis. The study presented 
in CHAPTER 2 of 137 adolescents (aged 10-18) with overweight and obesity demonstrated 
that postpubertal boys (Tanner stages 4-5) had significantly higher HOMA-IR than 
prepubertal boys, although this effect was not found in girls34. This was confirmed in the 
baseline descriptives of the 126 adolescents (age 10-17) with overweight/obesity and IR 
that participated in the PREVIEW study (CHAPTER 3). Here, too, pubertal (Tanner stages 
3-5) adolescents with morbid obesity demonstrated significantly higher HOMA-IR values 
compared to prepubertal adolescents with morbid obesity, and to prepubertal and pubertal 
adolescents with overweight and obesity35. Earlier studies showed that higher HOMA-IR in 
individuals with overweight/obesity might be a result of the increased ectopic fat storage 
related to obesity36,37. It has been postulated that persistent IR at the end of puberty, 
especially in those with morbid obesity, puts these postpubertal adolescents at especially 
high risk for β-cell exhaustion and T2DM development25,27,34. 
Mean HOMA-IR did not change significantly after one year of intervention but increased 
after two years. As described previously, IR of puberty typically nadirs at mid-puberty 
(CHAPTER 4). The stabilization of HOMA-IR after one year of intervention despite progression 
in pubertal state indicates that IR did not exacerbate further in the first year of intervention. 
Change in HOMA-IR after one year of study participation was positively related to 
change in BMI z-score, and HOMA-IR stabilized or decreased in individuals that showed a 
significant reduction in BMI z-score. In addition, HOMA-IR and BMI z-score were consistently 
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positively related in cross-sectional analyses at baseline and after one year of intervention. 
No direct associations were found between possible changes in food intake or PA with 
HOMA-IR change. It is possible that the stabilization of HOMA-IR despite the progression in 
pubertal stage in our cohort is due to the overall decrease in BMI z-score, or that the intra-
individual change in HOMA-IR after one year in puberty is smaller than what is reflected in 
the previously published cross-sectional studies25,27. The cross-sectional increase in HOMA-
IR in those studies might also be related to differences in mean BMI z-score per Tanner 
stage group. Nonetheless, the results from this study indicate that BMI z-score is one of 
the most important independent determinants of HOMA-IR in adolescents with overweight 
and obesity, as was shown by a constant positive relationship between IR and BMI z-score, 
IR being the highest in adolescents with the most severe obesity grade, and stabilization 
of IR after one year as BMI z-score decreased. This was a confirmation and extension of 
earlier studies observing a consistent positive association between BMI z-score and IR in 
adolescents25,36,37. 
After two years of PREVIEW intervention mean HOMA-IR increased as pubertal stage 
progressed further. BMI z-score had decreased significantly from baseline measurements 
(but not compared to data at 1 year of intervention). It is possible that this increase in IR 
is attributable to the peak in IR normally shown in mid-puberty, while relative BMI z-score 
change between one and two years of PREVIEW intervention was too small to counteract 
for this. However, these results do indicate a persistence of high IR at the end of puberty 
in adolescents with overweight and obesity in our data, as has also been suggested by a 
longitudinal study on pubertal IR by Goran et al31. No further longitudinal studies have been 
published on pubertal IR development in adolescents with overweight/obesity, but cross-
sectional observations from the COACH study and PREVIEW baseline study (CHAPTERS 2 
& 3), as well as that from other large cross-sectional studies, also indicate that adolescents 
with especially higher grades of obesity show a persistent instead of transient high IR during 
puberty27,29. Although these findings should be confirmed in larger studies with long follow-
up, they do emphasize the necessity to prevent further IR exacerbation during puberty, 
especially in adolescents with overweight and obesity.
BMI z-score was significantly reduced after one and two years of dietary and 
PA counselling 
Post-hoc analyses showed that after one year of PREVIEW participation mean BMI z-score 
decreased with -0.17 SD in adolescents with overweight/obesity and IR, and after two 
years this further decreased with -0.19 SD (CHAPTER 4). Recent meta-analyses of lifestyle 
intervention studies in children with overweight and obesity (but not necessarily IR) 
showed that a reduction of ≥-0.15 SD was related to significant clinical improvements in 
insulin sensitivity, lipid concentration (specifically total cholesterol and LDL-cholesterol 
concentrations), and normalization of blood pressure38,39. Cochrane meta-analyses recently 
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observed a mean BMI z-score reduction of -0.14 SD (95% CI -0.17; -0.12) after 6 months and 
-0.14 SD (95% CI -0.18; -0.10) at 12 months, which is less than the BMI z-score decrease that 
was observed in our present study4,40. Moreover, in previous lifestyle intervention studies 
those individuals with IR did not decrease BMI z-score after one to fourteen years or even 
increased their BMI z-score during intervention41-45. It is therefore promising that in this 
study, where participants were selected based upon their IR status, a BMI z-score decrease 
was observed that was both statistically significant and clinically relevant and which did not 
rebound after a prolonged time period. It should be mentioned that weight and BMI did 
increase during the study, even as BMI z-score decreased. This indicates that although an 
increase in energy intake must have taken place to result in these changes, this increase was 
relatively mild in relation to PA and growth to yield an overall BMI z-score reduction. 
Increased dietary restraint scores on the TFEQ were related to reduction of BMI z-score 
after one year in this population, indicating that individuals that acquired more conscious 
and controlled eating behaviours showed a reduction in BMI z-score. Increase in TFEQ 
hunger scores was positively related with BMI z-score change, indicating that those with 
increased hunger susceptibility (possibly as an effect of more controlled eating behaviours) 
did not decrease BMI z-score. This might be partly explained by genetic predispositions8. No 
associations were found between changes in PA and BMI z-score. 
No changes were observed in parameters of lipids or inflammation
After one and two years of intervention, a small but significant increase in fasting glucose 
concentration was observed which at two years also resulted in a higher HOMA-IR. After 
one year a small increase in ALT concentrations was detected in the imputed data, although 
this was not observed in the measured data of the completers at one year. No changes were 
observed in other parameters of glucose metabolism, lipids or inflammation parameters. 
Although some studies did observe a decrease in systolic and diastolic blood pressure or 
lipids at the end of the active intervention period, this was not confirmed in our and others 
studies10,11,15,16. Participants in our study presented with mean values within normal ranges 
for blood pressure, lipids, and parameters for liver function and inflammation at study onset, 
it is therefore possible that no change was observed since these values were already within 
the healthy range. 
RISK FACTORS FOR BMI Z-SCORE, IR AND INTERVENTION-RELATED 
HEALTH OUTCOMES
Habitual short sleep duration was positively related to BMI z-score 
As described previously, the second aim of the PREVIEW study was to assess the role of 
other risk factors that might be associated with BMI z-score and HOMA-IR change during the 
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PREVIEW intervention. Short sleep duration and sleep debt have been extensively related to 
increased risk of developing obesity in adults and adolescents, and to lesser extent, pubertal 
IR46-48. Sleep has therefore been proposed to be, in addition to food intake and PA, a third 
modifiable contributor to the development of obesity and IR46,48-54. 
For the study presented in CHAPTER 2, 137 adolescents with overweight or obesity were 
subjected to a cross-sectional polysomnography measurement. In prepubertal girls, but not 
girls in other pubertal stages or in boys, both total sleeping time (TST) and sleep efficiency 
(SE, calculated as TST/time in bed) were negatively related to HOMA-IR. This indicated that 
inadequate sleep duration may indeed negatively affect IR, possibly because longer sleep is 
a protective factor for glucose metabolism and pancreatic β-cell compensation26. 
In the follow-up study presented in CHAPTER 5, 67 adolescents with overweight/
obesity and IR of the PREVIEW study were subjected to a polysomnography. Habitual total 
sleeping time was inversely related to baseline BMI z-score and absolute fat mass and fat free 
mass, even after correcting for pubertal stage. This indicated that short sleep was not only a 
risk factor for developing overweight, but is also related to higher BMI z-score in adolescents 
that were overweight/obese at the start of the intervention. No associations were observed 
between parameters of sleep architecture and anthropometric or cardiometabolic 
outcomes, suggesting that overall absolute habitual sleep was more important in obesity 
than sleep quality. In 29 adolescents sleep assessments were repeated after one year of 
study participation. No decline in sleep duration was observed, which might be due to 
either the low number of adolescents participating in the follow-up study or the relatively 
short follow-up time. Possibly also as a consequence of stabilization of sleep duration and 
small sample size, no associations were observed between changes in parameters of sleep 
duration and architecture, and changes in anthropometric and cardiometabolic health 
parameters. 
The observation that habitual sleep was associated with BMI z-score at study onset is a 
confirmation of earlier studies that found a similar relationship in cohorts consisting of lean 
children and children with overweight/obesity. This might be explained by a few reasons, 
as presented by Quist et al48. First, shorter sleeping duration results in more opportunity 
to eat, which especially later in the day is often marked by intake of high-caloric foods and 
drinks. Second, inadequate sleep has been related to changes in hormones, particularly 
a decrease in leptin and increase in ghrelin, as well as influencing reward-related brain 
functions leading to a preference for energy-dense foods. This can also lead to higher 
energy intake. Lastly, inadequate sleep results in more daytime fatigue, which can lead to 
making less healthy food choices and a decrease in energy expenditure, while sedentary 
time is increased. Unfortunately, the sample size of this exploratory study was too small to 
study associations between sleep duration and physical activity or dietary intake. We can 
therefore only conclude that sleep is a risk factor for higher BMI z-score in adolescents even 
in those that were overweight/obese at study onset, and sleep hygiene might be a target for 
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prevention and treatment of obesity in youths, although this should be confirmed in future 
longitudinal studies. 
The latter part of CHAPTER 5 presents a comparison of objective and subjective 
measurements of sleep assessment, which are often used in paediatric research. The wide 
variety of sleep assessment methods limits the comparison of sleep studies performed in 
childhood cohorts. The golden standard for sleep assessment is polysomnography, but this 
is an invasive procedure (polysomnography requires overnight in-hospital measurements) 
as well as a costly and time-intensive one. Other commonly used methods are habitual 
sleep measurement using actigraph, and the use of sleep questionnaires such as the 
Pittsburgh Sleep Quality Index (PSQI), where higher scores indicate poorer sleep quality55. 
In this PREVIEW study both objective and self-reported sleep assessments were compared 
to each other. We observed that self-reported poor sleep quality on the PSQI questionnaire 
was inversely related to percentage of slow-wave and REM sleep, indicating deep sleep on 
the polysomnography. Furthermore, poor sleep duration scores were inversely related to 
habitual sleeping time, and wake-after-sleep-onset was related to self-reported daytime 
dysfunction scores. Although PSQI scores were indicative of polysomnography outcomes, 
polysomnography-measured and habitual sleep duration were not interrelated and 
only habitual sleep duration was related to anthropometric characteristics. It is possible 
that this is because habitual sleep measurement by actigraph was measured during 4 
consecutive nights at home, while polysomnography was measured during an overnight 
stay at the hospital. These results do however stress that objective and self-assessed sleep 
measurements measure different dimensions of sleep and may complement each other 
when combined. 
Increased aminotransferase concentration, indicative of NAFLD, was associated with IR 
and less BMI z-score decrease 
IR and non-alcoholic fatty liver disease often co-develop in adolescents and are suggested 
to influence each other56-63. Since IR appeared to be a risk factor for BMI z-score decrease 
during lifestyle intervention in children with obesity, we hypothesized that NAFLD might 
also affect intervention-related outcomes. A substudy of PREVIEW, presented in CHAPTER 
6, was therefore conducted to assess the possible role of NAFLD on BMI z-score, IR, and 
intervention-related outcomes of the lifestyle intervention. 
NAFLD was defined using alanine aminotransferase (ALT) concentrations above the 
upper limit of normal (ULN) values of >22.1 U/L for girls and >25.8 U/L for boys64. 32.5% of 
adolescents with overweight and obesity in this cohort presented with ALT concentrations 
above the ULN, which is higher than the estimated 3-13% in the general population but 
similar to an earlier study where 1/3rd of adolescents with obesity showed signs of NAFLD65. 
Baseline ALT concentrations and BMI z-score were independently related to HOMA-
IR after correcting for Tanner stage and sex. ALT concentration >ULN, indicating NAFLD, 
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was however not independently related to HOMA-IR or change herein, and only positively 
related to baseline HOMA-IR after adding sex and Tanner stage as covariates. This indicated 
that NAFLD has no direct effect on IR in adolescents, but rather that its relation with HOMA-
IR was mediated through BMI z-score change, which we and others have shown to be an 
important mediator of pubertal IR61-63. 
An important result of this study was that adolescents with baseline ALT concentrations 
above the ULN showed no BMI z-score decrease, while BMI z-score decreased in adolescents 
with normal ALT concentrations, and this difference was statistically significant. This 
indicated that elevated ALT concentration, indicating active NAFLD, at the start of lifestyle 
intervention negatively affected outcomes in adolescents with overweight and obesity. 
These results should be confirmed in larger studies, which should also further research the 
underlying mechanisms. However, as the results of this study clearly identify NAFLD as a 
risk factor for less BMI z-score decrease, we advise screening for NAFLD prior to the start of 
lifestyle intervention strategies in adolescents with overweight or obesity. 
CONCLUSIONS 
In conclusion, the results of the PREVIEW study add new insights into the effects of a high-
protein low-GI and moderate-protein moderate-GI diet on insulin resistance in adolescents 
with overweight and obesity who are at high risk to develop T2DM. Pubertal adolescents 
with morbid obesity were found to be at highest risk of T2DM development by exhibiting 
persistence of IR at the end of puberty, which was significantly higher than observed in 
adolescents that had overweight/obesity or were prepubertal.
No significant differences in reported protein intake and GI were observed between the 
two intervention groups, in spite of the different dietary instructions that that were provided 
to each group. In addition, no differences were observed between the intervention groups 
regarding IR, parameters of glucose or lipid metabolism, inflammation, liver transaminases, 
nor lifestyle factors at any timepoint. We therefore conclude that the dietary strategy as it 
was designed was not feasible. 
Changes in reported protein intake were not significantly different between timepoints 
and no effects of the intervention on IR was found. Nonetheless, HOMA-IR stabilized after 
one year of intervention and increased slightly after two years. The stabilization in HOMA-
IR after one year was positively related to change in BMI z-score. Post-hoc analyses also 
showed a significant and clinically relevant overall reduction of BMI z-score of -0.17 SD after 
one year, and -0.19 SD after two years of PREVIEW dietary and PA instructions. The reduction 
in BMI z-score was related to an increase in dietary restraint. 
Shorter habitual sleep duration was related to higher BMI z-score at study onset, but 
changes in sleep duration or parameters were not related to changes in BMI z-score or 
HOMA-IR. 
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Alanine aminotransferase concentrations above the upper limit of normal, indicative of 
NAFLD, were a risk factor for less BMI z-score decrease after one year of intervention but not 
directly related to HOMA-IR. 
Based upon the observations of the PREVIEW study in adolescents, we advise to 
screen adolescents for NAFLD prior to commencement of lifestyle intervention. Lifestyle 
intervention strategies aiming to decrease IR and BMI z-score in adolescents with overweight/
obesity should aim to increase awareness of dietary intake by increasing cognitive restraint, 
as this was found to be a target for BMI z-score reduction and IR stabilization in adolescents 
with overweight/obesity at high risk for developing T2DM.
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Summary
During puberty a physiological, transient increase in insulin resistance (IR) occurs, which 
might ultimately lead to hyperglycaemia and type 2 diabetes mellitus (T2DM). IR is a 
comorbidity of obesity and the level of IR appeared to increase with the level of obesity, 
with up to 52% of adolescents having IR. Moreover, adolescents can convert from IR to 
T2DM in as little as 21 months. Prevention of further increase of IR, especially in adolescents 
with overweight/obesity or other risk factors, might therefore decrease risk for T2DM 
development. 
This thesis aimed to gain more insight in determinants of pubertal insulin resistance, 
especially in adolescents with overweight/obesity at risk for T2DM development. In addition, 
the effects of a lifestyle intervention on IR in insulin resistant adolescents with overweight/
obesity are presented. In 137 adolescents with overweight and obesity from the Centre 
for Overweight Adolescent and Children’s Healthcare (COACH) associations of BMI z-score, 
pubertal stage, age and physical activity with IR were analysed (CHAPTER 2). In addition, 
the data of the PREVention of diabetes through lifestyle Intervention and population 
studies in Europe and around the World (PREVIEW) study in adolescents is presented. As 
part of the larger international PREVIEW randomized controlled trial, the PREVIEW study 
in adolescents aimed to assess the effects of a high-protein low-glycaemic index (GI) diet, 
compared to a moderate-protein moderate-GI diet, on IR and BMI z-score in adolescents 
with overweight/obesity and at high risk for developing T2DM. It was hypothesized that the 
HP diet would be superior in reducing IR in insulin resistant adolescents with overweight/
obesity, compared to the MP diet. 126 adolescents from the Netherlands, Spain and United 
Kingdom that had overweight or obesity and high IR were randomized into a high-protein 
low-GI (HP, 25En%) or moderate-protein moderate-GI (MP, 15En%) group (CHAPTER 3). In 
addition, all participants received instructions to increase physical activity (PA). At baseline, 
after one year and two years of intervention IR, BMI z-score, and cardiometabolic parameters 
were measured. Furthermore, lifestyle variables such as reported dietary intake, food intake 
behaviour, PA and sleep characteristics were measured and correlated with (changes in) IR 
and BMI z-score. 
Homeostatic Model Assessment of Insulin Resistance (HOMA-IR) was significantly higher in 
postpubertal boys compared to prepubertal boys, which is a confirmation of earlier studies 
(CHAPTER 2). In girls a similar, although not significant, trend was observed. In the PREVIEW 
study, too, postpubertal adolescents with morbid obesity showed significantly higher 
HOMA-IR compared to prepubertal subjects with morbid obesity, or overweight/obese 
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subjects at any pubertal stage (CHAPTER 3). This adds to current evidence indicating that 
especially adolescents with higher obesity status have high IR at the end of puberty. 
Both studies observed a positive relationship between BMI z-score and HOMA-IR, 
reaffirming current literature that higher BMI z-score, and thus higher obesity status, 
was related to higher IR. In the study of COACH participants a direct positive association 
between BMI z-score and HOMA-IR was observed in girls, while in boys there was a trend 
for this relationship (CHAPTER 2). However, after correcting for age, puberty stage and 
self-reported physical activity, BMI z-score and HOMA-IR were positively associated in boys, 
too. In the PREVIEW study the group was divided according to pubertal stage and obesity 
status. Markers of adiposity (BMI z-score, but also fat free mass index, fat mass index and 
fat percentage) were positively related to HOMA-IR (CHAPTER 3). Thus, adolescents with 
overweight/obesity are at higher risk of β-cell exhaustion and T2DM development, which 
requires optimization of therapeutic strategies for prevention of further IR increase.
Changes in reported protein intake were not significally different between at any timepoint, 
nor between the HP and MP intervention groups (CHAPTER 4). In addition, a drop-out rate 
of 34% after one year and 61% after two years of intervention was observed. As a possible 
consequence the groups did not significantly differ in changes in BMI z-score change, IR 
nor other cardiometabolic parameters. Maintaining the relatively high protein target of 
25En% in the HP group was obviously not feasible during extended periods of time with 
instructions alone. Achieving and maintaining a target of 25En% protein might only be 
feasible with vouchers or subsidies for foods high in protein, the use of protein supplements 
or meal replacements.
Nonetheless, after one year of PREVIEW intervention HOMA-IR stabilized despite pro-
gression in pubertal stage. Change in HOMA-IR was positively related to change in BMI 
z-score after one year, indicating that as adolescents reduced their BMI z-score they also 
reduced IR. Moreover, after one and two years of PREVIEW intervention a significant and 
clinically relevant BMI z-score reduction was observed in the total group. The change in BMI 
z-score was not attributable to one of the dietary strategies of the PREVIEW study. Change in 
BMI z-score was however inversely related to change in cognitive restraint of eating scores 
and positively to hunger scores on the Three Factor Eating Questionnaire (TFEQ). As the 
dietary restraint scores increased significantly after one and two years, this indicated that as 
adolescents changed their attitude towards food intake they decreased their BMI z-score. 
The reduction in BMI z-score was counteracted by an increase in hunger scores. 
In the cross-sectional COACH study self-reported physical activity, as reported in the 
Baecke questionnaire, was inversely related to HOMA-IR in boys (but not in girls) after 
correction for age, BMI z-score and puberty stage (CHAPTER 2). Baseline data of the PREVIEW 
study, too, showed that Baecke Sport scores were inversely related to glucose concentration, 
after correction for sex, pubertal stage, BMI z-score and fat mass percentage (CHAPTER 3). 
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After one and two years of PREVIEW participation accelerometry counts and minutes spent 
in moderate-to-vigorous physical activity increased significantly while sedentary time 
decreased, indicating compliance to the physical activity guidelines (CHAPTER 4). However, 
no direct, independent relationships between PA with IR or BMI z-score were observed. 
This thesis also aimed to explore associations of sleep characteristics and non-alcoholic fatty 
liver disease on (intervention-related changes in) BMI z-score and IR. Sleep characteristics, 
and especially short sleep duration and sleep debt, have been related to increased risk 
of developing obesity and IR in childhood. In the COACH study, total sleeping time and 
sleep efficiency (total sleeping time as a percentage of time spent in bed, measured by 
polysomnography) were inversely related to HOMA-IR, indicating that longer sleep duration 
and more quality sleep were related to less IR (CHAPTER 2). This observation was only found 
in prepubertal girls, and not in boys or girls that had already entered pubertal development. 
No direct associations between sleep duration or sleep architecture parameters and HOMA-
IR were observed in the PREVIEW study. We observed that habitual (actigraph-measured) 
sleep, but not polysomnography-measured sleep, was negatively related to BMI z-score at 
the onset of the study. While mean BMI z-score decreased significally after 1 year of study 
participation, sleep parameters did not change and were not associated with changes in 
anthropometric and cardiometabolic risk variables (CHAPTER 5). The relatively larger 
decrease in BMI z-score may have counteracted possible effects of sleep characteristics on 
HOMA-IR. 
Non-alcoholic fatty liver disease (NAFLD) has been associated with overweight/obesity 
and IR in adolescence. We assessed the role of NAFLD on changes in BMI z-score and HOMA-
IR during one year of PREVIEW intervention. The 32.5% of adolescents that had increased 
alanine aminotransferase (ALT) concentration at baseline, indicating NAFLD, showed 
significantly less BMI z-score reduction after one year intervention than the adolescents that 
had no signs of NAFLD (CHAPTER 6). ALT concentration was also positively related to HOMA-
IR at study onset. These results indicated that the presence of increased ALT concentrations 
negatively affected intervention outcomes in addition to predisposing to IR. 
In conclusion, this thesis aimed to gain insight in determinants of pubertal insulin resistance 
in adolescents with overweight/obesity, as well as presenting the effects of the PREVIEW 
lifestyle intervention on IR and BMI z-score in adolescents with overweight/obesity at 
high risk for T2DM development. Achieving and maintaining a high protein intake, as was 
recommended by the PREVIEW study, was not feasible and no effects of a HP diet on IR in 
adolescents with overweight/obesity were observed. We confirmed earlier studies that BMI 
z-score was positively related to HOMA-IR and showed that HOMA-IR stabilization after one 
year of intervention could be achieved by BMI z-score reduction. BMI z-score reduction was 
accomplished by increased dietary restraint in participants, which significantly increased 
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after dietary guidance. BMI z-score was not independently associated to change in those 
lifestyle variables nor to (change in) sleep characteristics. NAFLD was observed in 1/3rd of 
participants and was associated with significantly less BMI z-score during intervention. We 
would therefore recommend to put emphasis on increasing dietary restraint in therapeutic 
strategies, as this was related to decreased BMI z-score and IR stabilization in adolescents 
with overweight/obesity at high risk for T2DM development. Furthermore, we recommend 
to screen for the presence of NAFLD as this might counteract BMI z-score reduction. 
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Samenvatting
Tijdens de puberteit vindt er tijdelijk een fysiologische insulineresistentie (IR) plaats, die 
halverwege de puberteit piekt en aan het einde van de puberteit weer afneemt. De verhoogde 
glucosespiegels in het bloed worden dan gecompenseerd door insulineproductie in de 
β-cel van de pancreas. IR is een comorbiditeit van obesitas en de mate van IR lijkt samen 
te hangen met de mate van obesitas. Tot 52% van de adolescenten met overgewicht of 
obe sitas hebben een verhoogde IR. Bij hen is het met name van belang te voorkomen dat 
IR verder toeneemt tijdens de puberteit om het risico op het ontstaan van type 2 diabetes 
mellitus (T2DM) te verminderen. 
Het doel van de studies beschreven in dit proefschrift was meer inzicht te krijgen in deter-
minanten van insulineresistentie tijdens de puberteit. Het effect van een leefstijl interventie 
op IR en leeftijds- en geslacht gecorrigeerde BMI z-score werd onderzocht bij adolescenten 
met overgewicht of obesitas en insulineresistentie. Bij 137 adolescenten met overgewicht of 
obesitas van het Centre for Overweight Adolescent and Children’s Healthcare (COACH) werd het 
verband tussen IR en BMI z-score, puberteitsstadium, leeftijd en fysieke activiteit onderzocht 
(HOOFDSTUK 2). De PREVIEW studie bij adolescenten (PREVention of diabetes through lifestyle 
Intervention and population studies in Europe and around the World (PREVIEW) onderzocht 
het effect van een hoog-eiwit lage-glycemische index (GI) dieet, versus een medium-eiwit 
medium-GI dieet, op IR en BMI z-score. De hypothese was dat een hogere eiwitinname 
gunstiger zou zijn voor verlaging van de insulineresistentie en BMI z-score (HOOFDSTUK 
3). 126 adolescenten met overgewicht of obesitas en IR uit Nederland, Spanje en het 
Verenigd Koninkrijk werden gerandomiseerd in één groep die advies kreeg om een hoog-
eiwit laag-GI dieet te volgen (HP, 25En% eiwit), en één groep die instructies kreeg voor een 
medium-eiwit medium-GI dieet (MP, 15En%). Hiernaast werden deelnemers geïnstrueerd 
om hun fysieke activiteit te verhogen. Aan het begin van de studie, na één en na twee jaar 
leefstijlinterventie werden BMI z-score, IR en andere cardiometabole parameters gemeten. 
Hiernaast werden leefstijlfactoren zoals gerapporteerde voedselinname, voedselinname 
gedrag, fysieke activiteit en slaap parameters bepaald, en gecorreleerd met IR, BMI z-score 
en veranderingen hierin. 
Bij jongens aan het einde van de puberteit bleek de insuline resistentie (Homeostatic Model 
Assessment of Insulin Resistance (HOMA-IR)) significant hoger te zijn dan bij jongens aan het 
begin van de puberteit (HOOFDSTUK 2). Bij meisjes werd een vergelijkbare trend gezien. 
Uit de PREVIEW studie bleek ook dat adolescenten met morbide obesitas aan het einde van 
de puberteit een hogere HOMA-IR hadden dan adolescenten met morbide obesitas aan 
PSM 20200422 Proefschrift Elke Dorenbos (11246).indd   148 14-08-20   09:31
Samenvatting | Appendices
149
A
het begin van de puberteit; tevens was deze gedurende de hele puberteit hoger dan bij 
adolescenten met overgewicht of obesitas (HOOFDSTUK 3). Deze resultaten zijn in lijn met 
eerdere wetenschappelijke observaties, en lijken erop te wijzen dat vooral adolescenten 
met een hogere obesitasstatus ook aan het einde van de puberteit een hoge IR hebben. 
In beide studies waren BMI z-score en HOMA-IR positief gecorreleerd: een hogere IR 
hing dus samen met hogere BMI z-score. In de COACH studie bleek er bij meisjes een directe 
relatie tussen BMI z-score en HOMA-IR te zijn, bij jongens was deze aanwezig na correctie 
voor leeftijd, puberteitsstadium en gerapporteerde fysieke activiteit. In de PREVIEW studie 
werden de analyses gestratificeerd op basis van puberteitsstadium en obesitasgraad. Ook 
hier bleek dat obesitas (BMI z-score, maar ook vetvrije massa index, vetmassa index en 
vetpercentage) positief gerelateerd waren aan HOMA-IR (HOOFDSTUK 3). Samengevat 
kan worden geconcludeerd dat adolescenten met overgewicht en obesitas een hoger 
risico lijken te hebben op β-cel uitputting en ontwikkeling van T2DM. Deze observaties 
benadrukken het belang van optimalisering van therapeutische strategieën om een verdere 
toename van IR te voorkomen. 
Gedurende de twee jaar aangeboden leefstijlinterventie bleken er noch tussen de ver-
schillende meetmomenten, noch tussen de HP en MP groep, significante verschillen in 
gerapporteerde eiwitinname te zijn (HOOFDSTUK 4). Hiernaast bleek na één jaar 34% en 
na twee jaar 61% van de deelnemers uitgevallen te zijn. Als consequentie hiervan werden 
er geen verschillen gevonden tussen de HP en MP groep met betrekking tot veranderingen 
in BMI z-score, IR en andere cardiometabole parameters. Deze resultaten wezen erop dat 
het behalen en volhouden van een verhoogde eiwitinname gedurende lange tijd niet 
haalbaar was met enkel instructies. Mogelijk zou dit alleen haalbaar geweest zijn met 
vouchers of subsidies voor eiwitrijke producten, maaltijdvervangers of het gebruik van 
eiwitsupplementen. 
Desondanks bleek dat na één jaar PREVIEW leefstijlinterventie HOMA-IR gestabiliseerd 
was in de gehele groep, wat een indicatie vormde voor het enigszins beperken van toename 
van IR gedurende de puberteit. Verandering in HOMA-IR was positief geassocieerd met 
verandering in BMI z-score na één jaar, wat erop duidde dat afname in IR samenhing met 
afname van de BMI z-score. Na één en twee jaar interventie was de BMI z-score in de gehele 
groep significant gedaald. Deze verandering in BMI z-score was niet toe te schrijven aan 
verandering in één van de leefstijlfactoren. Wel scoorden de deelnemers na één jaar hoger 
op cognitief beheerst eetgedrag, wat geassocieerd was met de daling van de BMI z-score. 
In de COACH studie bleek gerapporteerde fysieke activiteit op de Baecke vragenlijst 
omgekeerd gerelateerd te zijn aan IR bij jongens na correctie voor leeftijd, BMI z-score en 
puberteitsstadium (HOOFDSTUK 2). Ook bij de PREVIEW studie waren gerapporteerde 
Baecke Sportscores gerelateerd aan lagere bloedglucoseconcentratie na correctie voor 
geslacht, puberteitsstadium, BMI z-score en vetpercentage (HOOFDSTUK 3). Na één en 
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twee jaar PREVIEW leefstijlinterventie bleken ook de objectief gemeten matig-tot-inten sieve 
fysieke activiteit te zijn toegenomen, terwijl sedentaire activiteit verminderd was (HOOFD-
STUK 4). De instructies om de fysieke activiteit te verhogen werden dus opgevolgd; echter 
dit was niet geassocieerd met de verandering in IR of BMI z-score. 
Tevens werden in dit proefschrift mogelijke associaties van slaap kenmerken en van niet-
alcoholische leververvetting met IR en BMI z-score (en interventie-gerelateerde veran-
deringen hierin) onderzocht. Een korte slaapduur werd in eerdere onderzoek in verband 
gebracht met een verhoogde kans op het ontwikkelen van IR en obesitas bij kinderen. In de 
COACH studie bleek dat totale slaaptijd en slaapefficiëntie omgekeerd gerelateerd waren 
aan HOMA-IR (HOOFDSTUK 2). Dit verband werd echter alleen gevonden bij meisjes aan 
het begin van de puberteit, en niet bij jongens en meisjes die verder in de puberteit waren. 
In de PREVIEW studie werd geen direct verband gevonden tussen slaapduur of slaap-
architectuur parameters en HOMA-IR. Bij aanvang van de studie bleek de gewoonlijke 
slaapduur omgekeerd gerelateerd te zijn aan de BMI z-score. Dit was niet het geval 
wanneer de slaapduur in de kliniek werd bepaald. Na één jaar PREVIEW interventie waren 
de slaapparameters niet significant veranderd, en associaties met de BMI z-score of andere 
variabelen was afwezig (HOOFDSTUK 5). Hierbij speelde waarschijnlijk daling van de BMI 
z-score een rol. 
Niet-alcoholische leververvetting (NAFLD) is in eerdere studies gerelateerd aan over-
gewicht/obesitas en IR tijdens de puberteit. In een van de studies beschreven in dit proef-
schrift werd de rol van NAFLD op veranderingen in BMI z-score en IR tijdens de PREVIEW 
leefstijlinterventie onderzocht. 32.5% van de adolescenten had bij aanvang van de studie 
verhoogde alanine aminotransferase (ALT) concentraties, indicatief voor de aanwezigheid 
van NAFLD. Deze adolescenten lieten een significant mindere afname van de BMI z-score 
na één jaar interventie zien, in vergelijking tot de adolescenten die geen aanwijzingen voor 
NAFLD hadden (HOOFDSTUK 6). Bij aanvang van de studie bleek de ALT concentratie tevens 
positief geassocieerd te zijn met HOMA-IR. Deze resultaten wijzen erop dat verhoogde ALT 
concentraties, suggestief voor NAFLD, de uitkomsten van de leefstijlinterventie negatief 
beïnvloedden en hiernaast geassocieerd waren met verhoogde IR. 
Samengevat was het doel van de studies beschreven in dit proefschrift inzicht te krijgen 
in determinanten van insulineresistentie. Het effect van een leefstijlinterventie op IR 
en BMI z-score werd onderzocht bij adolescenten met overgewicht/obesitas en IR. De 
gerandomiseerde, gecontroleerde klinische PREVIEW studie bij adolescenten bleek niet 
haalbaar te zijn, vanwege de uitval van deelnemers en daardoor gemis aan meetresultaten. 
Tevens werd er geen verandering en geen verschil in de eiwitinname van de twee dieet-
groepen waargenomen. Daardoor ontstonden er geen verschillen in HOMA-IR, noch 
in verandering in BMI z-score, tussen de groepen. De waargenomen daling in BMI 
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z-score was geassocieerd met een significante toename in cognitief beheerst eetgedrag. 
HOMA-IR stabiliseerde na één jaar, en was geassocieerd met de afname in BMI z-score. 
Verandering in de BMI z-score was niet gerelateerd aan verandering in leefstijlvariabelen 
of in slaapparameters. Aanwijzingen voor NAFLD bleek een risicofactor te zijn voor een 
significant verminderde afname in BMI z-score tijdens de leefstijlinterventie. Op basis van 
het onderzoek gepresenteerd in dit proefschrift wordt geadviseerd om bij de behandeling 
van adolescenten met overgewicht/obesitas en verhoogd risico op T2DM cognitief beheerst 
eetgedrag te stimuleren. Hiernaast adviseren wij om vóór aanvang van de behandeling te 
screenen op NAFLD omdat dit een risicofactor bleek voor minder BMI z-score afname. 
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Valorisation
A recent report estimated that, without proven effective interventions, in 2025 a total of 268 
million children will be overweight, of which 91 million will have obesity. Even in childhood 
obesity is already associated with a myriad of comorbidities affecting nearly every organ 
system, including but not limited to type 2 diabetes mellitus (T2DM), non-alcoholic fatty 
liver disease (NAFLD), as well as psychological consequences such as reduced quality of 
life. This thesis particularly focusses on the prevention of T2DM in adolescents. T2DM was 
typically considered to be an adult-onset disease, but in recent years 45% of new diabetes 
cases in adolescents were attributable to type 2. Moreover, up to 52% of adolescents with 
overweight present with IR, a known precursor of T2DM, and it is known that adolescents 
can convert from IR to T2DM much faster than adults. It is therefore important to gain more 
insight in IR in adolescence – and that research in this field is relevant, available and can be 
used for translation so that new strategies to prevent T2DM in youth can be developed. 
The PREVIEW study was designed to assess the feasibility and effects of a lifestyle intervention, 
consisting of increasing protein intake, on IR and BMI z-score in adolescents with overweight 
and obesity at high risk for developing T2DM. Adolescents (aged 10-17y) with overweight/
obesity and IR from the Netherlands, Spain and United Kingdom were randomized into two 
groups: a high-protein low-glycaemic-index (HP) group that was advised to increase protein 
intake to 25% of daily energy intake (En%), and a moderate-protein moderate-glycaemic-
index (MP) group that increased protein to 15En%. Adolescents were also encouraged to 
increase physical activity. The second aim of the PREVIEW study was to gain more knowledge 
about the relationship with possible modifiable risk factors, specifically sleep duration and 
architecture and NAFLD, with pubertal IR and intervention-mediated changes herein. 
Previous studies have shown that adolescents that have overweight/obesity and are also 
insulin resistant, are at risk for less or no BMI z-score reduction during lifestyle intervention 
compared to adolescents with overweight/obesity but without IR. In the PREVIEW study only 
adolescents with overweight/obesity and IR were selected, and mean BMI z-score decreased 
with -0.17 SD after one year and -0.19 SD after two years of intervention. This reduction is 
not only statistically significant, but also clinically relevant as BMI z-score reductions >-0.15 
have been related to improvement in glucose metabolism and cardiovascular risk markers. 
This shows that the advice to increase protein intake (in combination with instructions to 
increase physical activity) and personalized approach of the PREVIEW study are targets for 
successful treatment of adolescents with overweight/obesity – which is especially beneficial 
for those with IR as that were until now at risk for less intervention response. 
PSM 20200422 Proefschrift Elke Dorenbos (11246).indd   152 14-08-20   09:31
Valorisation | Appendices
153
A
Furthermore, the personalized instructions of the PREVIEW study rendered an overall 
increase in physical activity, especially moderate-to-vigorous activity and decrease in 
sedentary time, suggesting favourable changes in lifestyle parameters. After one year 
cognitive restraint of eating scores were significantly higher - indicating a more conscious 
attitude towards food intake - and this was directly associated with BMI z-score decrease. 
Thus, the results of this study indicated that increasing dietary restraint is a target for 
successful BMI z-score reduction in adolescents with overweight and obesity, which might 
be of benefit for patients as well as for clinicians and scientists aiming to improve current 
childhood obesity therapies. 
It was also observed that NAFLD, which was present in 1/3rd of the adolescents in this cohort, 
was a risk factor for less BMI z-score decrease after one year of intervention. As screening 
for NAFLD at treatment onset is a relatively easy, cheap and non-invasive procedure, we 
would recommend to incorporate this in treatment strategies as this will effectively identify 
individuals that might be in need of additional support to achieve successful BMI z-score 
decrease. 
None of the adolescents progressed to T2DM during the two years of study participation. 
After one year IR stabilization could be achieved despite progression of puberty, and this 
was related to decrease in BMI z-score. After two years HOMA-IR increased, suggesting that 
adolescents with overweight and obesity are at risk for persistence of high IR at the end 
of puberty, which is in line with cross-sectional observations from this and other studies. 
Thus, these results indicate the importance of preventing further IR exacerbation during 
puberty, especially in those with overweight/obesity as they are at risk for persistent high 
IR, but also demonstrate that it is possible to counteract IR increase and T2DM progression 
by decreasing BMI z-score. The results of the PREVIEW study are relevant to the society, 
because it provides a novel therapeutic strategy that successfully prevented IR increase and 
yielded BMI z-score decrease in a population that was previously at risk for less successful 
therapy outcomes. The PREVIEW study also identified several targets, e.g. increasing 
cognitive restraint of eating and screening for NAFLD, that are associated with BMI z-score 
decrease after one year of intervention and might thus aid clinicians and scientists aiming to 
improve current childhood obesity therapies. These results were shared with the scientific 
community and presented at several national and international conferences. 
Apart from the medical and societal relevance, the outcomes of this study also have an 
economical relevance. The costs of diabetes are rising rapidly and are estimated to be a 
$327mil per year in the USA alone. For children it has been shown that overweight and 
obesity lead to an incremental lifetime health costs of $19.000,- per individual (data of 2012), 
resulting in considerable economical burden considering the estimated number of T2DM 
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globally as reported at the beginning of this chapter. At this moment a cost-benefit analysis 
of PREVIEW is being performed. A similar lifestyle intervention in children with overweight 
and obesity estimated a lifetime economic benefit of €11384,- to €19120,- per individual, and 
estimated that the economic benefit of an intervention in childhood were 4 to 7 times higher 
than the costs. As the PREVIEW study was particularly successful in those adolescents with 
high risk for T2DM development (and thus higher lifetime healthcare costs), it is expected 
that this lifestyle intervention contributes to reduced healthcare costs for the treatment of 
childhood obesity and diabetes. 
Not only positive research results are valuable for the scientific and medical community. 
PREVIEW adds to a limited number of studies that aimed to increase protein intake in 
adolescents with overweight and obesity, and similar to our study most other studies 
observed that higher protein intake targets could not be achieved and maintained long-
term in free living settings. However, when higher protein targets were met (as was the 
case in studies with an in-centre or in-centre-supermarket design) this resulted in significant 
BMI z-score decrease and reduction in HOMA-IR. These results indicate that achieving high 
protein targets with advice alone were not feasible in adolescents in free living settings, and 
future studies assessing the benefits of high-protein diets in adolescents should consider the 
incorporation of meal replacement, vouchers for protein-rich meals or protein supplements 
in their design. 
Taken together, the PREVIEW intervention yielded a significant BMI z-score decrease in 
adolescents with overweight/obesity and IR, that were until now known to show significantly 
less BMI z-score decrease in conventional therapeutic strategies compared to peers without 
IR. In this group, that is at particularly high risk of developing T2DM, IR stabilized after one 
year of treatment which was associated to the reduction in BMI z-score. Increased dietary 
restraint scores were identified as targets for BMI z-score decrease, while NAFLD at study 
onset was related to less BMI z-score decrease after one year of study participation. A major 
strength of the study is that it was set in real-life settings, and the principles used in the 
PREVIEW study can therefore be very easily incorporated in other lifestyle interventions for 
adolescents with overweight and obesity. 
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Dankwoord
Hier is het resultaat van jarenlange inzet van mij én steun van jullie: mijn promotieboekje. 
Wat ben ik er trots op! 
Een promotie doe je nooit alleen. Daarom wil ik graag de vele mensen bedanken die me de 
afgelopen jaren geholpen hebben bij dit proces. 
Ik kan natuurlijk niet anders dan beginnen bij mijn promotieteam: prof. dr. Margriet 
Westerterp-Plantenga, dr. Anita Vreugdenhil, en dr. Tanja Adam. Beste Anita, in 2014 kwam 
ik als student bij COACH en het duurde niet lang voor jij mij vroeg om PREVIEW en het 
bijbehorende promotietraject over te nemen. Van het begin af aan hebben wij dit samen 
opgepakt. Bedankt voor je vertrouwen, doorzettingsvermogen en levensadviezen - “fake 
it till you become it” blijkt ook ver buiten het promotieleven erg nuttig te zijn ;-) Margriet, 
dank voor de mogelijkheid om als uw laatste PhD student te mogen promoveren en het 
vertrouwen om op diverse (inter)nationale congressen de studieresultaten te mogen delen. 
Tanja, dank voor de begeleiding en dat jouw deur altijd open stond voor een praatje. 
Tevens wil ik graag de leden van de leescommissie: prof.dr. Edward Dompeling, prof. dr. 
Edith Feskens, prof. dr. Hanno Pijl, prof. dr. Ronit Sverdlov en prof. dr. Edgar van Mil bedanken 
voor de beoordeling van en feedback op deze thesis. 
To all the members of the PREVIEW consortium, thank you for all your input on the many 
versions of the manuscripts and presentations. Hierbij wil ik Mathijs in het bijzonder 
bedanken. Ondanks dat de studie er voor ons totaal verschillend uit zag, heb je ontzettend 
veel voor de kinderstudie betekend en was het voor mij heel waardevol om met je te kunnen 
sparren over zowel de inhoud als het promoveren zelf. 
Bjorn Winkens, wat ben ik blij dat jij aansloot bij het werken aan de papers als mijn GPS 
(“grudgingly preferred statistician” - zoals je jezelf ooit noemde). Met jouw hulp, steun en 
eindeloze geduld hebben we menig voorheen onoplosbaar statistisch dilemma kunnen 
oplossen. Ook je relativerende en humoristische kijk op de wetenschap heb ik al deze tijd 
erg gewaardeerd. 
Loe Donselaar, ik heb regelmatig een middagje bij je mogen pipetteren en nog vaker 
samples langsgebracht voor de diverse studies. Dank voor al je hulp bij de analyses en mijn 
vragen hierover.
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Aan alle lieve collega’s van COACH: wat zijn jullie fijn! Vanaf het moment dat ik me bij jullie 
team mocht voegen, waren jullie als een warm bad. Ik heb ontzettend genoten van de jaren 
die we samengewerkt hebben. Nog iedere keer verwonder ik mij over de vele prachtige 
initiatieven en de manier waarop iedereen zo hard werkt om het leven van kinderen met 
overgewicht en obesitas gezonder, maar ook zo veel leuker te maken. Jullie maken het 
verschil! 
Uiteraard begon en eindigde mijn promotie onderzoek bij de kinderen: mijn doel is altijd 
geweest om iets bij te dragen voor betere zorg voor kinderen, nu en in de toekomst. 
Daarom wil ik in het bijzonder de kinderen en hun ouders die meededen aan PREVIEW 
en COACH bedanken voor hun vertrouwen en de manier waarop zij zo ontzettend hard 
hebben gewerkt. 
Bij de kindergeneeskunde was het altijd gezellig in de promovendi club. Lieve Bas, Britt v 
E., Britt D., Dillys, Dorien, Eduardo, Gabriëlle, Jesse, Johanna, Kylie, Lisanne, Maartje, Mark, 
Marlou, Minela, Nadine en Yvon: van velen van jullie heb ik al een boekje in de kast staan 
en er zullen er nog vele volgen. Het was ontzettend gezellig om samen met jullie hard te 
werken, maar zo mogelijk nog meer lol te maken. Ik wens jullie allemaal veel succes in de 
toekomst. 
Danilo, jij hebt mij geholpen om mijn eerste schreden binnen de kindergeneeskunde te 
zetten. Dank voor je steun en fijne gesprekken al deze jaren!
A special thanks to the Galactosemia Girls Estela, Ana, Britt, Inge, Britt and Minela: you 
have adopted me as one of your group and I have truly enjoyed all of our “coffee/cake/wine 
marathons”. 
Kim, het laatste jaar van mijn PhD heb jij als mijn mentor gefungeerd. Wat heb ik veel 
van je geleerd, zowel op wetenschappelijk als op persoonlijk gebied. Je luisterend oor, 
drive om het altijd nóg beter te doen, goede adviezen en moed om ook moeilijke keuzes te 
durven maken hebben me altijd geïnspireerd. Bedankt!
Aan alle lieve collega’s van de JGZ: dank voor jullie niet aflatende steun en enthousiasme 
over dit promotietraject.
Britt, jou als vriendin hebben is één van de beste dingen die uit dit promotietraject is 
voortgekomen :-) Je was en bent nog steeds een voorbeeld voor me. Op naar nog onwijs 
veel gezelligheid samen in de toekomst! 
Ruth, een paar jaar geleden sprak je de onsterfelijke woorden “we slepen, huilen, 
chocola- en koffie-nuttigen ons er wel doorheen” – en alleen de koffiedame weet hoe gelijk 
je had ;-). Zowel in Maastricht als in Veldhoven was je mijn buddy en heb je me onwijs kunnen 
laten lachen om alle (promotie en andere) perikelen waar we in verzeild raakten. Dankjewel!
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Karin, al 10 jaar lang (!) studeren, dokteren en promoveren we samen - en wat is het fijn 
om dat allemaal met jou te kunnen doen. Ik kijk nu al uit naar jouw promotie en de mooie 
tijd die we ook daarna samen kunnen delen :-) 
Gabriëlle – als een wervelwind kwam je mijn kantoor (en leven) in en sindsdien ben je 
mijn cabaretier, relativerend vermogen, luisterend oor, motivator en vooral vriendin. Dank 
voor vriendinnen zoals jij!  
Davy, we liepen de deur bij elkaar plat en ondanks dat de fysieke afstand nu groter is dan 
voorheen (ik vind nog steeds dat we weer buren moeten worden!) ben je  er altijd voor me. 
Dankjewel! 
Lex, ook jij bent ondertussen letterlijk aan het andere eind van het land gesetteld, maar 
wat is het fijn om alle hoogtepunten toch altijd samen te kunnen vieren. 
Lieve Bauke, Camille, Pauline en Yasmin: als overactieve geneeskunde studenten wilden 
wij “iets leuks” doen. Dat heeft geresulteerd in duizenden genezen teddyberen, geweldige 
projecten die we hebben opgezet op de kinderafdeling, tig wijnavondjes en vooral héél 
veel gezelligheid. Wat mooi om te zien hoe ieder van ons nu haar eigen weg gaat, maar we 
desondanks nog steeds zulke goede vriendinnen  zijn. 
Lieve Corien, Daniëlle en Mirjam: ik ben nog steeds onder de indruk van jullie onwijs 
goede proefschriften en hopelijk past dit proefschrift mooi in de rij. Corien, succes met de 
laatste loodjes. 
Elly, jij valt ondertussen meer in de categorie familie dan collega’s of vrienden. Jouw warmte 
en goede adviezen hebben ontzettend veel voor mij betekend en maakten al die lunches, 
wandelingen en keukentafelgesprekken die we mochten delen vaak het hoogtepunt van 
mijn week. Dankjewel voor alles! 
Monique en Linda, ik heb héél lang geprobeerd om de juiste woorden te vinden die ons 
beschrijven maar eigenlijk zijn die er niet ;-) Wat ben ik blij dat wij al meer dan een half leven 
alle hoogte- en dieptepunten samen kunnen meemaken, er samen om kunnen lachen, en 
dat jullie er altijd zijn. Met jullie is alles leuker :-)
Lieve Suzanne, José, Jerôme, hoe vaak ben ik wel niet op mijn fietsje naar Geldermalsen 
getrokken? Nog steeds voelen jullie een beetje als mijn adoptiefamilie. Wat fijn dat jullie er 
altijd voor me zijn. Su: heel veel succes met de allerlaatste loodjes! 
Aan alle Dorenbosjes/Heijnsdijkjes: wat ben ik blij met een familie zoals jullie. Ondanks dat 
het hele promotietraject en academische wereldje soms compleet onbegrijpelijk leken, 
hebben jullie me altijd in alles gesteund. Fijn om nu met jullie deze mijlpaal te kunnen vieren. 
Lieve oma, helaas kan je er vandaag niet bij zijn maar in gedachten zit je op de eerste rij. 
Wat zal het fijn zijn als we elkaar binnenkort weer in de armen mogen sluiten en dit samen 
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kunnen vieren. Ik hou van je! 
Liebe Gerti, Andreas und Christina, was für ein Glück dass ihr so ein wichtiger Teil meiner 
Familie geworden seid. Schon seit dem ersten Mal wo wir uns kennen gelernt haben und wir 
uns nur mit einem Wörterbuch verständigen konnten, habe ich mich trotzdem direkt sehr 
willkommen gefühlt. Wie schön, dass ihr auch heute dabei seid. 
Liefste pappa en mamma: er is werkelijk niets wat ik hier zou kunnen schrijven wat eer doet 
aan wat jullie voor mij betekenen. Ik ben ontzettend trots op en dankbaar voor een gezin als 
het onze. Jullie hebben Marlies en mij altijd gestimuleerd om het beste uit onszelf te halen 
en zijn daar zelf altijd het beste voorbeeld in geweest. Zonder jullie was dit boekje er niet 
geweest. Ik hou heel, heel veel van jullie. Lieve Marlies, je bent de leukste, grappigste, fijnste, 
stoerste en liefste zus die ik me kan wensen en ik ben trots op je! Je hebt ieder stapje (en 
koffer-incident) van het promoveren achter, voor en naast mij gestaan, en ik ben ontzettend 
blij dat jij ook vandaag letterlijk naast mij wil staan als paranimf :-)
Matthias, al bijna 10 jaar lang ben je mijn anker en degene die me de moed geeft om mijn 
dromen achterna te jagen. Jij maakt mijn leven zoveel mooier. Ik hou van je!
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